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Summary
Treatment of oncological and autoimmune diseases still remains a considerable chal-
lenge to modern medicine. Current therapy options such as chemotherapy and
radiotherapy in oncology and glucocorticoids or other conventional immunosuppres-
sive drugs for autoimmune diseases are often of limited efficacy. They suffer from
a lack of specificity, with respect to the eradication of tumour and immune cells,
respectively. The use of monoclonal antibodies in oncology allowed in some in-
stances specific targeting of tumour cells and thus, improved this situation in the
last decades. Some antibodies, such as anti-CD20 antibody Rituximab, targeting
normal and malignant B-cells, are meanwhile firmly established in oncological treat-
ment regimes. Interestingly, over the last years the anti B-cell activity of Rituximab
was used in addition in numerous studies for the treatment of autoimmune diseases.
Many strategies have been developed to further improve therapeutic activity of mo-
noclonal antibodies. One of them is the development of bispecific antibodies recog-
nising target cell antigens and effector cells or effector molecules at the same time.
The “bispecific concept” used in this work is the target cell restricted stimulation
of the death receptor CD95 (APO-1/Fas) with bispecific antibodies as described by
Jung et al. in 2000. Whereas initial experiments were performed using chemically
hybridised bispecific antibodies with CD20×CD95 specificity, the goal of this thesis
was the generation of recombinant antibodies within a suitable format.
To this end, a recombinant CD20×CD95 molecule in the so called FabSc format,
designated BS9520 was developed and characterised in various in vitro and in vivo
assays. It was found that the capability of this antibody to suppress the growth
of malignant B-cells in vitro and in vivo and to specifically deplete normal, acti-
vated B-cells from PBMC cultures was superior to that achieved with monospecific
clinically established anti-CD20 antibodies including a newly developed third gener-
ation Fc-optimized CD20 antibody. Moreover, the bispecific antibody was the only
reagent capable of significantly suppressing IgG production by activated B-cells in
vitro. These findings imply that the bispecific CD95×CD20 antibody might become
an attractive reagent for the treatment of B-cell malignancies as well as B-cell me-
diated autoimmune diseases.
In the second part of this work a completely new approach for the stimulation of
the CD95 death receptor on antigen specific B-cells was evaluated. For proof of
principle, the CD20 part in the BS9520 antibody was replaced by antigen fragments
(tetanus or diphtheria toxoid derivatives). We named these fusion proteins BS95TT
and BS95DT, respectively. Such protein should bind to B-cell receptor via their
toxoid part and with the CD95 antibody part to CD95 receptor on activated TT-
specific B-cells. Thereby, apoptosis is induced only in an antigen-specific fashion.
This approach could be used for the treatment of autoimmune diseases if the antigen
inducing auto-antibody production is known (such as Myasthenia gravis, multiple
sclerosis and others).
Zusammenfassung
Die Behandlung von onkologischen und Autoimmunerkrankungen ist nach wie vor
eine große Herausforderung fu¨r die moderne Medizin. Aktuelle Therapieoptionen wie
Chemotherapie und Strahlentherapie in der Onkologie und Glukokortikoide oder an-
dere immunsuppressive Medikamente fu¨r Autoimmunerkrankungen sind aufgrund
ihrer eingeschra¨nkten Spezifita¨t oft nicht effektiv genug. Durch die Verwendung von
monoklonalen Antiko¨rpern in der Onkologie konnte bei einigen Erkrankungen spez-
ifisches Targeting und damit eine verbesserte Therapie in den letzten Jahrzehnten
erreicht werden. Außerdem werden einige Antiko¨rper, die bereits fu¨r die Immunther-
apie von Krebs existieren (z. B. anti-CD20-Antiko¨rper Rituximab), zusa¨tzlich in
zahlreichen Studien fu¨r die Behandlung von Autoimmunerkrankungen verwendet.
In den letzten Jahrzehnten wurden viele Strategien entwickelt um die Wirksamkeit
von monoklonalen Antiko¨rpern zu verbessern. Eine dieser Strategien liegt in der
Entwicklung bispezifischer Antiko¨rper, welche Zielzellen und Effektorzellen oder Ef-
fektormoleku¨le gleichermaßen erkennen. Das in dieser Arbeit angewendete “Bispez-
ifische Konzept” beruht auf der Stimulierung des CD95 Todesrezeptores mit bispe-
zifischen Antiko¨rpern (beschrieben von Jung et al. in 2000). Wa¨hrend die ersten
Experimente mit chemisch-hybridisierten bispezifischen CD20×CD95 Antiko¨rpern
durchgefu¨hrt wurden, war das Hauptziel dieser Arbeit die Entwicklung von rekom-
binanten bispezifischen Antiko¨rpern in einem geeigneten Format.
Dazu wurde in der ersten Teil dieser Arbeit ein rekombinanter CD95×CD20 An-
tiko¨rper BS9520 im FabSc Format entwickelt und in unterschiedlichen in vitro und
in vivo Untersuchungen charakterisiert. Es wurde festgestellt, dass die Lyse von
humanen CD20 exprimierenden Lymphomzellen in vitro und in vivo durch BS9520
effizienter ausgelo¨st wurde als durch monospezifische CD20 Antiko¨rper. Dies schließt
einen neu entwickelten Fc-optimierten CD20 Antiko¨rper ein. BS9520 war auch in
der Lage normale, aktivierte B-Zellen selektiv zu depletieren und, im Gegensatz
zu monospezifischen CD20 Antiko¨rpern, die Antiko¨rperproduktion in vitro effizient
zu unterdru¨cken. Diese Ergebnisse bedeuten, dass der bispezifische CD95×CD20
Antiko¨rper ein prototypisches Reagenz zur Behandlung von B-Zell-vermittelten Au-
toimmunerkrankungen werden kann.
Im zweiten Teil dieser Arbeit wurde ein vo¨llig neuer Ansatz fu¨r die Stimulation der
CD95 Todesrezeptoren auf Antigen-spezifischen B-Zellen untersucht. Als prinzipiel-
ler Beweis fu¨r die Wirksamkeit dieser Technik wurde der CD20 Teil im bispezifischen
BS9520 Antiko¨rper durch Antigen-Fragmente ersetzt (Tetanus oder Diphtherie To-
xoid Derivate). Diese Fusionsproteine wurden als BS95TT und BS95DT bezeichnet.
Ein solches Protein sollte an B-Zell Rezeptoren u¨ber den Toxoid-Teil und mit dem
CD95-Antiko¨rper an CD95-Rezeptoren auf aktivierten B-Zellen binden. Auf diese
Weise sollte Apoptose nur in Antigen-spezifischen aktivierten B-Zellen induziert wer-
den. Dieser Ansatz ko¨nnte fu¨r die Behandlung von Autoimmunerkrankungen einge-
setzt werden, bei denen das Auto-Antiko¨rper induzierende Antigen bekannt ist (z.B.
Myasthenia gravis, Multiple Sklerose (MS) und andere).
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2 CHAPTER 1. INTRODUCTION
With more than 3 million new cases and 1.7 million deaths each year (WHO/Europe,
2016), cancer is the most important cause of death and morbidity in Europe after
cardiovascular diseases. A significant part of cancer diseases consists of haematologi-
cal malignancies – tumours affecting the blood, bone marrow, and lymphatic system.
Surgical treatment is obviously not possible and therapy, including hematopoietic
stem cell transplantation, is often of limited success,whereas side effects and treat-
ment costs are high.
Autoimmune diseases affect approximately 1 of 12 individuals living in the Western
Hemisphere, representing a significant cause of morbidity, chronic disability and
health-care burden (Li et al., 2015). The National Institutes of Health (NIH) esti-
mates, that up to 23.5 million Americans suffer from autoimmune diseases with rising
prevalence. This diverse group encompasses more than 100 diseases, including type-
1 diabetes, multiple sclerosis (MS), rheumatoid arthritis (RA), Crohn’s disease and
systemic lupus erythematosus (SLE). Although autoimmune diseases do not cause
high mortality, they are responsible for more than $ 100 billion in direct health care
costs annually in the US (AARDA, 2016). Thus, autoimmune diseases are among
the most expensive health disorders society has to face.
1.1 Haematological malignancies
Haematological malignancies are derived from one of the two major blood cell li-
neages: myeloid and lymphoid cells. The myeloid cell line produces granulocytes,
erythrocytes, thrombocytes, macrophages and mast cells; the lymphoid cell line B-,
T-, NK and plasma cells. Lymphomas, lymphocytic leukaemias, and myeloma de-
rive from lymphoid precursors, whereas acute and chronic myelogenous leukaemia,
myelodysplastic syndromes and myeloproliferative diseases are myeloid in origin
(Vardiman et al., 2009). The proposed WHO classification of haematologic malignan-
cies stratifies these neoplastic disorders primarily according to lineage: myeloid neo-
plasms, lymphoid neoplasms, mast cell disorders, and histiocytic neoplasms. Within
each category, distinct diseases are defined according to a combination of morphology,
immunophenotype, genetic features, and clinical syndromes (Harris et al., 2000).
B-cell malignancies belong to the group of lymphoid neoplasms. They represent a di-
verse collection of diseases, including most non-Hodgkin’s lymphomas (NHL), some
leukaemias and myelomas. Examples include B-cell acute lymphoblastic leukaemia
(B-ALL) accounting for 80-85% of childhood ALL (American cancer society, 2016),
chronic lymphocytic leukaemia (CLL), follicular lymphoma, mantle cell lymphoma
(MCL) and diffuse large B-cell lymphoma (DLBCL) (Zelenetz et al., 2013). B-cell
malignancies can be divided into 2 clinically relevant categories: indolent and ag-
gressive. Indolent malignancies, such as follicular lymphoma, small lymphocytic
lymphoma and marginal zone lymphoma, are characterised by slow growth and a
high initial response rate, followed by a relapsing and progressive disease course
(Guerard and Bishop, 2012; Vidal et al., 2012). Aggressive lymphomas, such as DL-
BCL, MCL and Burkitt’s lymphoma, are characterised by rapid growth and lower
initial response rates, with shorter overall survival (Dotan et al., 2010; Vidal et al.,
2012). B-ALL is characterised by its aggressiveness and short latency (Sanjuan-Pla
et al., 2015).
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Current therapy strategies for B-cell malignancies include radiation therapy, che-
motherapy and immunotherapy. Radiation therapy (also known as external beam
radiation) is used in early-stage limited disease, as consolidative therapy in aggres-
sive lymphomas that respond to chemotherapy and to manage some complications.
Chemotherapy, which kills rapidly-dividing cells, is used as a curative as well as
palliative intervention. Some of the chemotherapeutic drugs commonly used to
treat lymphoma include alkylating agents (Cyclophosphamide), platinum drugs (Cis-
platin, Carboplatin, Oxaliplatin), anti-metabolites (Methotrexate) and others like
Doxorubicin and Vincristine. In principle both, radiotherapy and chemotherapy
affect proliferating cells rather unspecifically, that is, not specific for tumour cells.
Small-molecule kinase inhibitors such as Ibrutinib promised improved specificity due
to their defined mode of action. Ibrutinib inhibits Bruton’s tyrosine kinase (BTK) –
a key component of B-cell receptor (BCR) signalling that functions as an important
regulator of cell proliferation and cell survival in various B-cell malignancies. Ibru-
tinib treatment leads to inhibition of downstream BCR signaling and cell apoptosis.
However, BTK is also involved in signalling pathways downstream of many other
receptors, including G protein-coupled chemokine receptors and Toll-like receptors
(TLRs) (Hendriks et al., 2014).
In contrast to conventional chemotherapy, cancer immunotherapy promises an in-
creased specificity. It’s goal is to induce or enhance immune responses to support
the immune system in defeating cancer. Cell-based therapy, useful for the treat-
ment of B-cell malignancies, includes hematopoietic stem cell transplantation (Bhatt
and Vose, 2014), adoptive transfer of NK-cells (Ljunggren and Malmberg, 2007) or
chimeric antigen receptors (CAR)-modified T-cells (Porter et al., 2011). Therapy
with biological agents consists mostly of therapeutic antibodies (Alemtuzumab, Ri-
tuximab) and cytokines such as interferon-α (Kirkwood, 2002). Newer therapeutic
agents for lymphomas and lymphocytic leukaemias such as nucleic acids (O’Brien
et al., 2005; Badros et al., 2005) and peptide vaccines (Kowalewski et al., 2015) are
still in the research phase.
1.2 B-cell mediated autoimmune diseases
A century ago Paul Ehrlich proposed that immune reactivity against self, which he
called “horror autotoxicus”, and which is now called autoimmunity, would be incom-
patible with life because of potentially devastating consequences for the host. But
this view was proven wrong after the demonstration of auto-antibodies and the emer-
gence of a theoretical basis for autoreactivity (Burnet, 1976). In the 1960s, it was
believed that all self-reactive lymphocytes were eliminated during their development
in the bone marrow and thymus and that a failure to eliminate these lymphocytes led
to autoimmune consequences. Since the late 1970s, a broad experimental evidence
has countered that belief, revealing that not all self-reactive lymphocytes are deleted
during T-cell and B-cell maturation. Normal healthy individuals have been shown
to possess mature, recirculating, self-reactive lymphocytes. Due to the fact that
the presence of such cells in the peripheral blood does not inevitably result in auto-
immune reactions, their activity must be regulated in healthy individuals through
clonal anergy or clonal suppression. A breakdown of this regulation can lead to ac-
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tivation of self-reactive clones of T- or B-cells, generating humoral or cell-mediated
responses against self antigens (Goldsby, 2003).
Very often the autoimmune damage of cells or organs is caused by auto-antibodies,
produced by activated B-cells (Table 1.2). A number of viruses and bacteria can
induce nonspecific polyclonal B-cell activation. Gram-negative bacteria, cytomega-
lovirus and Epstein-Barr virus (EBV) are all known to be such polyclonal activators,
inducing the proliferation of numerous clones of B-cells. If autoreactive B-cells are
activated by this mechanism, auto-antibodies can appear. For instance, during in-
fectious mononucleosis, which is caused by EBV, a variety of auto-antibodies are
produced, including those reactive to T- and B-cells, rheumatoid factors, and an-
tinuclear antibodies (Wucherpfennig, 2001). Similarly, B-cells from patients with
SLE produce large quantities of IgM in cell culture, suggesting that lymphocytes
have been polyclonally activated. Many patients suffering from acquired immune
deficiency syndrome (AIDS) also show high levels of auto-antibodies such as anti-
cardiolipin, anti-β2 GPI (β2-glycoprotein I), anti-DNA, anti-small nuclear ribonuc-
leoproteins (snRNP), anti-thyroglobulin, anti-thyroid peroxidase, anti-myosin, and
anti-erythropoietin antibodies (Zandman-Goddard and Shoenfeld, 2002).
In some autoimmune diseases, antibodies act as agonists, binding to hormone re-
ceptors replacing the normal ligand and stimulate inappropriate activity. This usu-
ally leads to an overproduction of mediators or cell proliferation. Conversely, auto-
antibodies may act as antagonists, binding hormone receptors but blocking receptor
function rather than stimulating it. This generally causes impaired secretion of me-
diators and gradual atrophy of the affected organ. For example, in autoimmune
thyroid disease (AITD) auto-antibodies bind to the thyroid stimulating hormone
receptor (TSHR) and can act as either agonists, mimicking the biological activity
of TSH, or as antagonists inhibiting the action of TSH (Sanders et al., 2010).
One representative example of a systemic autoimmune disease is SLE. Affected indi-
viduals may produce auto-antibodies to a vast array of tissue antigens, such as DNA,
histones, red blood cells (RBCs), platelets, leukocytes, and clotting factors; interac-
tion of these auto-antibodies with their specific antigens produces various symptoms.
Auto-antibodies specific for RBCs and platelets may lead to complement-mediated
lysis, resulting in haemolytic anaemia or thrombocytopenia, respectively. When
immune complexes of auto-antibodies with various nuclear antigens are deposited
along the walls of small blood vessels, a type III hypersensitive immune reaction
develops. The antigen-antibody complexes activate the complement system by ge-
nerating membrane-attacking complexes which damage the wall of the blood vessel,
resulting in vasculitis and glomerulonephritis (SK Mohanty, 2008). Many individu-
als with rheumatoid arthritis produce a group of auto-antibodies called rheumatoid
factors that are reactive towards determinants of the Fc region of IgG. The classic
rheumatoid factor is an IgM antibody. Such auto-antibodies bind to normal cir-
culating IgG, forming IgM-IgG complexes that are deposited in the joints. These
immune complexes can activate the complement cascade, and, as in the situation
described before, result in a type III hypersensitive reaction, which leads to chronic
inflammation of the joints (Leadbetter et al., 2002).
Current therapies for B-cell mediated autoimmune diseases include treatment with
immunosuppressive drugs or monoclonal antibodies which interact with some com-
ponents specifically involved in an autoimmune reaction.
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Table 1.1: Selected autoimmune diseases in humans
(Adapted from (Goldsby, 2003))
Disease Self-antigen Immune response
ORGAN-SPECIFIC AUTOIMMUNE DISEASES
Addison’s disease Adrenal cells Auto-antibodies
Autoimmune hemolytic RBC membrane proteins Auto-antibodies
anemia
Goodpasture’s syndrome Renal and lung Auto-antibodies
basement membranes
Graves’ disease Thyroid-stimulating Auto-antibody
hormone receptor (stimulating)
Hashimoto’s thyroiditis Thyroid proteins and cells TDTH cells,
auto-antibodies
Idiopathic thrombocyopenia Platelet membrane proteins Auto-antibodies
purpura
Insulin-dependent diabetes Pancreatic beta cells TDTH cells,
mellitus auto-antibodies
Myasthenia gravis Acetylcholine receptors Auto-antibodies
Pernicious anemia Gastric parietal cells; Auto-antibodies
intrinsic factor
Poststreptococcal Kidney Antigen-antibody
glomerulonephritis complexes
Spontaneous infertility Sperm Auto-antibodies
SYSTEMIC AUTOIMMUNE DISEASES
Ankylosing spondylitis Vertebrae Immune complexes
Multiple sclerosis Brain or white matter TH1 cells, TC cells,
auto-antibodies
Rheumatoid arthritis Connective tissue, IgG Auto-antibodies,
immune complexes
Scleroderma Nuclei, heart, lungs, Auto-antibodies
gastrointestinal tract, kidney
Sjogren’s syndrome Salivary gland, liver, Auto-antibodies
kidney, thyroid
Systemic lupus DNA, nuclear protein, Auto-antibodies,
erythematosus (SLE) RBC and platelet membranes immune complexes
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In general, introduction of antibody-based therapies in the last decades have demon-
strated promising results in oncology as well as in autoimmune diseases.
1.3 Antibody-based immunotherapy
The first therapeutic monoclonal antibody approved by FDA was the anti-CD3
antibody Muromonab (1986) used to prevent acute organ rejection (Emmons and
Hunsicker, 1987). It happened more than a decade after the development of the hy-
bridoma technology (Ko¨hler and Milstein, 1975). As a result of technological break-
throughs in the field of molecular biology and cloning, progress in the therapeutic
antibody field developed very fast in the 1980-1990ies. Currently antibody-based
therapeutics enjoy unprecedented success. There are more than 40 monoclonal anti-
bodies approved for clinical use in the European Union or United States (Antibody
Society, 2015) and hundreds are in clinical trials for treatment of various diseases
including cancer, immune disorders and infections.
1.3.1 Antibodies: structure and function
Antibodies, also known as immunoglobulins (Ig), are large (150 kDa – 900 kDa), Y-
shape proteins produced by plasma cells. They are used by the immune system
to identify and neutralize pathogens such as bacteria and viruses. An antibody
monomer contains two light chains and two heavy chains, which are linked by mul-
tiple disulphide bonds (Fig. 1.1 a).
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Figure 1.1: Structure of an IgG antibody with various humanized isoforms
a) murine antibody: VL and CL are variable light and constant light domains, respectively,
VH and CH are variable heavy and constant heavy domains, respectively; Fc part – frag-
ment crystallizable, Fab – fragment antigen-binding b) chimeric antibody: mouse constant
domains were exchanged to human constant domains; c) humanized antibodies: mouse con-
stant domains and framework regions (FRs) were exchanged to human sequences; d) fully
human antibody
In mammals, antibodies can be subdivided into five main classes or isotypes – IgA,
IgD, IgE, IgG and IgM according to the heavy chain they contain – α, δ, ǫ, γ or
µ respectively. They differ in the sequence and number of constant domains, hinge
structure and the valency of the antibody. IgA, for instance, is typically found
as a dimer and IgM as a pentamer. Antibody light chains fall into two classes in
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mammals, κ and λ (Cruse and Lewis, 2010). Most of the therapeutic antibodies
derive from IgGκ isotype.
An antibody recognises an antigen via complementarity-determining regions (CDRs).
These are short, hypervariable amino acid sequences found in the variable domains
of both light and heavy chains. Due to the fact, that those parts are the only
responsible for antigen binding, the remaining part of the antibody molecule can be
manipulated by in vitro genetic engineering approaches to reduce its immunogenicity.
Fig. 1.1 a depicts a normal murine antibody, the exchange of the murine constant
domains to human results in a chimeric antibody (Fig. 1.1 b) and exchange of the all
murine sequences except CDRs results in a humanised antibody (Fig. 1.1 c). Fully
human antibodies (Fig. 1.1 d) can be obtained using phage display (McCafferty et al.,
1990), transgenic animals (Mendez et al., 1997; Lonberg et al., 1994) or single cell
cloning (Traggiai et al., 2004) technology.
After binding to a target, the Fc part of the antibody molecule can recruit effec-
tor cells such as natural killer cells, macrophages, or neutrophils, and/or activate
the complement components in serum to destroy the target cells. These properties,
referred to as “antibody-dependent cellular cytotoxicity” (ADCC) (Wisloff et al.,
1974) , “antibody-dependent cellular phagocytosis” (ADCP) (Krauss et al., 1994)
and “complement-dependent cytotoxicity” (CDC) (Ross, 1989), are fundamental
aspects of natural antibody biology that are being manipulated to create therapeu-
tics with more potent biological activity and longer half-life. In addition to ADCC,
ADCP and CDC activities, the Fc region of an antibody is also responsible for the
long half-life of the molecule through its interaction with the neonatal receptor FcRn
(Roopenian and Akilesh, 2007).
1.3.2 Targets for antibody therapy
A key challenge of antibody-based cancer therapy is to identify antigens/targets
that are suitable for antibody-based therapeutics. They should be overexpressed,
mutated or selectively expressed on malignant cells compared to normal tissues.
Once a suitable target is identified, one can decide which mechanism of action will
be appropriate to achieve the desired therapeutic effect.
1.3.2.1 Targets for leukaemia/lymphoma
Cancer cells differ from normal cells due to genomic mutations in oncogenes and/or
tumour suppressor genes (Chow, 2010). Once the integrity of the genome is com-
promised, cells are more likely to aquire additional genetic defects, some of which
may give rise to tumour-associated antigens (overexpressed on tumour cells, but also
present on normal cells) (Sensi and Anichini, 2006). Leukaemias and lymphomas
have less mutations compared to other cancer types such as melanoma, lung and
bladder cancer (Lawrence et al., 2013). Thus it is particularly challenging to find
appropriate targets for monoclonal antibody (mAb)-based therapy expressed exclu-
sively on leukaemic cells. Most of the antigens targeted in leukaemia and lymphoma
are cell surface proteins also found on normal cells of the haemotopoietic system.
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The main targets for B-cell malignancies are currently CD20 and CD19 lympho-
cyte antigens. The CD20 molecule is expressed on all stages of B-cell development
except the first and last. It is a 297 amino acid phosphoprotein with four transmem-
brane domains. CD20 is found on B-cell lymphomas, hairy cell leukemia and B-cell
chronic lymphocytic leukemia making it a suitable biomarker for immunotherapy
targeting B-cell derived diseases. Rituximab was the first anti-CD20 monoclonal
antibody approved by the FDA for treatment of B-cell malignancies, and it is per-
haps the most extensively investigated drug in this field. It was first approved in
1997 for the treatment of low grade B-cell lymphoma, and subsequently was shown
to improve cure rates when added to the standard CHOP ((C)yclophosphamide,
(H)ydroxydaunorubicin, (O)ncovin, (P)rednisone) chemotherapy regimen for pa-
tients with diffuse large B-cell lymphoma (Lim and Levy, 2014).
In order to decrease immunogenicity and improve antitumour activity, new gen-
erations of anti-CD20 monoclonal antibodies are being developed (Cang et al.,
2012). Second-generation anti-CD20 antibodies (humanised molecules) include a
fully human type I anti-CD20 antibody Ofatumumab (Arzerra®) (Coiffier et al.,
2008), a humanised type I anti-CD20 antibody Veltuzumab (with complementarity-
determining regions (CDRs) identical to Rituximab, except for a single amino acid
change, Asp101 instead of Asn101 (Stein et al., 2004; Goldenberg et al., 2010))
and humanised type I anti-CD20 antibody Ocrelizumab differing from Rituximab at
several amino acid positions within the CDRs of the light chain and heavy chain
variable regions (Morschhauser et al., 2010).
The third-generation humanized anti-CD20 antibodies have an engineered Fc re-
gion to increase their binding affinity for the FcγRIIIa receptor and thus, enhanced
ADCC activity. Those include type II anti-CD20 antibody Obinutuzumab (Gazyva®,
GA-101) approved by FDA in 2013 (Goede et al., 2014), Ocaratuzumab (AME-133v,
LY2469298) (Ganjoo et al., 2015) and PRO131921 (Casulo et al., 2014) currently
undergoing active clinical development. Recent studies with CLL patients showed
superiority of GA-101 over Rituximab (Goede et al., 2014; Goede et al., 2015).
CD19 is an antigen expressed on B-cells from earliest detectable B-lineage cells
during development to B-cell blasts but is lost on maturation to plasma cells. It
is maintained on more than 95% B-cell malignancies (Ramos et al., 2014), making
this molecule an attractive target for antibody therapy. CD19 antibody is also ben-
efiting from the Fc-optimisation described above: a humanized CD19 monoclonal
antibody with an engineered Fc region (also known as XmAb5574 or MOR00208)
just completed Phase 1 clinical trial in patients with relapsed or refractory CLL
(Woyach et al., 2014) and Phase 2 clinical trial study is currently recruiting partic-
ipants (ClinicalTrials.gov Identifier: NCT02005289). Moreover, CD19 antibody is
part of bispecific CD19×CD3 antibody Blinatumomab (Bargou et al., 2008) and
also the first antibody used within chimeric antigen receptors (CAR) engineered
T-cells (Porter et al., 2011).
Anti-CD22 antibody Epratuzumab binds to the glycoprotein CD22 of mature and
malignant B-cells and is used in adult acute lymphoblastic leukaemia and DLBCL
therapy. Brentuximab vedotin is an antibody-drug conjugate directed to the protein
CD30 expressed in in classical Hodgkin lymphoma and systemic anaplastic large
cell lymphoma. Alemtuzumab is a monoclonal antibody that binds toCD52 present
on the surface of mature lymphocytes. It is used in the treatment of CLL, cutaneous
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T-cell lymphoma (CTCL) and T-cell lymphoma under the trade name Campath®.
Campath® was withdrawn from the markets in the US and Europe in 2012 to
prepare for a higher-priced relaunch of the same antibody under the trade name
Lemtrada for the treatment of multiple sclerosis (Thompson et al., 2013).
1.3.2.2 Targets for autoimmune diseases
Due to the fact that autoimmune disorders cover a plethora of diseases, it comes as
no surprise that research covers a wide range of approaches and therapeutic targets.
These approaches range from gene therapy to vaccines and a variety of cytokines.
Among these approaches, antibody therapy is most rapidly expanding, owing to the
favorable efficacy and safety profiles of these drugs and the better understanding of
the initial targets of altered immune regulation and activity in various diseases (Ros-
man et al., 2013). The major targets for antibody therapy in autoimmune diseases
can be divided in inflammatory cytokines, B-cells and co-stimulating molecules.
Anti-cytokines include anti-tumour necrosis factor antibodies (anti-TNF), used
to treat inflammatory conditions such as rheumatoid arthritis (RA), psoriatic arthri-
tis, juvenile arthritis, inflammatory bowel disease (Crohn’s and ulcerative colitis),
ankylosing spondylitis and psoriasis (Feldmann, 2002). In many cases these drugs
are able to reduce inflammation and stop disease progression. This effect can be
achieved with monoclonal antibodies such as Infliximab (Remicade®), Adalimumab
(Humira®), Certolizumab pegol (Cimzia®), and Golimumab (Simponi®) or fusion
proteins containing soluble TNF receptor such as Etanercept (Enbrel®).
Anti-BAFF antibody Belimumab (Benlysta®), previously known as LymphoStat-
B, is another drug addressing B-lymphocyte hyperactivity. It inhibits B-cell acti-
vating factor (BAFF) (Bossen and Schneider, 2006), also known as B-lymphocyte
stimulator (BLyS) (Kaveri et al., 2010) overexpressed in SLE. Belimumab binds to
BAFF, preventing BAFF from binding to B-cells. Without the survival factor BAFF,
B-cells get disrupted, and no longer contribute to the autoimmune damage of SLE.
Anti-interleukin-6 (IL-6) agents include drugs blocking this proinflammatory cy-
tokine. Tocilizumab (Actemra) is a humanized antibody directed against the IL-6
receptor and Siltuximab (Sylvant™) and Sirukumab are antibodies directed against
soluble IL-6 itself. Tocilizumab has been approved by the FDA in 2010 for rheuma-
toid arthritis and Sirukumab just entered into a Phase III clinical study for the
treatment of adults with moderately to severely active RA. Sirukumab is expected
to reduce the signs and symptoms of RA in patients with active RA who are refrac-
tory or intolerant to anti-TNFα agents (ClinicalTrials.gov Identifier: NCT01606761).
The Anti-interleukin-12 (IL-12) antibody ABT-874 just finished Phase III clini-
cal trials (ClinicalTrials.gov Identifier: NCT00570986) for psoriasis and Phase II tri-
als for Crohn’s disease (ClinicalTrials.gov Identifier: NCT00562887). ABT-874 has
previously been developed for the treatment of multiple sclerosis; however, by May
2007, development for this indication was discontinued (Ding et al., 2008).
An alternative approach to specifically inhibit B-cell activity in autoimmune dis-
eases is the depletion of B-cells using monoclonal antibodies recognising the surface
molecules CD19, CD20 and CD22. Compared to immunomodulation by cytokine
blockade this approach seems to be more specific. B-cell directed anti-CD20 an-
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tibodies such as Rituximab (chimeric), Obinutuzumab (humanized), Ofatumumab
(human), and Ocrelizumab (humanized) are established reagents in this field. Anti-
CD19 afucosylated human monoclonal antibody MEDI-551 is able to deplete all B-
cell subtypes from pro-B-cell stage to plasma cell (Herbst et al., 2010). Anti-CD22
antibody Epratuzumab depletes mature CD27+ B-cells. All of these antibodies show
potential not only in oncology, but also in treatment of inflammatory autoimmune
disorders (Ramos-Casals et al., 2012).
Other targets for autoimmune disorders are the cell adhesion molecules α4-integrin
and α1-integrin (CD11a). Natalizumab (Tysabri®) used for treatment of MS and
Crohn’s disease binds α4-integrin, which may heterodimerize with integrin β1 to
form α4β1 integrin (also known as VLA-4), or with integrin β7 to form α4β7 inte-
grin; both α4β1 and α4β7 are present on T- and B-cells and serve as attachment
ligands for VCAM (vascular cell adhesion molecules) on endothelial cells. Natali-
zumab prevents α4β1 binding to VCAM and α4β7 binding to mucosal addressin
cellular adhesion molecule-1 (MAdCAM-1) and thus prevents T-cell extravasation
into the brain or gut, respectively. Because both MS and Crohn’s disease feature
inflammatory T-cells as a significant part of the disease pathology, preventing ac-
cess of these cells to target organs should have substantial clinical effects (Kappos
et al., 2007; Major, 2010). Another humanized monoclonal antibody, Efalizumab
(Raptiva®) used in psoriasis patients, binds the α1 integrin molecule CD11a on T-
and B- cells, blocking attachment to the ICAM (intercellular adhesion molecules) on
endothelial cells and infiltration into the layers of the skin (Vugmeyster et al., 2004).
Unfortunately, despite therapeutic success patients treated with Natalizumab and
Efalizumab have a higher risk to develop progressive multifocal leukoencephalopathy
(PML) (Major, 2010). Due to the risk of PML, Efalizumab was withdrawn from the
market in 2009. Natalizumab was withdrawn from the market by its manufacturer
in 2004, but after a review of safety information and no further deaths, the drug
was re-approached for the US market in 2006.
1.3.3 Bispecific antibodies
Most therapeutic antibodies today are full length unconjugated IgG molecules. Thus,
they exert their activity via ADCC, CDC or by blocking molecules with unwanted
biological activity. Bispecific antibodies comprise two different binding specificities
fused to a single molecule. It opens up new opportunities for therapeutic applications
by redirecting potent effector systems to diseased areas or by increasing neutralizing
or stimulating activities of antibodies. Bispecific antibodies are thus able to improve
efficacy and selectivity of natural effector functions and to expand effector functions
to those not exerted by natural immunoglobulins (Fanger et al., 1992; Cao and
Suresh, 1998).
The concept of dual targeting with bispecific antibodies is based on the binding
of multiple disease-modifying molecules within one drug. In contrast to a combi-
nation of different therapeutic antibodies, bispecific antibodies make development
less complex because manufacturing, preclinical and clinical testing is reduced to a
single, bispecific molecule. Therapy with a single dual-targeting drug rather than
combinations should also be less complicated for patients (Kontermann, 2012).
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1.3.3.1 Generation of bispecific antibodies
The first chemically hybridized bispecific F(ab’)2 molecule was prepared by Brennan
et al. in 1985. They described the preparation of bispecific antibodies by chemical
combination of monoclonal IgG1 fragments (Brennan et al., 1985). To dissociate
reduced immunoglobulin half-molecules under mild conditions, they used pepsin hy-
drolysis method described by Nisonoff et al. (Nisonoff and Mandy, 1962). After
that, the authors reduced F(ab’)2 to F(ab’), stabilized them and fused different
specificities in one antibody molecule. In 1991 Jung et al. reported important sim-
plifications of the published procedures for the chemical generation of bispecific and
trispecific F(ab’)-hybrid fragments (Jung et al., 1991). They achieved reduction and
subsequent modification of purified F(ab’)2 fragments in one step without the need
to stabilize F(ab’) groups.
An alternative and more effective method for the generation of bispecific antibodies is
to generate cell lines constantly producing bispecific antibodies. Milstein and Cuello
in 1983 were the first in this field. They described hybrid hybridomas, producing
bispecific antibodies. When two myeloma cells producing monoclonal antibodies
are fused, the derived hybrids are capable of co-dominantly expressing the antibody
genes of both parents (Milstein and Cuello, 1983). However, this procedure produces
a mixture of hybrid antibodies with various assortments of chains, which must be
fractionated to yield the desired bispecific molecules.
The dominant production platform for antibody therapeutics nowadays relies on re-
combinant antibody technology capable of generating bispecific antibodies in various
formats (Jeong et al., 2011; Huston and George, 2001). Development of bispecific
antibodies for clinical applications have mainly focused on the retargeting of dif-
ferent effector cells of the immune system to tumour cells, although various other
therapeutic strategies have been evaluated. However, such antibodies differ from
the usual IgG structure of monoclonal antibodies and their development is therefore
challenging so that progress is only slow, as reflected by the fact that as yet only
two bispecific antibodies has been approved by the FDA. Developments in the field
of antibody engineering have resulted in new approaches to improve the efficacy and
safety of therapeutic antibodies. This had a substantial impact on the generation
of novel bispecific antibody formats and led to a progress in the field. More than 45
different bispecific formats have been established in the past two decades (Konter-
mann, 2012). Fig. 1.2 and table 1.2 summarise modern scaffolds used for generating
of bispecific antibodies. ScFv molecules, as an universal building block, are often
fused to the N-terminus or the C-terminus of the of the heavy or light chain of an
antibody. Generally this modification does not compromise productivity, although
issues regarding antigen-binding activity or stability and aggregation arise.
1.3.3.2 Mechanisms of action of bispecific antibodies
Engaging T-cells
Cytotoxic T lymphocytes (CTLs) are considered to be the most potent killer cells
of the immune system. Under physiological conditions, recognition and killing of a
target cell is a highly controlled process involving antigen-specific binding of the T-
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IgG2 F(ab’)2
IgG
IgG-ScFv
ScFv-IgG
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Figure 1.2: Selected bispecific antibody formats.
Black and grey are indicating different antibody specificities. Antibody constant domains
are shown in white ellipses (Adapted from (Kontermann, 2012)).
Table 1.2: Physiological properties of selected antibody formats
Summary of salient properties of intact antibodies, enzymatic fragments, recombinant
fragments and smaller scaffolds. Adapted from (Freise and Wu, 2015)
Format Composition MW Serum Clearance Reference
(kDa) t1/2 route
Intact IgG (VH +VL)2 150-160 1-3 weeks Hepatic (Ogasawara et al., 2013)
F(ab’)2 (VHCH1+VLCL)2 110 8-10 h Hepatic (Lu¨tje et al., 2014)
Minibody (scFv+CH3)2 75 5-10 h Hepatic (Tavare´ et al., 2014)
Fab VHCH1+VLCL 50-55 12-20 h Renal (Chakravarty et al., 2014)
Diabody (scFV)2 50 3-5 h Renal (Tavare´ et al., 2014)
scFv VH +VL 28 2-4 h Renal (Kim et al., 2014)
Nanobody VH (Camelid) 12-15 30-60min Renal (Bannas et al., 2014)
Affibody Z domain of 7 30-60min Renal (Strand et al., 2014)
protein A
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cell receptor to major histocompatibility complexes (MHCs) on target cells. In order
to be fully activated, CTLs need a second stimulus mainly provided by interaction
of membrane-bound CD80/CD86 molecules with CD28 on T lymphocytes during
the process of T-cell activation by antigen-presenting cells.
Bispecific antibodies used for the retargeting of CTLs have the advantage of bypas-
sing MHC-restricted target-cell recognition by CTLs, a process that is often inade-
quate due to downregulation or loss of MHC molecules on tumour cells (Buben´ık,
2003). Most bispecific antibodies developed for the retargeting of CTLs are directed
against CD3, which is a multi-subunit complex associated with the T-cell receptor
(TCR), but other trigger molecules such as CD2 or the TCR itself have also been
evaluated (Fanger et al., 1992). The first successful bispecific antibody Blinatu-
momab, approved by the FDA in 2014 for the treatment of acute lymphoblastic
leukemia (ALL), combines two binding sites: a CD3 site for T-cells and a CD19 site
for the target B-cells (Bargou et al., 2008).
Other studies have shown that binding of certain monoclonal antibodies to CD28 can
induce CTL-mediated cytotoxicity without the need for a first activation through
the TCR complex (Tacke et al., 1997). These supraagonistic antibodies bind to a
particular epitope (60–65 a.a.) on CD28 different from the region that interacts
with B7 (99–104 a.a.) (Lu¨hder et al., 2003). A nonsupraagonistic anti-CD28 an-
tibody was used to construct a bispecific tandem ScFv molecule directed against
the melanoma-associated glycoprotein (Grosse-Hovest et al., 2003). This antibody,
r28M, was able to induce efficient tumour cell killing in vitro and in vivo in a CD3-
independent way (Grosse-Hovest et al., 2005).
Engaging NK cells and Fc receptors
Another group of effector cells consists of those naturally recruited by binding to
Fc receptors. These include natural killer (NK) cells, monocytes/macrophages and
polymorphonuclear leukocytes (PMNs) (e. g. neutrophils). Consequently, bispecific
antibodies have been generated for the retargeting of these effector cells by binding
to Fc receptors such as FcγRI (CD64), FcγRIII (CD16), and FcαR (CD89).
Bispecific antibodies directed against Fc receptors are able to extend ADCC to
cells normally not or only inefficiently recruited by conventional antibodies, such
as PMNs or monocytes and macrophages. These cells are retargeted by binding to
CD89 or CD64, respectively, and eliminate target cells directly through cytotoxicity
or phagocytosis (Deo et al., 1998; Sundarapandiyan et al., 2001). In addition, since
some Fc receptors such as CD64 are also present on antigen-presenting cells, bispe-
cific antibodies can indirectly enhance antitumour immunity by increased antigen
presentation (van Spriel et al., 2000).
Both, CTLs and NK cells kill target cells by the perforin/granzyme pathways. The
granule exocytosis pathway utilizes perforin to traffic the granzymes to appropriate
locations in target cells, where they cleave critical substrates that initiate DNA frag-
mentation and apoptosis; granzymes A and B induce death via alternate, nonover-
lapping pathways. The CD95/CD95L system is responsible for activation-induced
cell death but also plays an important role in lymphocyte-mediated killing under
certain circumstances (Russell and Ley, 2002).
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1.4 Apoptosis and other types of cell death
Apoptosis is the most common form of eukaryotic cell death and occurs in embryo-
genesis, metamorphosis, tissue atrophy, and tumour regression (Wyllie et al., 1980).
It plays a central role for cell differentiation, removal of the damaged cells and the
homoeostasis of the immune system. Two major pathways leading to apoptosis are
now well established: the extrinsic pathway, that is mainly executed via death re-
ceptors on the cell surface promoting recruitment and activation of caspase-8 and
caspase-10 within membrane receptor complexes (Wilson et al., 2009), and the in-
trinsic pathway, which involves the activation of BH3-only proteins which promote
caspase activation by permeabilizing the mitochondrial outer membrane leading to
cytochrome c release and the formation of the Apaf-1/caspase-9 apoptosome (Na-
gata, 1999; Peter et al., 2007; Peter and Krammer, 2003; Strasser et al., 2009). In
both pathways (Fig. 1.3), activation of upstream initiator caspases (either caspase-8
or caspase-9) leads to a cascade of additional caspase activation events that collec-
tively dismantles the cell to produce the apoptotic phenotype (Martin et al., 2012;
Taylor et al., 2008).
Members of the caspase family of cysteine proteases target several hundred proteins
for restricted proteolysis leading to cell shrinkage, membrane blebbing, DNA frag-
mentation, chromatin condensation and, finally, cell destruction (Nicholson, 1999;
Creagh et al., 2003). Multiple membrane alterations, most notably the externaliza-
tion of phosphatidylserine, have been detected on apoptotic cells. These membrane
alterations trigger the terminal event of the demolition phase – the recognition and
consumption of the dead cell by phagocytes and perhaps the most important aspect
of the entire process (Fadok et al., 1992; Martin et al., 1995; Savill and Fadok, 2000).
Because apoptotic cells are typically recognised and engulfed by macrophages be-
fore leakage of their intracellular contents, they appear to be capable of attracting
the attention of such cells by secreting molecules with chemotactic properties such
as a chemoattractant lipid, lysophosphatidylcholine (Lauber et al., 2003) or S19 ri-
bosomal protein and aminoacyl-tRNA synthetases (Horino et al., 1998; Wakasugi
and Schimmel, 1999) that would not normally be present in the extracellular space.
Therefore, apart from limiting direct cell damage caused by the release of cytoplas-
mic contents, one of the main benefits of controlled cell death through apoptosis is
to prevent unwanted immune responses (Taylor et al., 2008).
Activation-induced cell death (AICD) belongs to apoptotic programmed cell
death caused by the interaction of Fas receptor (Fas, CD95) and Fas ligand (FasL,
CD95 ligand). It occurs as a result of repeated stimulation of specific T-cell recep-
tors (TCR) and it eliminates activated T-cells no longer needed after the immune
response to maintain the peripheral immune tolerance (Kabelitz and Janssen, 1997).
In T-cell dependent humoral responses, AICD of B-cells is known to be initiated
by Fas ligand on T-cells stimulating Fas receptor on B-cells (Figgett et al., 2013).
Therefore an alteration of the process may lead to autoimmune diseases (Zhang et al.,
2004). In conclusion: AICD is a negative regulator for activated lymphocytes.
Before the details of apoptotic cell death and signalling will be discussed more
thoroughly, it is worth to mention other types of regulated cell death.
Immunogenic cell death or immunogenic apoptosis is a form of cell death caused
by some cytostatic agents such as anthracyclines, oxaliplatin and bortezomib, or
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Figure 1.3: Schematic representation of the molecular pathways leading to
apoptosis
In the extrinsic pathway (a) upon ligand binding to specific receptors the DISC complex
is formed and caspase 8 activated. In the intrinsic pathway (b) release of cytochrome c
from the mitochondria result in the formation of the apoptosome and activation of caspase
9. Caspase 8 and 9 then activate downstream caspases such as caspase 3 resulting in cell
death. The two pathways are connected through the cleavage of the BH3-only protein Bid.
(Adapted from (Favaloro et al., 2012) and (Wehrli et al., 2000))
Abbreviations: DISC – death-inducing signalling complex, DD – death domain, FADD
– Fas-associated protein with death domain, DED – death effector domain, Bid –
BH3 interacting-domain, tBid – truncated Bid, Bcl-2 – B-cell lymphoma 2, Bax –
Bcl-2-associated X protein, Bak – Bcl-2 homologous antagonist/killer, Smac – second
mitochondria-derived activator of caspases,Omi – serine protease HtrA2,AIF – apoptosis-
inducing factor, Apaf-1 – Apoptotic protease activating factor 1.
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radiotherapy and photodynamic therapy. At the molecular level, it has been shown
that the immunological silhouette of these cell death pathways is defined by a set
of molecules called ’damage-associated molecular patterns (DAMPs)’ (Garg et al.,
2010). Unlike normal apoptosis, which is mostly nonimmunogenic or even tolero-
genic, immunogenic apoptosis of cancer cells can induce an effective antitumour
immune response through activation of dendritic cells (DCs) and consequently acti-
vation of specific T-cell response (Spisek and Dhodapkar, 2007).
Autophagy, sometimes referred to as Type II cell death, is the basic catabolic
mechanism that involves degradation of unnecessary or dysfunctional cellular com-
ponents through the actions of lysosomes (Lin et al., 2013). Autophagy allows the
degradation and recycling of cellular components (Lin et al., 2013). During this pro-
cess, targeted cytoplasmic constituents are isolated from the rest of the cell within a
double-membraned vesicle known as an autophagosome. The autophagosome then
fuses with a lysosome and its cargo is degraded and recycled (Patel et al., 2012).
There are three different forms of autophagy that are commonly described, namely
macroautophagy, microautophagy and chaperone-mediated autophagy (Peracchio
et al., 2012).
Necroptosis is a recently described regulated form of necrotic cell death. Necrotic
death is generally a result of an overwhelming cytotoxic insult, and requires no
specific molecular events in order to occur. However, in the last decade, a regulated
form of it has been characterized and termed necroptosis, because it shares features
of apoptosis and necrosis. Like apoptosis, a defined molecular cascade controls
necroptosis. Like necrosis, necroptosis is characterized by swelling of the cell and its
organelles leading to cell rupture. Rupture results in the release of cellular contents,
a number of which serve as damage-associated molecular patterns (DAMPs) such as
mitochondrial DNA (mtDNA), high mobility group protein B1 (HMGB1), IL-33, IL-
1α or S100 calcium-binding protein A9 (S100a9), which can potentiate inflammation
(Kaczmarek et al., 2013).
Pyroptosis was first described in 2001 (Cookson and Brennan, 2001). It is a
pro-inflammatory caspase 1-dependent programmed cell death, triggered by various
pathological stimuli, such as stroke, heart attack or cancer, and is crucial for con-
trolling microbial infections (for example, Salmonella, Francisella and Legionella)
(Bergsbaken et al., 2009). In this process, immune cells use a range of mecha-
nisms to sense intracellular and extracellular ‘danger’ signals generated by invading
pathogenic microorganisms or by the host in response to tissue injury (Matzinger,
2002). Toll-like receptors (TLRs) initiate a signalling cascade that leads to cellu-
lar activation and production of inflammatory cytokines, such as tumour necrosis
factor (TNF), IL-6, IL-8 and type I interferons (IFNs), in response to extracellular
signals (Kawai and Akira, 2007). Nod-like receptors (NLRs) function in the recog-
nition of danger signals introduced into the host cell cytosol (Kufer and Sansonetti,
2007). This leads to caspase 1-dependent pyroptosis and release of the inflamma-
tory cytokines IL-18 and IL-1β. The mechanism and outcome of this form of cell
death are distinctly different from these aspects of apoptosis, which actively inhibits
inflammation (Fink and Cookson, 2005).
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Figure 1.4: Death receptors and their respective ligands:
six human death receptors (CD95, CD120a, DR3, CD261, CD262, CD358), are known to
date. All are type I membrane proteins that contain two to four cysteine-rich extracellular
domains and a cytoplasmic sequence named ’death domain’ (DD). The known ligands for
these death receptors are shown. DR6 is at present an orphan receptor. Adapted from
(Wehrli et al., 2000)
1.4.1 Apoptosis receptors and their ligands
In many immune cells, and particularly in lymphocytes, cell death can be triggered
by the specific engagement of a subset of the tumor necrosis factor (TNF) receptor
family. The best characterized ligands of these receptors to date are soluble or
membrane-bound FasL and TNF-α. This form of cell death plays a critical role in
the deletion of auto-reactive immune cells to limit inflammatory responses (Lalaoui
et al., 2015).
However, FasL and TNF-α are not the only molecules responsible for triggering and
induction of apoptosis. In general, apoptosis can be induced through the activa-
tion of death receptors including CD95 (Fas, APO-1), CD120a (TNFR1, p55/p60
TNFR), TRAMP (WSL-1, APO-3, DR-3, LARDDR3), CD261 (TRAIL-R1, DR4)
and CD262 (TRAIL-R2, DR5, APO-2, TRICK-2, KILLER). These receptors are
activated by their respective ligands which belong to the TNF Superfamily (SF)
of cytokines, namely CD95L (FasL, APO-1L), TRAIL (APO-2L), TNF and TL1A
(Fig. 1.4).
All of the mentioned death receptors are type I membrane proteins that contain two
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to four cysteine-rich extracellular domains and a cytoplasmic sequence named ’death
domain’. Death receptor ligands usually initiate signalling via receptor oligomeri-
sation, which in turn results in the recruitment of specialized adaptor proteins and
activation of caspase cascades. For DR6 (also known as TNFRSF21), the sixth DD-
containing receptor, a specific amino-terminal cleavage fragment of the β-amyloid
precursor protein (APP), N-APP, was recently described as a ligand. No ligand for
DR6 belonging to the TNF SF has been identified, at least so far, and caspase-8
does not seem to be involved in this signalling (Nikolaev et al., 2009).
1.4.2 The CD95 death receptor
In 1989, Trauth et al. described the discovery of an apoptosis inducing receptor.
They named this receptor APO-1, anticipating that it might be the first of a series
receptors of this kind (Trauth et al., 1989). At the same time Yonehara et al.
described a cell surface molecule, termed Fas, that could be triggered to induce
apoptosis by an agonistic monoclonal antibody (Yonehara et al., 1989). Sequencing
and cloning of the APO-1/Fas proteins and cDNAs, respectively, showed that APO-1
and Fas were identical (Itoh et al., 1991; Oehm et al., 1992). Later the 5th Workshop
on Leukocyte Typing (Schlossman, 1995) suggested the name CD95 for this receptor.
The significance of CD95 mediated apoptosis was shown in experiments with mice
which carried mutations in the genes encoding either for CD95 receptor or for CD95
ligand. These animals developed massive lymphadenopathy and lymphoproliferative
syndromes (Watanabe-Fukunaga et al., 1992; Takahashi et al., 1994; Rieux-Laucat
et al., 2003). CD95 messenger RNA (mRNA) is expressed in the thymus, heart, lung
and ovary (Watanabe-Fukunaga et al., 1992). CD95 receptor is also very important
in the liver. It is expressed in the developing (French et al., 1996) and mature
liver tissue (Leithauser et al., 1993). A physiological role of CD95 in maintaining
liver homeostasis has been suggested since mice deficient in CD95 develop increased
cellularity and substantial liver hyperplasia (Adachi et al., 1995).
CD95/Apo-1/Fas is a transmembrane molecule and a member of the TNF/nerve
growth factor receptor superfamily and serves as the prototypic death receptor in and
outside the immune system. CD95-dependent apoptosis is triggered by the CD95
ligand (CD95L) which induces clustering of surface CD95 (Fig. 1.5 a). Oligomeri-
sation initiates the recruitment of the ‘CD95 (Fas) associated protein with death
domain’ (FADD) and procaspase-8 to form the ‘death-inducing signaling complex’
(DISC). Procaspase-8 undergoes autocatalytic cleavage in the DISC resulting in the
generation of active caspase-8, which dissociates from the DISC to proceed with the
activation of the caspase cascade that leads to apoptotic cell death (Krammer et al.,
2007; Strasser et al., 2009).
1.4.3 Ambivalence of CD95-mediated apoptosis
In case of cancer cells, the function of CD95 is ambivalent. It was found that
most malignant cells express CD95 receptor, but appear to be refractory to CD95-
induced cell death. Undermining the immune system and suppressing the anti-
tumour response are essential events during oncogenesis allowing tumour formation
(Hanahan and Weinberg, 2011). In this context, the CD95/CD95L system can
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Figure 1.5: The simplified CD95 signaling pathway
a) Apoptosis and programmed necrosis. Upon binding of the trimerized CD95L, FADD is
recruited to the DD of CD95. Procaspase-8 subsequently binds FADD through its DED
to form the DISC, which is inhibited in the presence of FLIP. DISC formation prevents
RIPK activation and programmed necrosis. Autoproteolytic cleavage of procaspase-8 at
the DISC leads to apoptosis, whereas procaspase-8 phosphorylation leads to ERK acti-
vation. Active caspase-8 cleaves caspase-3, which is inhibited in the presence of IAP. b)
Nonapoptotic pathways. Activation of CD95 (or cross-activation through RTKs or inte-
grins) leads to the phosphorylation of the DD through SFKs. The phosphorylated DD can
serve as a docking site for SH2 adaptors, including the p85 subunit (not shown) of PI3K.
PI3K-dependent activation of AKT, which is inhibited by PTEN, induces migration and
survival. PI3K might also lead to ERK activation in a Ras-dependent or -independent
manner. CD95 also leads NFB activation, probably through RIPK, and to JNK activa-
tion through a yet unknown mechanism ultimately increasing proliferation (Adapted from
(Tang et al., 2011) and (Martin-Villalba et al., 2013)).
Abbreviations: CD95L - CD95Ligand; FADD - Fas-associated protein with death do-
main; FLIP - FLICE-like inhibitory protein; IAP - inhibitor of apoptosis , RIPK -
receptor-interacting protein kinase; ERK - extracellular signal-regulated kinase; NFκB
- nuclear factor κB; JNK - c-jun N-terminal kinase; PTEN - phosphatase and tensin
homolog; P - phosphotyrosine; PI3K - phosphoinositide 3-kinase; PIP2 - phosphatidyli-
nositol 4,5-bisphosphate; PIP3 - phosphatidylinositol (3,4,5)-trisphosphate; SH2 - src
homology domain 2; SFK - src-family kinase; RAS - rat sarcoma; RTK - receptor tyro-
sine kinase.
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elicit both tumourigenic and tumour suppressing roles in the pathogenesis of cancer
(Ehrenschwender and Wajant, 2009).
The molecular mechanisms mediating CD95-resistance are complex and involve both
post-receptorial and pre-receptorial events (Inaba et al., 1999). Post-receptorial
resistance mechanisms are known to include expression of truncated CD95 receptor
lacking the intracytoplasmic signaling domain (Cascino et al., 1996), over-expression
of bcl-2 (Itoh et al., 1993) and bcl-XL proteins (Boise et al., 1995), expression of
caspase regulators such as FLICE-like inhibitory protein (FLIP) (Irmler et al., 1997)
and inhibitor of apoptosis proteins (IAP) (Deveraux et al., 1998; Inaba et al., 1999)
(See Fig. 1.5 a). Pre-receptorial resistance can be mediated by the soluble CD95
(sCD95) protein, which antagonizes both anti-CD95 antibody and CD95L killing in
a dose-dependent manner (Cheng et al., 1994; Papoff et al., 1996). sCD95 was found
to be elevated in the serum from patients with B- and T-cell leukaemias (Knipping
et al., 1995) and nonhaematopoietic malignancies such as melanoma, breast cancer,
and colon cancer (Midis et al., 1996). In addition to the full-length CD95 mRNA,
those cells expresses alternatively spliced mRNA variants coding for sCD95 proteins
(Cheng et al., 1994). To date, eight mRNA variants of CD95 receptor have been
described, which are translated into seven isoforms of the protein. Another example
of pre-receptorial resistance the downregulation/loss of CD95 expression has been
found in a variety of malignancies (e.g., pulmonary adenocarcinomas, esophageal
cancer, melanoma) (Leithauser et al., 1993; Hahne et al., 1996; Shin et al., 1999).
Work by Marcus Peter’s laboratory using cells from breast, ovary, skin, lung, and
kidney tumours showed that not only apoptotic signaling is blocked and that CD95
activation increases motility and invasion (Martin-Villalba et al., 2013; Barnhart
et al., 2004). There is evidence that, in addition to inducing cell death, in at least
some cell lines CD95 can mediate other activation signals, including increased pro-
liferation in human T-cells (Alderson et al., 1993) and fibroblasts (Aggarwal et al.,
1995).
Collectively, these observations indicate that CD95-mediated signaling is not limited
to the induction of cell death. Indeed, there are CD95-dependant pathways respon-
sible for survival, migration and proliferation (Fig. 1.5 b) and the regulation of this
pathway is still not completely clear.
1.4.4 Therapeutic stimulation of CD95 death receptor
Despite the dichotomy described above, the use of programmed cell death for clinical
purpose e.g. against cancer is being discussed as attractive therapeutic option since
development of agonistic antibodies against the CD95 receptor in 1989 (Trauth
et al., 1989; Yonehara et al., 1989). First it was shown that single i.v. injection of
agonistic mouse anti-human CD95 antibodies (IgG3) into nu/nu mice carrying a
xenotransplant of human B-cell tumour induced regression of this tumour (Trauth
et al., 1989). However, the therapeutic use of anti-CD95 antibodies is precarious,
since this receptor is expressed also on normal cells, in particular hepatocytes. In
principle, there are two fundamental problems of using CD95 antibodies: a specificity
and a sensitivity problem:
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Figure 1.6: Bispecific antibodies
directed to two different antigens on the same cell may bind in a monocellular (a) or
bicellular (b) way. Mutual cross-linking of both antigens induces apoptosis if the antibody
binds in bi-cellular way. Bystander lysis (c) may occur in the presence of target cells if
the bystander cell carries CD95 but not the target antigen.
(Adapted from (Herrmann et al., 2008))
• A systemically application of hamster anti-mouse CD95 antibody (clone JO2,
IgG2λ) induces apoptosis of hepatocytes and an acute hepatic failure in nor-
mal mice (constitutes the specificity problem) (Ogasawara et al., 1993).
• Primary tumour cells are often refractory to CD95 stimulation. The reason
may be the absence of CD95 expression or defective receptor-associated sig-
nalling (constitutes the sensitivity problem) (Hammond et al., 2007).
With respect to the solution of the specificity problem, it was shown that bispecific
TA×CD95 antibodies (against Target Antigen and CD95) induce apoptosis selec-
tively on antigen positive tumour cells (Wajant, 2006; Jung et al., 2001). Fig. 1.6
illustrates possible binding mechanisms of bispecific antibody in mono- (a) or bi-
cellular (b) way. Effective crosslinking of CD95 on the cell surface requires trans
engagement of CD95 and the target antigen (bicellular binding) (Herrmann et al.,
2008) and thus bystander killing of cells not expressing the target antigen may occur,
but only in the vicinity of target antigen and CD95 expressing cells Fig. 1.6 b.
Target cell restricted CD95 activation as outlined above solves the specificity but
not the sensitivity problem: many tumour cells have lost their susceptibility to
CD95-mediated cell death either by down-regulation of CD95 or by regulation of
proapoptotic and antiapoptotic intracellular proteins towards resistance (Bullani
et al., 2002; Xerri et al., 1998). This problem is now well recognised and numerous
compounds have been described which are capable of enhancing the susceptibility
of tumour cells towards apoptotic cell death. The presence of sensitizing reagents
such as cycloheximide and various cytostatic drugs could enhance CD95-mediated
killing of the tumour cells (Herrmann et al., 2008).
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1.5 The objectives of the thesis
Whereas chemically hybridized bispecific F(ab’)2-fragments targeting CD20 and the
death receptor CD95 were already shown to selectively kill B-cell lymphoma cells
carrying both antigens (Jung et al., 2001), the main goal of this work was to develop
recombinant bispecific CD95×CD20 antibodies. They should be able to trigger apop-
tosis specifically on malignant B-cells as well as on normal activated B-cells carrying
CD20 and CD95 on their surface. These therapeutic agents should be suitable for
production and purification from eukaryotic cell cultures in pharmaceutical quality
and quantity.
The therapeutic effect of these recombinant molecules on malignant and normal ac-
tivated B-cells should be compared to monospecific clinically established anti-CD20
antibodies. These antibodies include parental monospecific CD20 antibody 2H7
(used for the generation of commercial antibody Ocrelizumab) and FDA-approved
anti-CD20 antibody Rituximab widely used for lymphoma therapy as well as for
the treatment of some autoimmune diseases. Additionally, recombinant bispecific
CD95×CD20 should be compared to the improved monospecific “third generation”
therapeutic antibodies against CD20 that are carrying optimisation in antibody Fc-
part for enhancement of the therapeutic efficacy.
In the second part of this work a concept for bispecific CD95×Ag fusion proteins
able to trigger apoptosis specifically on antigen-specific B-cells should be developed.
For the proof of principle antigen fragments from Tetanus (TT) and Diphtheria
(DT) toxoids (as a control) were coupled to CD95 antibodies to check whether those
proteins are able to deplete Tetanus specific B-cells in PBMC cultures from freshly
immunized donors.
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2.1 Materials
2.1.1 Instruments
A¨KTAprime chromatography system Amersham Biosciences AB, Uppsala, Swe-
den
A¨KTApure chromatography system GE Healthcare Bio-Scieces, Uppsala, Swe-
den
Balance PT600 Sartorius AG, Go¨ttingen
Biosafety cabinet Technoflow 3F150-IIGS Integra Biosciences Deutschland GmbH,
Fernwald
Cell-harvester Inotech Biosystems International, Inc.,
Rockville, USA
Centrifuge Heraeus Biofuge fresco Thermo Electron Corporation, Waltham,
USA
Centrifuge Heraeus Megafuge 1.0 Thermo Electron Corporation, Waltham,
USA
Centrifuge Sorvall RC5C Plus Thermo Fisher Scientific, Inc., Schwerte
CO2 incubator BINDER GmbH, Tuttlingen
Diaphragm vacuum pump type MD 4C Vacuubrand GmbH & Co.KG, Wertheim
Dionex™ UltiMate™ 3000 BioRS system Thermo Fisher Scientific, Inc., Germering
Elektrophoresis Power Supply EPS 600 &
3500
Pharmacia LKB Biotechnology, Uppsala,
Sweden
ELISA reader Spectra Max 340 Molecular devices, LLC., Sunnyvale, USA
FACS Calibur flow cytometer BD Biosciences, Heidelberg
FACS Canto™ II flow cytometer BD Biosciences, Heidelberg
FPLC system Pharmacia LKB Biotechnology, Uppsala,
Sweden
Freezer (-80°) E 80-450 S Colora Messtechnik GmbH, Lorch
Heating bath circulator Julabo 19 Julabo Labortechnik GmbH & Co.KG,
Staufen
Incubated Shaker Multitron Infors AG, Bottmingen, Switzerland
Magnetic stirrer RTC Basic IKA®-Werke GmbH & Co.KG, Staufen
Microplate counter 2450 MicroBeta2™ PerkinElmer, Inc., Rodgau
Microscope Axiovert 25 Carl Zeiss AG, Oberkochen
Microwave oven Super Crousty 1100W Krups GmbH, Offenbach
Multichannel Pipette DV12-200C Abimed GmbH, Langenfeld
Nanodrop™ 1000 spectrophotometer Thermo Fisher Scientific, Inc., Schwerte
pH electrode InLab Expert Pro Mettler Toledo GmbH, Albstadt
Refrigerator Liebherr Premium Liebherr Hausgera¨te Ochsenhausen
GmbH, Ochsenhausen
Peristaltic pump P-1 Pharmacia LKB Biotechnology, Uppsala,
Sweden
Platform shaker Duomax 1030 Heidolph Instruments GmbH & Co.KG,
Schwabach
Pipetboy acu Integra Biosciences Deutschland GmbH,
Fernwald
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PIPETMAN® Pipettes P10, P20, P200,
P1000
Gilson, Inc., Middleton, USA
SMART® System Pharmacia Biotech AB, Uppsala, Sweden
Thermocycler PTC-100 MJ Research, Inc., St. Bruno, Canada
Thriller Thermoshaker Incubator PEQLAB Biotechnologie GmbH, Erlan-
gen
UV Transilluminator FLX-20M and TFX-
20M
Vilber Lourmat Deutschland GmbH,
Eberhardzell
Vortex mixer VF2 IKA®-Werke GmbH & Co.KG, Staufen
2.1.2 Plastic and glass supply
15mL polystyrene conical tubes BD Biosciences, Heidelberg
50mL polypropylene conical tubes Greiner Bio One International GmbH,
Frickenhausen
Amicon Ultra-4 Centrifugal Filter Units
MWCO 10 kDa and 30 kDa
Merck Millipore Corporation, Schwalbach
Beakers (Duran® glass) Schott AG, Mainz
Beakers (plastic) Vitlab GmbH, Grossostheim
Bottletop Filter (0.22µm) Merck Millipore Corporation, Schwalbach
Broome style mouse restrainer Kent Scientific Corporation, Torrington,
USA
Chromacol™ Amber Glass Crimp/Snap
Top Vials (03-FIRV(A))
Thermo Fisher Scientific, Inc., Schwerte
Chromacol™ Cap snap cap polyethylene
11mm
Thermo Fisher Scientific, Inc., Schwerte
Cell culture multiwell plates (6, 24, 96 well
Format)
Greiner Bio One International GmbH,
Frickenhausen
Cell Culture Treated TripleFlasks™ Nunc™, Thermo Fisher Scientific, Inc.,
Denmark
Cellstar® Cell Culture Flasks (25 cm2,
75 cm2 and 175 cm2)
Greiner Bio One International GmbH,
Frickenhausen
Centrifuge bottles 250mL nalgene™ Thermo Fisher Scientific, Inc., Schwerte
Combitips Eppendorf AG, Hamburg
Cryovials Greiner Bio One International GmbH,
Frickenhausen
Dialysis tubing visking, cellulose type
27/32 & 8/32 inch, MWCO 14 kDa
Carl Roth GmbH+Co.KG, Karlsruhe
Electroporation cuvettes (4mm electrode
gap)
PEQLAB Biotechnologie, Erlangen
ELISA plates (Maxisorp) Nunc™ & Thermo Fisher Scientific, Inc.,
Langenselbold
Eppendorf tubes (0.5mL, 1.5mL, 2mL) Eppendorf AG, Hamburg
Erlenmeyer Flasks Schott AG, Mainz
Erlenmeyer shape Duran® filtering flask
with KECK™ assembly set
Schott AG, Mainz
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FACS tubes 0.5mL 38mm×6.5mm
polystyrene
Sarstedt AG & Co., Nu¨rmbrecht
FACS tubes 5mL, 12mm×75mm
polystyrene
BD Biosciences, Heidelberg
Filtermate A, printed PerkinElmer, Inc., Rodgau
Glass bottles Duran® (0.5 L, 1 L, 2 L) Schott AG, Mainz
Measuring cylinders (Duran® glass) Schott AG, Mainz
Millex® Syringe-driven Filter unit
(0,22µm)
Merck Millipore Corporation, Schwalbach
Nalgene™ Cryo 1° Freezing Container Thermo Fisher Scientific, Inc., Schwerte
Needles 27G×1/2 in. BD Biosciences, Heidelberg
Neubauer cell counting chamber Brand GmbH & Co., Weinheim
Pasteur Pipettes (Long size) Ulbrich Wilhelm GdbR, Bamberg
PCR Softtubes 0.5mL Biozym Scientific GmbH, Hessisch Olden-
dorf
Petri dishes Greiner Bio One International GmbH,
Frickenhausen
Pipette tips (10µL, 200µL, 1000µL) Starlab GmbH, Hamburg
Pipette tips with plug barrier SafeSeal-
Tips
Biozym Scientific, Hessisch Oldendorf
Safety-Multifly® Needles 21G×3/4 in. Sarstedt AG & Co., Nu¨rmbrecht
Serological pipets, BD Falcon™
polystyrene (2mL, 5mL, 10mL, 25mL)
BD Biosciences, Heidelberg
Serological pipets Costar (50mL) Corning Incorporated, Amsterdam,
Netherlands
Syringes BD Luer-Lok™ (5mL, 20mL,
50mL)
BD Biosciences, Heidelberg
Syringe SubQ 1mL BD Biosciences, Heidelberg
2.1.3 Chemicals and reagents
Acetic acid Carl Roth GmbH & Co.KG, Karlsruhe
Agarose NEEO Ultra Carl Roth GmbH & Co.KG, Karlsruhe
Ampicillin Carl Roth GmbH & Co.KG, Karlsruhe
Ampuwa water Fresenius Kabi GmbH & Co.KG, Bad
Homburg
β-mercaptoethanol Carl Roth GmbH & Co.KG, Karlsruhe
Bacto Agar Becton Dickinson GmbH, Heidelberg
Bacto yeast extract Becton Dickinson GmbH, Heidelberg
Bacto tryptone Becton Dickinson GmbH, Heidelberg
Bovine serum albumin (BSA) Carl Roth GmbH & Co.KG, Karlsruhe
Calcium chloride Sigma-Aldrich Chemie, Steinheim
Chloroform Merck KGaA, Darmstadt
Diethyl ether Merck KGaA, Darmstadt
Dimethyl sulfoxide (DMSO) Merck KGaA, Darmstadt
Disodium phosphate Merck KGaA, Darmstadt
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Disposable PD-10 Desalting Columns GE Healthcare Bio-Scieces, Uppsala, Swe-
den
DTNB (5,5’-Dithiobis (2-nitrobenzoic
acid))
Sigma-Aldrich Chemie, Steinheim
DTT (1,4-dithiothreitol) Sigma-Aldrich Chemie, Steinheim
Dulbecco’s Phosphate Buffered Saline
(DPBS) 10×
Bio Whittaker Lonza, Verviers, Belgium
Diphtheria toxin[Glu52] Sigma-Aldrich Chemie GmbH, Steinheim
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich Chemie GmbH, Steinheim
Ethanol Merck KGaA, Darmstadt
Ethidium bromide Carl Roth GmbH & Co.KG, Karlsruhe
G418 Biochrom AG, Berlin
Glycine Carl Roth GmbH & Co.KG, Karlsruhe
Glycerol Carl Roth GmbH & Co.KG, Karlsruhe
HiLoad™ 16/60 Superdex™ 200 prep grade
column
GE Healthcare Bio-Scieces, Uppsala, Swe-
den
Hydrochloric acid Merck KGaA, Darmstadt
Kanamycin sulfate Carl Roth GmbH & Co.KG, Karlsruhe
KappaSelect 1mL HiTrap column GE Healthcare Bio-Scieces, Uppsala, Swe-
den
KappaSelect Sepharose GE Healthcare Bio-Scieces, Uppsala, Swe-
den
Magnesium chloride Merck KGaA, Darmstadt
Manganese(II) chloride Sigma-Aldrich Chemie GmbH, Steinheim
Methanol Merck KGaA, Darmstadt
Mini-PROTEAN® TGX™ Precast Gels Bio-Rad Laboratories GmbH, Mu¨nchen
MOPS (3-(N-morpholino)propanesulfonic
acid)
Carl Roth GmbH & Co.KG, Karlsruhe
Phosphoric acid Merck KGaA, Darmstadt
Phenol/Chloroform/Isoamylalkohol
(25/24/1)
Carl Roth GmbH & Co.KG, Karlsruhe
Pokeweed mitogen (PWM) Sigma-Aldrich Chemie GmbH, Steinheim
Potassium chloride Merck KGaA, Darmstadt
Potassium acetate Merck KGaA, Darmstadt
Protein A Sepharose GE Healthcare Bio-Scieces, Uppsala, Swe-
den
Protein L, biotinylated Thermo Fisher Scientific, Inc., Schwerte
Sodium acetate Carl Roth GmbH & Co.KG, Karlsruhe
Sodium azide Merck KGaA, Darmstadt
Sodium Dihydrogen Phosphate Monohy-
drate
Merck KGaA, Darmstadt
Streptavidin-polyHRP (horseradish perox-
idase)
Immunotools, Friesoythe
Superdex 200™ increase 10/300 GL co-
lumn
GE Healthcare Bio-Scieces, Uppsala, Swe-
den
Superdex 200 PC3.2/30 column GE Healthcare Bio-Scieces, Uppsala, Swe-
den
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Tetagam P CSL Behring GmbH, Marburg
Tetanus toxoid purified Statens serum institute, Copenhagen,
Denmark
Tetanus toxoid Astarte biologics,Bothell, USA
Thymidine, [Methyl-3H] Hartman analytic GmbH, Braunschweig
TMB Microwell Peroxidase Substrate sys-
tem (2-C)
KPL Inc., Gaithersburg, USA
Tris-Base Sigma-Aldrich Chemie GmbH, Steinheim
Tris-HCl Sigma-Aldrich Chemie GmbH, Steinheim
Trypan blue Sigma-Aldrich Chemie GmbH, Steinheim
Tween-20 Merck KGaA, Darmstadt
Ultima Gold™ PerkinElmer, Rodgau
2.1.4 Enzymes
Calf Intestinal phosphatase (CIP) New England Biolabs GmbH, Frankfurt
Pepsin (from porcine gastric mucosa) Merck KGaA, Darmstadt
Restriction endonucleases New England Biolabs GmbH, Frankfurt
or Thermo Fisher Scientific, Inc., Vilnius,
Lithuania
T4 DNA Ligase Thermo Fisher Scientific, Inc., Vilnius,
Lithuania
2.1.5 Markers and DNA ladders
1 kb Plus DNA Ladder New England Biolabs GmbH, Frankfurt
100 bpDNA Ladder New England Biolabs GmbH, Frankfurt
PageRuler® Prestained Protein Ladder,
10 to 180 kDa
Thermo scientific, Vilnius, Lithuania
2.1.6 Solutions and buffers
2.1.6.1 Commercial solutions for cell culture
Dulbecco’s Phosphate buffered saline
(DPBS)
Lonza Group Ltd, Basel, CH
Fetal calf serum (FCS) Biochrom AG, Berlin
Iscove’s Modified Dulbecco’s Medium
(IMDM)
Lonza Group Ltd, Basel, CH
L-Glutamine (100x) Lonza Group Ltd, Basel, CH
LSM1077 Lymphocyte PAA Laboratories GmbH, Pasching, Aus-
tria
MEM non-essential amino acids (100x) PAA Laboratories GmbH, Pasching, Aus-
tria
Sodium pyruvate (100mM) PAA Laboratories GmbH, Pasching, Aus-
tria
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Penicillin-Streptomycin Solution (100x) PAA Laboratories GmbH, Pasching, Aus-
tria
RPMI 1640 medium Lonza Group Ltd, Basel, CH
Trypan-Blue-Solution Sigma-Aldrich Chemie GmbH, Steinheim
Accutase® solution Sigma-Aldrich Chemie GmbH, Steinheim
Panexin NTS PAN-Biotech GmbH, Aidenbach
2.1.6.2 Media for cell culture
Freezing medium 90% (v/v) FCS
10% (v/v) DMSO
IMDM Complete medium IMDM medium
10% (v/v) FCS
L-Glutamine (1x)
MEM non-essential amino acids (1x)
Sodium pyruvate (1mM)
Penicillin (100U/mL)
Streptomycin (100µg/mL)
50µM β-mercaptoethanol
IMDM Pan medium IMDM medium
10% (v/v) PANEXIN NTS
L-Glutamine (1x)
MEM non-essential amino acids (1x)
Sodium pyruvate (1mM)
Penicillin (100U/mL)
Streptomycin (100µg/mL)
50µM β-mercaptoethanol
RPMI 1640 Complete medium RPMI 1640Medium
10% (v/v) FCS
L-Glutamine (1x)
MEM non-essential amino acids (1x)
Sodium pyruvate (1mM)
Penicillin (100U/mL)
Streptomycin (100µg/mL)
50µM β-mercaptoethanol
2.1.6.3 Chromatography buffers
Acetate buffer pH4 0.06M Sodium acetate
0.07M Acetic acid
0.1M NaCl
pH adjusted with 37%HCl
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0.1M Glycine/0.1M Citrate-Buffer 0.05M Trisodium citrate dihydrate
pH2.4 and pH4.2 0.05M Citric acid
0.1M Glycine
0.15M NaCl
in ddH2O
pH adjusted with HCl
0.1M Glycine-Buffer 0.1M Glycine
pH2.3 in ddH2O
pH2.3 adjusted with HCl
0.1M Phosphate-Buffer pH7.2-7.3 0.07M Disodium phosphate
0.03M Sodium Dihydrogen Phosphate
Monohydrate
0.1M NaCl
in ddH2O
pH7.2-7.3 adjusted with NaOH
0.01 M NaOH 1% (v/v) 1M NaOH buffer
in ddH2O
20% ethanol 20% (v/v) of 100% ethanol
in ddH2O
2.1.6.4 Buffers for SDS-PAGE
10x Tris/Glycine/SDS Buffer Bio-Rad Laboratories GmbH, Mu¨nchen
Laemmli Sample Buffer Bio-Rad Laboratories GmbH, Mu¨nchen
Roti®-Blue 5x colloidal coomassie stain-
ing solution
Carl Roth GmbH & Co. KG, Karlsruhe
2.1.6.5 Buffers for flow cytometry
7-AAD Viability staining solution BioLegend GmbH, Fell
FACS-Buffer DPBS
0.02% (w/v) Sodium azide
1% (v/v) FCS
2.1.6.6 Buffers for ELISA
Blocking buffer 10% (v/v) BSA
in ddH2O
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Wash buffer 0,05% Tween-20
in DPBS
Stop solution 1M Phosphoric acid (H3PO4)
2.1.6.7 Buffers and chemicals for molecular biology
Ampicillin stock solution (100mg/m)] Ampicillin in ddH2O
Kanamycin stock solution (100mg/mL) Kanamycin in ddH2O
dNTP-stock solution (10mM) dATP, dCTP, dGTP, dTTP (each 10mM)
in ddH2O
Gel Loading Dye, Purple (6 x) New England Biolabs GmbH, Frankfurt
LB-Medium 10 g Bacto-tryptone
5 g Bacto-yeast extract
5 g NaCl
ad 1L ddH2O pH7
LB-Plates 10 g Bacto-tryptone
5 g Bacto-yeast extract
5 g NaCl
15 g Bacto-Agar
ad 1L ddH2O
LB-Amp-Plates 10 g Bacto-tryptone
5 g Bacto-yeast extract
5 g NaCl
15 g Bacto-Agar
ad 1L ddH2O pH7
1mL ampicillin stock solution
LB-Kan-Plates 10 g Bacto-tryptone
5 g Bacto-yeast extract
5 g NaCl
15 g Bacto-Agar
ad 1L ddH2O pH7
1mL kanamycin stock solution
TAE-Puffer 40mM Tris-Base
20mM acetic acid
1mM EDTA
in ddH2O
TfbI 30mM potassium acetate
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50mM MnCl2
100mM KCl
10mM CaCl2
15% (w/v) Glycerine
adjusted with 0.2M acetic acid to pH5.8
sterile-filtered
TfbII 10mM MOPS pH7
75mM CaCl2
10mM KCl
15% (w/v) Glycerol
sterile-filtered
2.1.7 Cell lines and bacteria strains
All cell lines in this work used are listed in the table 2.13.
Table 2.13: Cell lines
Name Cell type, reference Source
SP2/0 Ag14 mouse myeloma, LGC Standards GmbH, Wesel
(Shulman et al., 1978)
Jurkat human acute T-cell-leukemia cell line D. Schendel, Mu¨nchen
(Schneider et al., 1977)
Daudi human Burkitt’s Lymphoma cell line P. Fisch, Freiburg
(Klein et al., 1968)
SKW6.4 human B lymphoblast cell line P.Krammer, Heidelberg
(Saiki and Ralph, 1983)
C1R-B7 human B lymphoblast cell line W.Walter, Mainz
(Storkus et al., 1989)
Raji human Burkitt’s lymphoma cell line European Collection of Cell Cultures (ECACC)
(Pulvertaft, 1964)
JY human B lymphoblastoid cell line European Collection of Cell Cultures (ECACC)
(Swaroop and Xu, 1993)
SK-Mel-63 human malignant melanoma B. Gu¨ckel, Tu¨bingen
(Fogh et al., 1977)
Bacteria strain E.coli DH5-α used in this work was purchased from MBI Fermentas,
St. Leon Rot
Genotype:
F−(Φ80d∆(lacZ)M15)recA1 endA1 gyrA96 thi-1hsdR17(r−κm
+
κ) supE44 relA1 deoR ∆(lacZYA-
argF)U169
2.1.8 Antibodies
Monoclonal and polyclonal antibodies listed in the tables 2.14 and 2.15 were used
for analytical methods (flow cytometry, ELISA and Western-blot) and for functional
immunobiological assays.
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Table 2.14: Unconjugated antibodies
Name Special feature Specificity Isotype Species Source
2H7 human CD20 Igγ1/κ Mouse BioLegend GmbH, Fell
2H7 korr human CD20 Igγ1/κ Chim. mouse/human Ab N.Teichweyde, Tu¨bingen
2H7 SDIE SDIE opt. human CD20 Igγ1/κ Chim. mouse/human Ab L.Grosse-Hovest, Tu¨bingen
anti-Tetanus Hc Rabbit serum C fragment of Tetanus toxin polyclonal Rabbit Novus Biologicals, Littleton, USA
anti-Diphtheria Rabbit serum Diphtheria toxin polyclonal Rabbit Abcam, Cambridge, UK
APO-1 human CD95 Igγ2a/κ Mouse P.Krammer, Heidelberg
APO-1 hum human CD95 Igγ2a/κ Chim. mouse/human Ab L.Grosse-Hovest, Tu¨bingen
EGFR human EGFR Igγ1/κ Chim. mouse/human Ab L.Grosse-Hovest, Tu¨bingen
EGFR SDIE SDIE opt. human EGFR Igγ1/κ Chim. mouse/human Ab E.Pyz, Tu¨bingen
Flebogamma human Ab polyclonal Igγ Human Grifols international S.A.
Goat anti-mouse Igγ mouse Igγ polyclonal Goat Dianova GmbH, Hamburg
Goat anti-human Igγ human Igγ polyclonal Goat Dianova GmbH, Hamburg
Rituximab human CD20 Igγ1/κ Chim. mouse/human Ab Hoffmann-La Roche AG, Basel
UCHT-1 human CD3 Igγ1/κ Chim. mouse/human Ab L.Grosse-Hovest, Tu¨bingen
χ9.2.27-DE human CSPG4 Igγ1/κ Chim. mouse/human Ab L.Grosse-Hovest, Tu¨bingen
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Table 2.15: Conjugated antibodies
Name Conjugation Specificity Isotype, Fragment Species Source
anti-Mouse Igγ RPE Mouse Igγ polyclonal Goat Dianova GmbH, Hamburg
Fc-RPE Fc specific F(ab’)2-Fragment
anti-Mouse Igγ + Igµ (H+L) RPE Mouse Igγ und Igµ polyclonal Goat Dianova GmbH, Hamburg
-RPE H + L specific F(ab’)2-Fragment
anti-Human Igγ RPE human Igγ polyclonal Goat Dianova GmbH, Hamburg
Fc-RPE Fc specific F(ab’)2-Fragment
anti-Human Igγ APC human Igγ polyclonal Goat Dianova GmbH, Hamburg
Fc-APC Fc specific F(ab’)2-Fragment
anti-Human Biotin F(ab’)2-Fragment polyclonal Goat Dianova GmbH, Hamburg
F(ab’)2-Biotin specific whole IgG
anti-Rabbit APC IgG (H+L) polyclonal Donkey Dianova GmbH, Hamburg
Igγ-APC specific Igγ F(ab’)2-Fragment
anti-Human CD4 FITC human CD4 Igγ1/κ Mouse own production, Tu¨bingen
anti-Human CD8a APC human CD8 Igγ1/κ Mouse BioLegend GmbH, Fell
anti-Human CD14 FITC human CD14 Igγ1/κ Mouse BioLegend GmbH, Fell
anti-Human CD19 Pacific Blue human CD19 Igγ1/κ Mouse BioLegend GmbH, Fell
anti-Human CD19 PE human CD19 Igγ1/κ Mouse BioLegend GmbH, Fell
anti-Human CD56 BV421 human CD56 Igγ1/κ Mouse BioLegend GmbH, Fell
anti-Human CD138 PE human CD138 Igγ1/κ Mouse BioLegend GmbH, Fell
Mouse Igγ1 κ FITC FITC Isotype control Igγ1/κ Mouse BioLegend GmbH, Fell
Mouse Igγ1 κ PE PE Isotype control Igγ1/κ Mouse BioLegend GmbH, Fell
Mouse Igγ1 κ APC APC Isotype control Igγ1/κ Mouse BioLegend GmbH, Fell
Mouse Igγ1 κ Pacific Blue Pacific Blue Isotype control Igγ1/κ Mouse BioLegend GmbH, Fell
2.1. MATERIALS 35
2.1.9 Kits
Anti-Tetanus Toxoid ELISA (IgG) Euroimmun, Lu¨beck
BD® CompBead Anti-mouse Igκ Becton Dickinson GmbH, Heidelberg
cDNA Synthesis system Roche, Basel, Switzerland
CloneJET PCR Cloning Kit Thermo Fisher Scientific, Inc., Vilnius,
Lithuania
Cytoplasmic and Nuclear RNA Purifica-
tion Kit
Norgen Biotec Corp., Ontario, Canada
KAPA HiFi PCR Kit KAPA Biosystems, Cape Town, South
Africa
NucleoSpin® Gel and PCR Clean-up Macherey-Nagel, Du¨ren
QIAprep® Spin Miniprep Kit Qiagen GmbH, Hilden
QIAGEN® Plasmid Maxi Kit Qiagen GmbH, Hilden
QIAquick® Gel Extraction Kit Qiagen GmbH, Hilden
QIFIKIT® DAKO Deutschland GmbH, Hamburg
2.1.10 DNA sequences
2.1.10.1 Oligonucleotides
All oligonucleotides used for sequencing or cloning were purchased from Sigma-
Aldrich Chemie GmbH (Mu¨nchen), Biomers GmbH (Ulm) or Eurofins Genomics
(Ebersberg).
Oligonucleotides for cloning of bispecific CD20×CD95 antibodies in the
FabSc format
2H7 SpeI-rev 5’-tataactagt1ttatcatttcagctccagcttggtcccagcaccgaacgtggg-3’
BspEI CD20 HL-hin 5’-aaaatttccgga2caggcttatctacagcagtctggggctgag-3’
Oligonucleotides for cloning of CD95-Ag fusion proteins
CRM197C186G-hin 5’-catggcccaggccggc3gccggcaacagag-3’
CRM197C186G-rev 5’-ctctgttgccggcgcc3ggcctgggccatg-3’
CRM197C201G-hin 5’-gcagctccctgagcggc3atcaacctgg-3’
CRM197C201G-rev 5’-ccaggttgatgcc3gctcagggagctgc-3’
CRM197R173Q-hin 5’-gacaagaggcaagcag4ggccaggacgc
CRM197R173Q-rev 5’-gcgtcctggccctg4cttgcctcttgtc-3’
CRM197R193Q-hin 5’-caacagagtgcgacaa4tctgtgggcag-3’
CRM197R193Q-rev 5’-ctgcccacagattg4tcgcactctgttg-3’
1SpeI restriction site
2BspEI restriction site
3Mutation Cys→Gly
4Mutation Arg→Gln
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Diph-C-hin 5’-catttatccgga5ggcgctgacgacgtgg-3’
Diph-R-rev 5’-gccgggactagt6tatcaggacttgatctcg-3’
Diph-T-hin 5’-tttaatccgga5tctgtgggcagctccctgag-3’
Diph-T-rev 5’-ctgggactagt6tatcaaaaaggctgggtcttg-3’
TetC-1−451-hin 5’-cagccctccgga5aagaacttgg-3’
TetC-80-hin 5’-cagccctccgga5aacgatatgttcaataac-3’
TetC271-rev 5’-ctgattcctgtagcgtcttgataactagt6cccag-3’
TetC451-rev 5’-ctgggactagt6tatcaatcg-3’
Oligonucleotides for sequencing
Kons1-hin 5’-gggtgcaaaagagcggccttctagaag-3’
Kons1-rev 5’-tgcagggtcccaaggcagtgctgggtg-3’
Kons2-hin 5’-ccagactcaaacttaccctacctttatc-3’
Kons2-rev 5’-ggtctgttatgccaagctctgtctatg-3’
Kons3-hin 5’-tgtgacatagaagctgcaatagtcag-3’
Kons3-rev 5’-ccaggatattaaccaatgagtgta-3’
CH2-hin 5’-caaaacccaaggacaccctc-3’
pA-rev 5’-ggaggtaggtgtcagagtcc-3’
mRNA-hin1 5’-acatatgtacaatgtcctcaccacag-3’
kmRNA-hin 5’-atgagccacacaaactcagggaaagctcg-3’
pJET1.2 Forw 5’-cgactcactatagggagagcggc-3’
pJET1.2 Rev 5’-aagaacatcgattttccatggcag-3’
T7 promoter 5’-taatacgactcactataggg-3’
Intron-rev 5’-gattcccgtttgcagagaatcttgg-3’
M13-hin 5’-gtaaaacgacggccagt-3’
M13-rev 5’-aacagctatgaccatg-3’
2.1.10.2 DNA sequences
CD20 VH-VL L. Grosse-Hovest, Tu¨bingen
GenBank: #AJ937362.1
CSPG4 VH-VL L. Grosse-Hovest, Tu¨bingen
GenBank: #AJ459797.1 and #AJ459796.1
APO-1 VH and VL L. Grosse-Hovest, Tu¨bingen
(See Appendix 6.3, page 125)
Tetanus Hc Fragment Eurofins MWG Operon, Ebersberg
(GenBank: #1AF9 A)
Diphtheria Toxoid CRM197 GeneArt®, Regensburg
(GenBank: #1007216A)
5BspEI restriction site
6SpeI restriction site
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2.1.10.3 Plasmids for the cloning of nucleic acids
pJET1.2/blunt was used for standard manipulation of PCR products and DNA frag-
ments prior to insertion into expression vectors according to the manufacturer in-
structions. For mapping and manipulation of the insert, the pJET1.2/blunt cloning
vector multiple cloning site contains two BglII recognition sequences that flank the
insertion site. The vector contains a lethal restriction enzyme gene that is disrupted
by ligation of a DNA insert into the cloning site. As a result, only bacterial cells
with recombinant plasmids are able to form colonies. In addition, the vector con-
tains a T7 promoter for in vitro and in vivo transcription. Sequencing of the insert
was performed with the sequencing primers of the kit. Further details and genetic
elements of this vector are described in the Fig. 2.1.
NF-CU-N297Q expression vector generated by M.Durben (Durben et al., 2015) was
used as a starting material for cloning of bispecific CD95×CD20 antibodies in the
FabSc format. Further details and genetic elements of this vector are provided in
Fig. 2.2.
2.1.10.4 Expression vectors
Two types of vectors were used for the expression of antibodies and antibody-fusion
proteins in the mouse myeloma cell line Sp2/0:
• For the expression of the antibody κ-light chain, a vector based on pPCR-
Script-vector was used. The lacZ promoter- and termination sequence were
removed. Further details and genetic elements of this vector are described in
the Fig. 2.3.
• For the expression of the antibody heavy chain, a vector based on fusion vector
pcDNA× pPCR (L.Grosse-Hovest, Tu¨bingen) was used. The CMV promoter
was replaced by a promoter for the mouse IgG heavy chain and the termination
sequence for bovine growth hormone was removed. Further details and genetic
elements of this vector are provided in the Fig. 2.4.
38 CHAPTER 2. MATERIALS AND METHODS
Figure 2.1: Genetic elements of the pJET1.2/blunt cloning vector
rep (pMB1) – replicon (rep) from the pMBI plasmid responsible for the replication of
pJET1.2 (1762 bp – 1148 bp); replication start (1162± 1); blaApR – β-lactamase gene con-
ferring resistance to ampicillin (2782 bp – 1922 bp); eco47IR – lethal gene eco47IR enabling
positive selection of the recombinants (753 bp – 16 bp); PlacUV 5 – modified promoter for
expression of the eco47IR gene at a level sufficient to provide positive selection (892 bp
– 769 bp); T7 promoter – T7 RNA polymerase promoter forin vitro transcription of the
cloned insert (305 bp – 324 bp); Multiple cloning site (MSC) – mapping, screening and
excision of the cloned insert (422 bp - 328 bp); insertion site (coloured in blue) – blunt
DNA ends for ligation with insert (371 bp – 372 bp).
2.1. MATERIALS 39
Figure 2.2: Genetic elements of the NF-CUN297Q heavy chain vector
Major parts of the vector:
This vector is based on the backbone of the fusion vector pcDNA× pPCR. It contains
a promoter sequence for mouse IgG-heavy chain (53 bp – 1230 bp). The leader sequence
segmented by one intron, which is coded between promoter sequence and variable domain
(VH). The VH domain coding for the FLT3 (clone 4G8) antibody is flanked by AatII
and ClaI restriction sites. VH domain and first constant region of the heavy chain (CH1)
are separated by intron containing µ-enhancer-element. CH1 domain is followed by a
modified CH2 domain of human IgG1 and the ScFv-fragment of CD3 antibody (UCHT1).
Modification of the CH2 domain of human IgG1 consists of the amino acid substitutions
and deletions (EU-index) C226S; C229S; E233P; L234V; L235A; ∆G236; D265G; N297Q;
A327Q; A330S). The coding section for ScFv on the C-terminus is flanked by BspEI and
SpeI restriction sites. Promoter, introns and poly-A-region are obtained from genomic
sequence from mouse C57BL/6 antibody locus (GenBank #AJ487681). Coding sequences
for constant domains are from human Igγ1-chain. The vector contains a blaApR - β-
lactamase gene and a phosphotransferase-gene (P-Trans) sequences for ampicillin and
neomycin resistance.
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Figure 2.3: Genetic elements of the APO-1 κ-chain vector
This vector is based on the backbone of the pPCR-ScriptTMAmpSK(+)Cloning-Vector,
without LacZ promoter- and termination sequence. It contains the promoter sequence
from mouse κ-chain (K-Prom) gene. The leader sequence segmented by one intron is
coded between promoter sequence and variable domains (VL). The VL domain is flanked
by XhoI and SpeI restriction sites. VL domain and constant region of the light chain (CL)
are separated by intron containing κ-enhance -element. The vector contains blaApR –
β-lactamase gene conferring resistance to ampicillin. Promoter, introns and poly-A-region
are obtained from genomic sequence from mouse C57BL/6 light chain antibody locus
(GenBank #AJ487682).
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Figure 2.4: Genetic elements of the BS9520 heavy chain vector
Major parts of the vector:
This vector is based on the backbone of NF-CU-N297Q heavy chain expression vector
depicted on the Fig. 2.2. The VH domain for a mouse APO-1 antibody is flanked by AatII
and ClaI restriction sites. The coding sequences for constant domains are from human IgG-
chain. CD20 ScFv (VH -VL) at the C-terminus is flanked by BspEI and SpeI restriction
sites. In case of control antibody BS95Mel the CD20 ScFv element was exchanged by a
CSPG4 specific ScFv (VH -VL) antibody fragment.
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2.2 Molecular biology methods
2.2.1 Isolation and purification of nucleic acids
2.2.1.1 Isolation of Plasmid-DNA from bacteria cultures
Isolation of Plasmid-DNA from bacterial cultures was performed using commercial
kits from Qiagen. Depending on the required amount of DNA different kits were used.
Isolation was performed according to the QIAprep® Spin Plasmid-DNA Miniprep
Kit or QIAGEN® Plasmid-DNA Maxiprep Kit manufacturer’s instructions. QIA-
GEN plasmid purification protocols are based on a modified alkaline lysis procedure
(Bimboim and Doly, 1979).
2.2.1.2 Isolation of cytoplasmic RNA and cDNA synthesis
Mature, cytoplasmic RNA from antibody producing transfected Sp2/0 cells was
isolated to verify the RNA sequence for potential splicing sites using Cytoplas-
mic & Nuclear RNA Purification Kit. Isolation was performed according to the
manufacturer’s instructions. Isolated RNA was applied to cDNA synthesis using
cDNA synthesis system, according to the manufacturer’s protocol. ssDNA was sub-
sequently proceeded to polymerase chain reaction (PCR) using mRNA-hin1 and
pA-rev oligonucleotides to amplify DNA sequences, coding for antibody heavy chain
(PCR is described in the section 2.2.2.4).
2.2.1.3 Purification of DNA from the agarose gel
Gel purification was used to isolate and purify DNA fragments based on size. The
procedure starts with standard agarose gel electrophoresis, which separates DNA by
their length. Following electrophoresis, DNA bands were cut out of the agarose gel.
DNA fragments were purified using commercial gel purification kits according to the
manufacturer’s instructions. For the fragments ≥10 kb NucleoSpin® Gel and PCR
clean up Kit was used. Smaller fragments (≤10 kb) were purified using Qiaquick®
Gel Extracion Kit.
2.2.1.4 Phenol-chloroform extraction and precipitation of DNA
The Phenol-chloroform extraction was performed to purify the expression vectors
after preparative digestion (linearization) with restriction endonucleases. DNA solu-
tion was mixed with an equal volume of ready-to use Phenol/Chloroform/Isoamyl-
alcohol (25/24/1) mixture and vortexed vigorously to mix the liquid phases. After
centrifugation of the sample the upper aqueous phase was removed carefully into
the new 1.5mL tube to avoid transfer of any proteins, concentrated in the interface.
The sample was extracted two more times with an equal volume of chloroform to
remove trace amounts of phenol.
For the precipitation of nucleic acids 10% (v/v) of 3M sodium acetate solution
pH5.2 and 2.5 volumes of the absolute ethanol were added to the aqueous phase.
The sample was frozen at -80°C for 20min and centrifugated at 4°C and 17900× g
in the microcentrifuge for 20min. The supernatant was carefully decanted and the
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DNA pellet was air dried on the clean bench. Subsequently the DNA was dissolved
in 40-50µL ddH2O.
2.2.2 Handling of nucleic acids
2.2.2.1 Digestion of DNA with restriction endonucleases
Restriction enzymes of Type II and Type IV were used in this work. The most
common Type II enzymes cut DNA at defined positions close to or within their
recognition sequences. Cleavage leaves a 3’-hydroxyl on one end of each cut and
a 5’-phosphate on the other end. Type IV enzymes recognize and cleave modified,
typically methylated DNA (DpnI).
Restriction digestion was used for analysis or preparation of DNA fragments. Ana-
lytical restriction digestion was performed as follows:
1µg DNA
1µL 10×Reaction buffer
2U Restriction endonuclease
ad 10µL ddH2O
DNA was subjected to digestion for 1 h at appropriate temperature recommended
by manufacturer.
Preparation of larger amounts of DNA (for cloning or transfection) was performed
as follows:
30µg DNA
10µL 10×Reaction buffer
40U Restriction endonuclease
ad 100µL ddH2O
DNA was subjected to digestion for 3-4 h at appropriate temperature recommended
by manufacturer.
2.2.2.2 Dephosphorylation of 5’ and 3’ ends of DNA
Plasmids were treated with Calf intestinal phosphatase (CIP) before performing
ligation of dsDNA fragments with blunt or sticky ends to form recombinant DNA
plasmids. In this step 5’-phosphate is removed to ensure that the vector does not re-
circulate during ligation. 1000U CIP was added to the DNAmixture after restriction
digestion and incubated for 1 h at 37°C.
2.2.2.3 Ligation of nucleic acid fragments
Ligation was used to join dsDNA fragments with blunt or sticky ends to insert DNA
fragments into the plasmids or expression vectors.
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Ligation of DNA fragments into pJET1.2/blunt vector
1µL pJET1.2/blunt clonig vector
1 : 3 molar ratio
over vector
DNA-Insert (Blunt-End)
10µL 2× reaction buffer
1µL T4 DNA Ligase (5U/µL)
Total volume 20µL
The reaction mix was incubated at room temperature for 10min – 30min.
Ligation of DNA into Expression vectors
50-100 ng Plasmid
1 : 5 molar ratio
over vector
Insert
2µL 10× ligation buffer
1µL T4 DNA Ligase (5U/µL)
Total volume 20µL
The reaction mix was incubated at room temperature for 10min.
2.2.2.4 Polymerase chain reaction
Polymerase chain reaction was used for amplification and mutagenesis of specific
DNA fragments in vitro. For the amplification of DNA fragments specific sense-
and anti-sense primers complementary to the 3’ end of the sense and anti-sense
DNA sequences were generated (Kleppe et al., 1971; Mullis and Faloona, 1987).
PCR reaction was performed in 3 steps using KAPA HiFi DNA polymerase and
following cycling parameters:
Initial denaturation 95°C 5min
Denaturation 98°C 20 sec
Primer annealing Tm± 10°C 15 sec
Extension 72°C 30 sec/kb
Final extension 72°C 5min
Cooling 4°C Hold
Inverse PCR reaction with the same polymerase and the same cycling parameters
was used for site-directed mutagenesis. Using this approach with a circular fully
methylated plasmid as template and oligonucleotide pairs (approx. 30 bp in length)
containing the desired mutation in the middle, a linearised un-methylated vector
is created that incorporates the mutation. The linearised vector was re-circulated
via PCR. After that reaction mixture was subjected to DpnI digestion to destroy
the methylated and hemi-methylated DNA template. Chemically competent E. coli
were transformed with 10µL of this mixture (Bacterial transformation is described
in the section 2.3.1.2 on page 46).
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2.2.3 Analysis of nucleic acids
2.2.3.1 Agarose gel electrophoresis
Agarose gel electrophoresis was used to separate DNA by size (e.g. length in base
pairs) for visualization and purification. Agarose gels were commonly used in con-
centrations of 1% to 1.5% depending on the size of DNA fragments. The required
amount of agarose powder was mixed with the TAE buffer and heated in a microwave
oven for 1-3min (until the agarose was completely dissolved). Agarose solution was
cooled for 5min and ethidium bromide (EtBr) was added to a final concentration of
0.5-1µg/mL. The DNA-samples were mixed with 1/6 volume of the loading buffer
before running an agarose gel. A molecular weight ladder (100 bp or 1 kb Plus) was
loaded with the samples for determination of size of the DNA-fragments. Agarose
gel electrophoresis was performed using TAE buffer at 80-150V. DNA fragments
were visualized using UV light (254 nm).
2.2.3.2 Nucleic acid quantification
Concentration of nucleic acids in aqueous solution was determined by spectropho-
tometric analysis at the wave length 230 nm, 260 nm and 280 nm using Nanodrop™
1000 UV-Vis spectrophotometer. An Absorbance (A) of 1 corresponds to a concen-
tration of 50µg/mL for double-stranded DNA (dsDNA), 40µg/mL for RNA and
33µg/mL for single-stranded DNA (ssDNA). The ratio of absorbance at 260 and
280 nm was used to assess the purity of DNA and RNA. A ratio of ≈ 1.8 was accepted
as “pure” for DNA; a ratio of ≈ 2.0 was accepted as “pure” for RNA. If the ratio is
appreciably lower in either case, it may indicate the presence of protein, phenol or
other contaminants that absorb strongly at or near 280 nm.
2.3 Microbiology and cell biology methods
2.3.1 Bacteria
2.3.1.1 Preparing chemically competent cells
E. coli DH5α bacteria were plated out on LB plates without antibiotics the day
before starting the liquid culture for the competent cells. The plate straight from
37°C was used to start the cultures. 5mL of LB medium were inoculated with 1
clone of E. coli DH5α and incubated overnight at 250 rpm and 37°C. In the morning,
the overnight culture was diluted to at least 1:100 in 100mL and incubated for
further 1-2 h at 250 rpm and 37°C until the optical density (O.D.) of the culture
reached 0.2-0.3 at 550 nm. The cells were centrifuged for 10min at 1619× g and
4°C. Supernatant was discarded, the pellet resuspended in 20mL of ice-cold TfbI
buffer and incubated on ice for 20-30min. The cells were centrifuged again for 5min
at 719× g and 4°C. Supernatant was discarded and the pellet was resuspended in
4mL of ice-cold TfbII buffer. Aliquots with 100 or 200µL of this suspension were
frozen in 1.5mL tubes and stored immediately at -80°C.
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2.3.1.2 Transforming chemically competent E. coli DH5α with plasmid-
DNA
For the transformation of chemically competent bacteria, the required number of
aliquots was thawed on ice, mixed with plasmid DNA (≤1µg) or the ligation re-
action mix (see Ligation 2.2.2.3 on the page 43) and incubated on ice for 45min.
Subsequently, a heat shock was performed for 1min at 42°C. The tubes were placed
on ice immediately. 300µL LB medium was added to each tube and incubated for
1 h at 37°C and 250 rpm. 100µL of each suspension was plated out on LB plates
containing the appropriate antibiotic. The plates were incubated overnight at 37°C.
2.3.1.3 Cultivation of bacteria
Bacteria were cultivated for amplification of plasmid DNA. Single bacteria colonies
from a selective plate were picked with a sterile pipette tip and transferred to a new
selective master-plate. Pipette tip was then dropped into a tube with 1-5ml LB
medium containing 100µg/mL of the appropriate selective antibiotic to inoculate
the culture.
For the isolation of plasmid DNA with QIAGEN® Plasmid-DNA Miniprep Kit, the
cultures were incubated for 12-16 h at 37°C with vigorous shaking.
For the isolation of plasmid-DNA with QIAGEN® Plasmid-DNA Maxiprep Kit, the
cultures were incubated at the same conditions for 6 h and then diluted 1/1000 into
200mL of LB medium containing the appropriate antibiotic. Erlenmeyer flasks with
bacteria cultures were incubated for 12-16 h at 37°C with vigorous shaking.
2.3.2 Eukaryotic Cells
All cell lines and human peripheral blood mononuclear cells (PBMC) were main-
tained at 37°C and 5% CO2 (for RPMI medium) or 7% CO2 (for IMDM medium)
in a cell incubator.
2.3.2.1 Thawing cryopreserved cells
Cryovials containing frozen cells were removed from liquid nitrogen or -80°C freezer
and thawed rapidly (≤1min) in a 37°C water bath. The cell suspension was slowly
diluted with pre-warmed IMDM or RPMI complete medium and centrifuged at
200× g for 5min. After the centrifugation, the supernatant was decanted without
disturbing the cell pellet. The cells were gently re-suspended in complete growth
medium, and transferred into the appropriate culture vessel and environment.
2.3.2.2 Subculturing mammalian cells
Adherent cells were detached from the culture flask before subcultivation. To this
end, the medium was aspirated from the cell culture flask. The cell layer was rinsed
once with 10mL DPBS and 2.5 - 5mL Accutase® was added to the flask to cover
the cell layer. The flask was incubated at room temperature (RT) for 5 to 10min up
to a maximum of 1 h. Subsequently the cells were gently dispersed and an aliquot
of the detached cells was added to fresh medium in new flasks.
2.3. MICROBIOLOGY AND CELL BIOLOGY METHODS 47
Suspension cells were diluted with fresh medium in new flasks with desired cell
density.
2.3.2.3 Viability measurement and cell count
Viability of the cells was determined by Trypan blue exclusion. The cell sample was
diluted 1:2 or 1:10 (depending on cell density) in Trypan blue solution. The cell
suspension was transferred into a hemacytometer and examined immediately under
a microscope.
The number of viable cells in the chamber was used to calculate the cell concentration
in the sample. The number of cells in the 0.1mm3 chamber multiplied by the factor
of 104 and with the dilution factor results in cell concentration per 1mL medium.
2.3.2.4 Cryopreservation of cells
Cells were pelleted by centrifugation at 250× g and the supernatant was discarded.
The cells were re-suspended in freezing medium in a concentration of 106 - 107
cells/mL and aliquoted into cryovials. Cells were frozen slowly 1°C/min. This was
done by placing vials in a freezing container placed in a -80°C. After 24 h frozen cells
were transferred to liquid nitrogen storage.
2.3.2.5 Stable transfection of eukaryotic cells
For stable transfection 2× 107 Sp2/0-Ag14-cells were washed three times with 50mL
ice-cold IMDM medium without supplements. Centrifugation was performed at
200× g. The cell pellet was resuspended in 200µL IMDM, mixed with linearized
expression vectors and transferred into a cold electroporation cuvette with 0.4 cm
gap width. Electroporation was performed at 230V und 975µF. The cells were then
transferred immediately into 12mL of warm IMDM complete medium and, after
serial dilution, seeded into 96-well plates (50µL/well).
Selection for stable transfected cells was accomplished by adding the antibiotic G418
(end concentration: 1mg/mL) 24 h after transfection. 7-10 days after transfection
cells were monitored for antibiotic-resistant clones. 14-20 days after transfection cell
culture supernatants from growing clones were tested for the presence of recombinant
antibodiesby flow cytometry.
2.3.2.6 Cultivation of antibody-producing transfected cells
Antibody-producing Sp2/0 cells were cultivated in IMDM complete medium supple-
mented with 1mg/mL G418. The cells were kept at a density of 2-3× 105 cells/mL.
Cell were expanded in 175 cm2 cell culture flasks to the final volume of 1-2 liter and
cultivated until approx. 50% of all cells were dead. Cell culture supernatant was
harvested by centrifugation at 6000× g, supplemented with 0.02% (w/v) NaN3 and
filtrated using 0.22µm bottletop filter. Depending on the purification strategy the
supernatant was adjusted to pH7.6 (KappaSelect) or pH8 (ProteinA) and stored
at 4°C.
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2.3.2.7 Cultivation of antibody-producing hybridoma cell lines
Antibody-producing Sp2/0 hybridoma cells were cultivated in IMDM Pan medium
(IMDM supplemented with chemically defined serum substitute for suspension cells
PANEXIN NTS) at a cell density of 2 - 3× 105 cells/mL. Cells were expanded in
TripleFlask™ cell culture flasks to a final volume of 1 - 2 L. Afterwards the cells were
kept in culture until approx. 50% of all cells were dead. Finally cell culture super-
natant was harvested by centrifugation at 6000× g, supplemented with 0.02% (w/v)
NaN3 and filtrated using 0.22µm bottletop filter. For purification with ProteinA
the supernatant was adjusted to pH8 and stored at 4°C.
2.3.2.8 Isolation of human PBMC from whole blood
Human PBMCs were separated from heparinised blood by a density gradient cen-
trifugation method using Ficoll-Hypaque solution.
To this end heparinised blood was diluted 1:2 with DPBS and 25mL of diluted
cell suspension was carefully layered over 15mL Ficoll-Hypaque solution in a 50mL
conical tube. The cells were centrifuged at 561× g for 30min in a swinging-bucket
rotor without brake. The layer of mononuclear cells was carefully transferred from
the interphase to a new 50mL conical tubes, washed by adding DPBS to 50ml and
centrifugation 300× g for 10min. Supernatant was removed completely. For removal
of platelets, the cell pellet was resuspended in 50mL of DPBS and centrifuged at
200× g for 10min. The cell pellet was resuspended in the appropriate amount of
RPMI complete medium or DPBS.
2.3.2.9 Isolation of human PBL using red blood cell lysis
RBC lysis buffer containing ammonium chloride was used to remove red blood cells
(RBC) from whole blood and bone marrow samples. To this end, 10× RBC lysis
buffer was diluted prior to use to 1× working concentration with room temperature
bidist. water. For purification of human peripheral blood leukocytes (PBL) 15 vol-
umes of 1× RBC lysis buffer were added to the cell sample, gently vortexed and
incubated for 10-15 minutes at the room temperature. As soon as the cell suspen-
sion became clear, the cells were centrifuged at 350×g for 5 minutes. Supernatant
was aspirated without disturbing pellet, the cells were washed at 350×g for 5 min-
utes with DPBS and resuspended in the appropriate buffer depending on following
experiments.
2.4 Protein biochemistry and analytical methods
2.4.1 Chromatography
2.4.1.1 Affinity chromatography
The principle of affinity chromatography is based on a reversible interaction between
a protein and a specific ligand coupled to a chromatography matrix. In this work
two types of ligands were used. Antibodies containing a complete Fc part (mouse
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IgG, chimeric IgG) were purified using ProteinA media and chimeric antibodies
without CH3-domain were purified using KappaSelect media.
ProteinA affinity chromatography
ProteinA is a bacterial protein purified from Staphylococcus aureus. The basis for
purification of IgG is the high affinity of proteinA for the Fc region of polyclonal
and monoclonal IgG antibodies.
Cell culture supernatants prepared and filtered as described in 2.3.2.7 on page 48
were applied to the column (equilibrated with 0.1M phosphate buffer pH8) at the
flow rate of 50mL/h using a peristaltic pump. All unbound material was removed
by washing with at least 10 column volumes and determined by UV absorbance at
280 nm.
ProteinA is also able to bind bovine IgG. However, binding of bovine IgG to Pro-
teinA is weaker than binding of chimeric (mouse/human) IgG. To avoid contamina-
tion with bovine IgG containing FCS, elution buffers with different pH-values were
used. Bovine IgG was eluted using 0.1M glycine / 0.1M citrate buffer at pH4.2 and
chimeric antibodies at pH2.5. After elution the column was re-equilibrated with bin-
ding buffer, washed with ddH2O and stored in 20% ethanol at 4°C. Collected eluate
was dialysed against DPBS using dialysis tubing or disposable PD-10 columns.
KappaSelect affinity chromatography
The KappaSelect ligand is a camelbody directed against the constant domain (CL)
of human Igκ and is useful for purification of constructs lacking the Fc region.
Cell culture supernatants prepared and filtered as described in section 2.3.2.6 on
page 47 were applied to the DPBS equilibrated KappaSelect column at the flow
rate of 50mL/h using a peristaltic pump or at the flow rate of 2mL/min using an
A¨KTAprime system. All unbound material was washed out using DPBS. Antibodies
were eluted with 0.1M glycine buffer pH2.5, the column was re-equilibrated with
DPBS, washed with ddH2O and stored in 20% ethanol at 4°C.
2.4.1.2 Size-exclusion chromatography
Two types of size exclusion chromatography were applied in this work. FPLC system
(Pump-type P500, control unit LCC501, single channel UV-monitor UV-1, fraction
collector FRAC-100) or A¨KTA pure system were used for the preparative separation
of proteins. For analytical gelfiltration SMART® System or Dionex™ UltiMate™
3000 BioRS system were used.
Preparative size-exclusion chromatography
Preparative size-exclusion chromatography was used to separate monomeric anti-
body fraction from multimers, aggregates and smaller protein fragments or salts.
Max. 4mL protein solution was injected in a 5mL loop, and loaded onto Superdex™
200 Prep Grade 16/60 HiLoad column and separated at a flow rate 50mL/h. DPBS
or 0.1M phosphate buffer were used as a running buffer. Separated proteins were
detected by UV absorbance at 280 nm and collected in prepared tubes filling fraction
collector.
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Analytical size-exclusion chromatography
Analytical size exclusion chromatography was used to characterize purified antibo-
dies with respect to their approx. molecular weight, aggregation and contamina-
tion. SMART® System equipped with Superdex 200 PC3.2/30 column or Dionex™
UltiMate™ 3000 BioRS system equipped with a Superdex200™ increase 10/300 GL
column were used for these experiments.
For analysis 10µg protein was diluted in 50µL DPBS and applied onto the columns.
Separated proteins were detected by UV absorbance at 280 nm and 220 nm. Molec-
ular weight was determined using absorption profiles of calibration proteins.
The peak retention volume of the calibration proteins listed in the table 2.25 was
used as a standard for the SMART® System. The void volumes of the columns
were determined using blue dextran.
Table 2.25: Calibration proteins for SMART®
Protein Molecular weight (kDa)
Catalase 232 kDa
Aldolase 158 kDa
Albumin 67 kDa
Ribonuclease A 13.7 kDa
The peak retention time of the calibration proteins listed in the table 2.26 was used
as a standard for the Dionex™ UltiMate™ 3000 BioRS system.
Table 2.26: Calibration proteins for Dionex™ UltiMate™ 3000 BioRS
Protein Molecular weight (kDa)
Thyroglobulin (bovine) 670 kDa
γ-globulin (bovine) 158 kDa
Ovalbumin (chicken) 44 kDa
Myoglobin (horse) 17 kDa
Vitamin B12 1,35 kDa
2.4.2 Generation of antibody F(ab’)-fragments
Antibodies were digested with pepsin at a ratio of 30µg pepsin for 1mg antibody in
a 0.1M sodium acetate buffer (pH 4.0) containing 0.1M sodium chloride. F(ab’)2
fragments were purified from the intact antibodies and pepsin using preparative
size exclusion chromatography (Superdex™ 200 Prep Grade 16/60 HiLoad column).
Reduction and subsequent modification of purified F(ab’)2 fragments were achieved
in one step through reaction with a mixture of 10mM DTT (1,4-Dithiothreitol)
and 40mM Ellmans reagent DTNB (5,5’-Dithiobis (2-nitrobenzoic acid)) for 24 h.
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F(ab’) fragments were purified from the (ab’)2 fragments and DTT/DTNB mixture
using preparative size exclusion chromatography (Superdex™ 200 Prep Grade 16/60
HiLoad column).
2.4.3 Protein gel electrophoresis
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was per-
formed by using precast Mini-Protean® TGX™ polyacrylamide gels. SDS is an
anionic detergent. When it is dissolved, its molecules have a net negative charge
within a wide pH range. A polypeptide chain binds amounts of SDS proportional
to its relative molecular weight. The negative charges on SDS destroy most of
the complex structure of proteins, and are strongly attracted toward an anode in
an electric field. Because the charge-to-mass ratio is nearly the same among SDS-
denatured polypeptides it allows size-dependent separation of the proteins in the
range of 5–250 kD.
For analysis 2µg protein was diluted with sample buffer with or without reducing
agent (β-mercaptoethanol). Diluted samples were incubated at 95°C for 5min. Sep-
aration of the proteins was performed at U=200V. Following electrophoresis, the gel
was stained with Roti®-Blue colloidal coomassie staining solution to visualize the
proteins. The gel was incubated with staining solution with gentle agitation for 1 h
and was then rinsed in a staining tray and destained for 1–3 h with ddH2O water.
2.4.4 Flow cytometry
Flow cytometry (Fluorescence-activated cell sorting or FACS) measures optical and
fluorescence characteristics of single cells or microscopic particles based on their
physical properties, internal complexity and surface staining.
In this work flow cytometry was applied using different protocols for several different
purposes :
• to measure binding avidity of monoclonal antibodies (characterisation of anti-
bodies)
• to quantify cell surface molecules on different cell lines
• to evaluate expression of certain proteins on the surface of PBL and PBMC
• to determine antibody mediated killing of resting and activated PBMC
2.4.4.1 FACS titration of monoclonal antibodies
For measurement of binding activity, cells (Daudi (CD20+), Jurkat (CD95+), SKW6.4
(CD20+/CD95+) or SK-Mel (CSPG4+)) were incubated with appropriate antibodies
(or cell culture supernatants) in round-bottom 96well plates (1.5× 105 cells/well) for
30min at 4°C. The cells were washed twice with 200µL FACS buffer, centrifuged
at 561× g and stained with 50µL of PE- or APC-conjugated goat-anti-human Fcγ
secondary antibodies according to the manufacturer’s instructions. After incubation
for additional 30min the cells were washed again and analysed by flow cytometry
using a FACSCalibur™ instrument and CellQuestPro Software (BD Biosciences).
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2.4.4.2 Quantification of cell surface molecules by FACS analysis
Quantification of CD20 and CD95 expression on different B-lymphoma cell lines
used in proliferation inhibition experiments (see 2.5.1.1) was performed using DAKO
QIFIKIT®.
Different cell lines (2× 105 cells/sample) were incubated in duplicates with uncon-
jugated mouse anti-human CD20 (clone 2H7), anti-human CD95 (APO-1) or un-
related antibodies at saturating concentrations (10µg/mL) for 30min at 4°C. The
cells were then washed twice with 200µL FACS buffer, centrifuged at 561× g and
stained with 50µL of FITC-conjugated goat-anti-mouse secondary antibodies ac-
cording to the manufacturer’s instructions. After incubation for additional 30min,
the cells were washed again and analysed by flow cytometry using a FACSCalibur™
instrument and CellQuestPro Software (BD Biosciences).
Data analysis was performed using calibration curve and the following equation:
log x = a× log z + b (2.1)
a: Linear factor
b: Ordinate intercept
x : Antibody-Binding Capacity
z : Mean fluorescence intensity
Antigen density was calculated based on measured fluorescence intensity of the cells
compared to determined fluorescence intensity of the calibration beads.
2.4.4.3 Expression of surface molecules on PBMC
To evaluate expression of certain proteins on the surface of PBMC, Fc receptors
were blocked with Flebogamma (50µg/mL) for 15min. 1× 106 cells/sample were
stained with directly labelled CD95 antibodies. Gates for different cell populations
were determined using FMO (”‘fluorescence minus one”’) controls in which one
experimental antibody within a mixture was replaced by an isotype control labeled
with corresponding dye (Tung et al., 2004) (Roederer, 2001). Samples were measured
in technical duplicates. AnnexinV expression was measured in activated B- and T-
cells within PBMC cultures to assess induction of apoptosis. Cell samples were
measured after 4 h of antibody treatment (1µg/mL). To this end, the cells were
incubated with labelled antibodies washed, stained with PE-AnnexinV and analyzed
by flow cytometry. Acquisitions were performed using the FACSCanto™ II cell
analyzer. For data analysis FlowJo software (TreeStar, USA) was used.
2.4.4.4 FACS depletion analysis of human PBMC
For measurement of antibody mediated killing of resting and activated B-cells (de-
scribed in section 2.5.1.2), different PBMC populations were quantified by flow cy-
tometry. In all FACS experiments binding to Fc receptors was blocked with Fle-
bogamma (50µg/mL) for 15min. 1× 106 cells/sample were stained with mouse anti
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human CD4-FITC, CD8-APC and CD19-PacificBlue antibodies for 30min. Dead
cells were excluded by staining with 7-Aminoactinomycin D (7-AAD). The lympho-
cyte population was defined by light scatter characteristics and the percentage of
remaining B- and T-cells after antibody treatment was assessed using compensa-
tion particles. By the acquisition of equal numbers of compensation particles (BD
Biosciences) in each sample, absolute cell counts could be determined and used to
calculate the percentage of remaining B- and T-cells. Samples were measured in
technical duplicates. Acquisitions were performed using the FACSCanto™ II cell
analyzer. For data analysis FlowJo software (TreeStar, USA) was used.
In some experiments induction of apoptosis in activated B and T cells within PBMC
cultures was measured after 4 h of antibody treatment (1µg/mL). To this end, the
cells were incubated with labeled antibodies (CD4-FITC, CD19 PacificBlue) washed,
stained with PE-AnnexinV and analyzed by flow cytometry.
2.4.5 IgG ELISA
ELISA (Enzyme-linked Immunosorbent Assay) was used for quantification of human
IgG secretion by activated B-cells in vitro.
To this end, an adapted sandwich procedure was performed. Maxisorp 96well plates
were coated with 50µL of 1 : 1000 diluted goat anti-human IgGγ or 5µg/mL Tetanus
toxoid in DPBS at 4°C over night. After blocking with 100µL of 10% BSA in DPBS
for 1 h, ELISA was proceeded by incubation steps with the following reagents, sepa-
rated by extensive washing: (i) sample dilutions of PBMC supernatants, (ii) 1 : 10000
diluted biotinylated mouse IgG anti-human IgG F(ab’)2, (iii) 1 : 5000 diluted poly-
HRP Streptavidin and (iv) TMB Microwell Peroxidase Substrate System. Reaction
was stopped using 1M phosphoric acid. Optical density at 450 nm was determined
using a Spectra Max 340 ELISA reader. Antibody concentration was calculated us-
ing standard curves obtained by diluting human IgG (Flebogamma) or TetagamP,
respectively, in RPMI complete medium.
2.5 Functional immunobiological assays
2.5.1 In vitro experiments
2.5.1.1 Proliferation inhibition assay
For the determination of antibody-dependent cellular cytotoxicity (ADCC) lym-
phoma target cells (SKW6.4, JY, C1R and Raji) were incubated with varying con-
centrations of different antibodies with and without PBMC. The cells were incubated
for 24 h in 96well plates and then pulsed with 0.5µCi/well [methyl-3H]-thymidine.
After 20 h cells were harvested on a Printed FiltermateA and the precipitated ra-
dioactivity was determined in a liquid scintillation counter. % inhibition of prolifera-
tion was calculated according to the formula: 100-(x/x0× 100), where x and x0 are
counts (cpm) measured in experimental wells (x) and in wells without antibodies
(x0). Each data point represents the mean value of triplicate samples.
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2.5.1.2 Inhibition of antibody production by pokeweed mitogen- or antigen-
stimulated PBMC
For the verification of B-cell depletion from PBMC cultures upon incubation with
antibodies freshly isolated PBMC from healthy donors or from individuals recently
immunized with Tetanus toxoid (TT) were stimulated for 6 days with 1µg/mL poke-
weed mitogen (PWM) (Daniel and Krammer, 1994) and 25 ng/mL TT, respectively,
as described by Lum et al (Lum and Culbertson, 1985). Cells were washed twice,
adjusted to 3.2× 106 cells/mL in 24 well plates and incubated with antibodies for
another 2 days. To prevent detection of the therapeutic antibodies as newly pro-
duced human IgG in PWM stimulated cultures, antibody concentrations used were
0.1µg/mL and 1µg/mL in cultures stimulated with PWM and TT, respectively.
After incubation, cells were analysed by flow cytometry (see 2.4.4.4 on page 52) and
panclonal or TT specific human IgG were measured in the cell culture supernatants
by ELISA (see 2.4.5 on page 53).
2.5.2 In vivo experiments
All animal experiments were performed in accordance with the German animal
protection law and approved by the Tu¨bingen Regional Administrative Council
(Regierungspra¨sidium); approval numbers: IM6/08 and IM2/12.
2.5.2.1 Determination of antibody serum half-life
C57BL/6 mice were purchased from Janvier (Le Genest-Saint-Isle, France). For de-
termination of serum half-life, mice were injected intravenously (i.v.) with 50 µg of
the respective antibodies (3 animals per antibody). After 0.5, 1, 2 and 4 hrs (FabSc)
or 0.5, 3, 6 and 24 h (IgG-antibodies) mice were bled and serum was obtained. Serum
concentrations were measured by incubating SKW6.4 cells with diluted serum sam-
ples. The amount of antibody bound to the cells was determined by flow cytometry
and concentration values were calculated using a calibration curve obtained with
samples that contained defined amounts of purified antibodies diluted in mouse
serum (C57BL/6).
2.5.2.2 Severe combined immunodeficient (SCID) mouse xenograft model
In vivo immunotherapy trial
Immunodeficient male C.B.-17 SCID-mice (CB17/lcr-PrkdcSCID/CRL) were pur-
chased from Charles River (Sulzfeld, Germany). SCID mice were kept under specific
pathogen free (SPF) conditions. 4-5 weeks old mice were injected i.v. with a lethal
dose of 107 SKW6.4 lymphoma cells in 200µL DPBS at day 0. As soon as they
developed paralysis of the hind legs, animals were sacrificed and SKW6.4 cells were
recovered from the bone marrow of these mice as described in next paragraph. These
“SCID-SKW6.4” cells were expanded and used for all the following experiments with
SCID mice.
To determine survival after challenge with tumour cells, groups of 8 C.B.-17 SCID
mice were injected at day 0 with 107 “SCID-SKW6.4” cells i.v. Mice treated with
monospecific antibodies were injected intraperitoneal (i.p.) with 60µg of respective
2.5. FUNCTIONAL IMMUNOBIOLOGICAL ASSAYS 55
antibody at day 1, animals treated with bispecific antibodies with 20µg at days
1, 2 and 3. Animals developing visible tumours, sense disturbances or paralysis
of the hind legs were sacrificed and tumour growth was confirmed by necroscopy.
After termination of the experiment at day 120, surviving mice were sacrificed and
subjected to necroscopy and histological examination (Histological examination was
performed by Dr.med. vet. M.Wo¨lm, Hamburg).
Isolation of SKW6.4 cells from mouse bone marrow
For isolation of bone marrow, mice were sacrificed and bone marrow cells were
isolated from the hind legs. The femur was dissected from surrounding muscles and
excess tissue was removed using sterile forceps and scissors, keeping the ends of the
bone intact. The intact bones were soaked in 70% ethanol in a sterile Petri dish for
2min as disinfection. After rinsing bones in sterile culture medium, both ends of
the femurs were trimmed carefully using sterile, sharp scissors to expose the interior
marrow shaft. The content of the marrow was flushed with 2ml of culture medium
using a 5ml syringe with a 29G×1/2 needle. The content was collected into a sterile
50ml centrifuge tube and washed with media for 5min at 250× g. The supernatant
was removed and the cell pellet was resuspended in the appropriate amount of
RPMI complete medium. The cells were cultivated under standard conditions in a
cell incubator.
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To generate recombinant bispecific reagents that selectively stimulate the CD95
death receptor on CD20 positive B-cells, CD95×CD20 bispecific antibodies were
developed and characterised in the first part of this work. All new constructs are
based on the FabSc format (a F(ab) fragment linked to a Single Chain antibody) as
depicted in Fig. 3.2 (Durben et al., 2015). Three expression vectors were used for
assembling the new recombinant antibodies: one carrying the sequence for bispeci-
fic FLT3×CD3 antibody in the FabSc format (NF-CUN297Q Fig. 2.2) and two for
APO-1 antibody heavy (Fig. 2.4) and light (Fig. 2.3) chains. Parts of these vectors
were removed or replaced with the sequences for CD95×CD20 bispecific antibodies.
The main cloning steps are depicted in Fig. 3.1. An overview of the bispecific FabSc
antibodies generated in the first part of this work is depicted in Fig. 3.2.
At the beginning of this work the bispecific CD95×CD20 antibodies will be charac-
terised using standard analytical assays. As a next step, the antibodies will be func-
tionally compared to clinically established monospecific CD20 antibodies used for
the treatment of B-cell lymphomas. In vitro and in vivo experiments using different
malignant B-cell lines will be performed to address this question. Since monospe-
cific CD20 antibodies are currently applied not only for haematological, but also
for autoimmune diseases, the bispecific CD95×CD20 antibodies will be compared
to the monospecific CD20 antibodies also with respect to their capability to deplete
normal, activated B-cells and to suppress antibody production.
The generation and characterisation of new fusion proteins stimulating CD95 recep-
tor on antigen-specific activated B-cells will be reported in the last part of this work.
Tetanus toxoid (TT) and diphtheria toxoid (DT) antigens were selected for these
experiments as model antigens. An expression vector for CD95×CD20 antibodies
generated in the first part of this work was used for cloning and construction of the
fusion proteins. The CD20 part was replaced with various non-toxic parts of TT and
DT. B-cell suppressive activity of these antigen-specific reagents will be compared in
vitro to the CD95×CD20 antibody and established monospecific CD20 antibodies.
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Figure 3.1: Cloning strategy for the construction of BS9520 and BS2095
antibodies
(a) Schematically represented NF-CUN297Q heavy chain expression vector (coding for
FLT3×CD3 antibody in the FabSc format; all parts of this vector are described in Fig. 2.2
on page 39) was used as a starting material. First ScFv (VH -VL) for UCHT1 antibody
at the C-terminus was replaced using BspEI and SpeI restriction sites with the (b) ScFv
of desired specificity: ScFv for CD20 antibody (VH -VL) for BS9520 construct or ScFv
for CD95 antibody (VH -VL) for BS2095 construct. The whole Fc part of these interim
constructs was subsequently transferred into NheI and SpeI digested expression vectors
(c) for CD95 heavy chain Fig. 2.4 or expression vector for heavy chain antibody directed
against CD20.
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3.1 Generation and characterisation of recombi-
nant bispecific antibody constructs
3.1.1 Generation of recombinant bispecific antibodies
For construction of the recombinant bispecific CD95×CD20 antibody, the FabSc-
format consisting of an N-terminal F(ab)-part linked to a C-terminal Single chain
antibody by an Fc-attenuated CH2 domain was used (Durben et al., 2015). Cys-
teines in the hinge region were replaced by serines (C226S, C229S) and the CH3
domain was removed in order to prevent formation of disulfide bonds and to avoid
dimerisation of the molecule. In all constructs 3 amino acids (GQP) from the CH3
domain and an additional serine-glycine linker were inserted between the CH2 do-
main and the single chain. Usually, the CH2 domain within an IgG molecule is
glycosylated at asparagine (N297). In order to abrogate this glycosylation and,
subsequently binding to FcγRIIIa receptor (Arnold et al., 2007) or lectin receptors
(Sjo¨wall et al., 2015), asparagine in the CH2 domain was replaced with glutamine
(N297Q). Remaining mutations in the CH2 domain (L234V, L235A, G236∆ (Wines
et al., 2000), D265G (Sazinsky et al., 2008), A327Q, A330S (Liu et al., 2014)) were
implemented in order to prevent binding of the antibody to Fc-receptors.
This backbone was used for production of CD95×CD20 antibodies as well as a
control antibody in the FabSc format. The first generated recombinant bispecific
CD95×CD20 antibody contained an N-terminal F(ab)-part of a chimeric antibody
against human CD20 (χCD20, clone 2H7) linked to a murine single chain anti-
body against human CD95 (clone APO-1) in VH-VL orientation at the C-terminus
(Fig. 3.2 a). This construct was designated BS2095 meaning BiSpecific-CD20-
CD95. The second recombinant bispecific CD95×CD20 antibody, named BS9520
(Fig. 3.2 b), consisted of the antibody clones mentioned above in the opposite orienta-
tion. N-terminal F(ab)-part of a chimeric antibody against human CD95 (χCD95)
was linked to a C-terminal mouse single chain antibody against human CD20 in
VH-VL orientation.
As a negative control for the functional assays, an antibody in the same format with
N-terminal F(ab)-part of chimeric antibody against human CD95 and unrelated
antibody (melanoma-associated chondroitin sulfate proteoglycan 4 (CSPG4)) on
the C-terminus as a mouse single chain in VH-VL orientation was generated and
designated BS95Mel meaning BiSpecific-CD95-Melanoma (Fig. 3.2 c).
All recombinant antibodies were purified from cell culture supernatant of stably-
transfected Sp2/0 cells using KappaSelect affinity chromatography. Eluted proteins
were desalted in Dulbecco’s phosphate buffered saline (DPBS) by dialysis through
a semipermeable cellulose membrane or preparative size exclusion chromatography.
3.1.2 Characterisation of recombinant bispecific antibodies
Characterisation of recombinant antibodies was routinely performed using analyti-
cal size exclusion chromatography and SDS-PAGE. Binding properties of bispecific
antibodies were analysed by flow cytometry using appropriate cell lines.
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Figure 3.2: Schematic illustration of the bispecific FabSc antibodies
CD95×CD20 antibodies: (a) BS2095 and (b) BS9520 and the CD95×CSPG4 antibody (c)
BS95Mel.
3.1.2.1 Size exclusion chromatography
10µg of each protein was loaded onto a Superdex 200 analytical size exclusion chro-
matography (SEC) column. Elution profiles of the constructs are depicted in Fig. 3.3.
The calculated molecular weight of BS2095 and BS9520 is approximately 86 kDa. In
the elution profile of BS2095 (containing single chain antibody against CD95) no
peak representing this size is detectable (Fig. 3.3 a). Rather, a large amount of ag-
gregated protein appears in the void volume of the column. In contrast, the elution
profile of the BS9520 construct (containing CD95 antibody as a N-terminal F(ab)-
part) shows only one peak at the expected size (Fig. 3.3 b). Thus it appears that
the CD95 antibody as a single chain causes complete aggregation of the BS2095
molecule. Based on these results, BS9520 was chosen for all the following experi-
ments. The same antibody format and orientation was used to generate the control
antibody BS95Mel.
Analysis of the purified control antibody BS95Mel was performed on Superdex 200™
increase 10/300 GL column using Dionex™ UltiMate™ 3000 BioRS system7. The elu-
tion profile of this antibody contains one peak of the expected size (approx. 90 kDa),
a small amount of antibody multimers appearing just in front of the main peak and a
small amount of antibody fragments behind the main peak (Fig. 3.4). The antibody
monomer was separated from the multimer and smaller proteins using a FPLC sys-
tem (Pharmacia LKB Biotechnology) equipped with a HiLoad™ 16/60 Superdex™
200 prep grade column (Appendix Fig. 6.1, page 125).
3.1.2.2 SDS-PAGE and verification of amino acid sequence
For further characterisation of BS9520 and BS95Mel antibodies, these reagents were
analysed by SDS-PAGE and compared to parental chimeric anti-CD95 monoclonal
antibodies (χCD95). Fig. 3.5 represents SDS-polyacrylamide gel electrophoresis of
7Dionex™ UltiMate™ 3000 BioRS system equipped with Superdex 200™ increase 10/300 GL
column and calibration proteins described in Fig. 3.4 were used in all the following experiments
with analytical size exclusion chromatography because of the system replacement in the laboratory.
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Figure 3.3: Analytical size exclusion chromatography of BS2095 and
BS9520 antibodies
SEC elution profiles of (a) the recombinant BS2095 and (b) the recombinant BS9520 anti-
bodies. 10µg of purified antibody were separated using SMART® System equipped with
a Superdex 200 column (PC3.2/30).
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Figure 3.4: Analytical size exclusion chromatography of BS95Mel
a) SEC elution profile of the recombinant BS95Mel antibody after a) initial KappaSe-
lect purification and b) additional preparative FPLC separation. 10µg of purified an-
tibody were separated using a Dionex™ UltiMate™ 3000 BioRS system equipped with
Superdex 200™ increase 10/300 GL column.
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the antibodies under non-reduced (lanes 2-4) and reduced (lanes 6-8) conditions
compared to a pre-stained protein ladder. The upper band in lane 2 (calculated
molecular weight 86 kDa) represents the BS9520 antibody. The bands below seem
to represent separated heavy and light antibody chains (calculated molecular weight
62.7 kDa and 23.6 kDa respectively). They are comparable to the bands obtained
under reduced conditions (lane 6). The upper band in lane 3 (calculated molecu-
lar weight 90 kDa) represents BS95Mel antibody. Again, the bands below seem to
be monomeric heavy and light chains (calculated molecular weight 66.3 kDa and
23.6 kDa respectively). The (upper) band in lane 4 shows parental chimeric anti-
CD95 antibody APO-1 under non-reduced conditions (calculated molecular weight
150 kDa). Under reduced conditions (lane 8) only two bands are visible. The upper
band is heavy chain and the band below is the light chain (calculated molecular
weight 51 kDa and 23.6 kDa respectively).
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Figure 3.5: Non-reducing and reducing SDS-PAGE
Bispecific BS9520 and BS95Mel antibodies were compared to parental monospecific χCD95
antibody under non-reduced (lanes 2-4) and β-mercaptoethanol reduced (lanes 6-7) con-
ditions. Pre-stained protein ladder (lanes 1 and 5) indicates molecular weight in kDa.
Verification of amino acid sequence of bispecific antibodies
In order to verify the antibody mRNA sequence for potential splicing cites and
thus, the proper amino acid sequence, mature cytoplasmic mRNA from antibody
producing transfected Sp2/0 cells was isolated and transcribed to complementary
DNA (cDNA) as described in 2.2.1.2 section on page 42. cDNA sequences cod-
ing for the heavy chain of BS9520 and BS95Mel antibodies were amplified, cloned
into commercial pJET1.2/blunt vector, sequenced and compared to the theoretical
antibody heavy chain sequence. The sequencing results revealed that one part of
mRNA coding for the heavy chain of BS9520 as well as BS95Mel constructs was
indeed alternatively spliced resulting in a mixture of proteins of the correct size and
1.6 kDa smaller protein lacking the Hinge region (Table 3.1). This may account for
the “heavy chain split” observed upon SDS-PAGE analysis (Fig. 3.5, lane 7).
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Table 3.1: Verification of amino acid sequences of FabSc bispecific antibody heavy chains
Parts of one correct nucleotide and amino acid sequences are compared to alternatively spliced sequences obtained by analysis of cDNA
synthesised from mRNA of transfected BS9520 and BS95Mel producing Sp2/0 cells.
CH1 domain Hinge
Position ... 206 214
Correct aac acc aag gtg gac aag aaa gtt gag ccc aaa tct tgt gac aaa act cac aca agc cca ccg agc cca
N T K V D K K V E P K S C D K T H T S P P S P
Spliced aac acc aag gtg gac aag aaa gtt — — — — — g– — — — — — — — — —
N T K V D K K V
CH2 domain
Position . . . 229 250
Correct gca cca cct gtg gca ggc ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag gac acc ctc atg atc
A P P V A G P S V F L F P P K P K D T L M I . . .
Spliced -ca cac ctg tgg cat gac cgt cag tct tcc tct tca cct caa aaa aga agg aca acc tca tga tct
A P P V A G P S V F L F P P K P K D T L M I . . .
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Figure 3.6: FACS analysis:
Binding of the recombinant BS9520 antibody (black circle) to (a) CD20+/CD95− Daudi
cells compared to parental anti-CD20 antibody (open triangle) as well as F(ab’) fragment
thereof (black triangle) and (b) to CD95+/CD20− Jurkat cells compared to parental anti-
CD95 antibody (open squares). Detection was performed using a PE-labelled Goat anti-
Human Fcγ secondary antibodies.
3.1.2.3 Binding analysis
Binding activity of the BS9520 antibody was evaluated by flow cytometry as de-
scribed in section 2.4.4.1 on page 51. The CD20+/CD95− Daudi human Burkitt’s
Lymphoma cell line and the CD95+/CD20− Jurkat human acute T-cell leukaemia
cell line were used for this purpose.
As depicted in Fig. 3.6 a, expression of the CD20-binding antibody part in the sin-
gle chain format resulted in a significant loss of affinity compared to the normal,
bivalent anti-CD20 antibody (clone 2H7) and to the monovalent F(ab’) fragments
thereof (prepared as described in section 2.4.2 on page 50). Anti-CD20 antibody
2H7 in IgG format is detectable at concentrations ≥0.1 nM and is saturated at the
concentration 100 nM. The same antibody as a purified F(ab’) fragment is detectable
at the concentration ≥1 nM and is saturated at the concentration approx. 300 nM.
BS9520 is detectable at the concentration ≥12 nM and not saturated even at the con-
centration of 670 nM. In contrast, the activity of BS9520 towards CD95 (Fig. 3.6 b),
is only moderately reduced compared to the parental anti-CD95 antibody (APO-1).
Binding of the BS9520 antibody on Jurkat cells is detectable at ≥0.5 nM and satu-
rated at the concentration of ≥100 nM.
Binding of the purified monomeric BS95Mel control antibody was also evaluated
by flow cytometry. As depicted in Fig. 3.7, BS95Mel antibody is able to bind on
both cell lines with a good affinity. Binding on SK-Mel cells was detectable at a
concentration of ≥0.5 nM and saturated at a concentration ≥10 nM. The binding
activity of BS95Mel on Jurkat cells is detectable at 0.5 nM and saturated at the
concentration of ≥10 nM. The binding of BS95Mel detected using CD95+ Jurkat
cells correspond to the results obtained with BS9520 antibody (Fig. 3.6).
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Figure 3.7: FACS analysis:
Binding of the recombinant BS95Mel antibodies to (a) CSPG4+/CD95− Sk-Mel cells com-
pared to parental anti-CSPG4 antibody and (b) to CD95+/CSPG4− Jurkat cells compared
to parental anti-CD95 antibody (APO-1). Detection was performed using a PE-labelled
Goat anti-Human Fcγ secondary antibodies.
3.2 Induction of apoptosis in B-lymphoma cells
In this section the suppression and depletion of various B-cell lymphoma cell lines
by monospecific clinically established CD20 antibodies will be compared to that
achieved by the recombinant bispecific BS9520 antibody described in the previous
section (Fig. 3.9).
3.2.1 Quantification of CD20 and CD95 expression on vari-
ous B-lymphoma cell lines
Expression of surface CD20 and CD95 on various B-lymphoma cell lines used in cyto-
toxicity assays was quantified with QIFIKIT® by flow cytometry using indirect im-
munofluorescence assay as described in section 2.4.4.2 on page 52. Cell samples were
labelled with mouse anti-human CD20 antibody (clone 2H7), mouse anti-human
CD95 antibody (clone APO-1) or with mouse anti-human CD3 (clone UCHT1) as
an isotype control at saturating concentration (10µg/mL). Under these conditions,
the number of bound primary antibody molecules corresponds to the number of
antigenic sites present on the cell surface. To quantify bound primary monoclo-
nal antibodies, the cells were incubated, in parallel with the QIFIKIT® beads, with
FITC conjugated polyclonal goat anti-mouse immunoglobulins at saturating concen-
tration. A calibration curve was constructed by plotting the fluorescence intensity of
the individual calibration bead populations against the number of antibody binding
sites on the beads. The number of antigenic sites on the specimen cells were then
determined by interpolation and summarized in table 3.2 with the indicated range
for each sample (measurement was performed in duplicates).
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Table 3.2: Quantitative determination of CD20 and CD95 expression on
different lymphoma cell lines
Cells CD95 expression CD20 expression CD3 expression
(molecules per cell)
SKW6.4 103 692± 1 044 323 931± 4 864 0
C1R 36 547± 373 121 796± 0 0
JY 155 019± 1 556 636 509± 6 365 0
Raji 20 872± 108 630 144± 0 0
Jurkat 10 301± 55 0 46 152± 237
3.2.2 Functional assays in vitro
In the initial experiments, specific cytotoxicity of BS9520 antibody was tested on
different CD20+/CD95+ B-cell lymphoma cell lines using a [methyl-3H]-thymidine
incorporation assay (Fig. 3.8). Proliferation of SKW6.4, C1R and JY cell lines
was successfully inhibited at concentrations ≥100 ng/ml. The cytotoxic activity of
BS9520 against Raji cells was marginal, although these cells express CD20 as well
as CD95 (Table 3.2).
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Figure 3.8: Proliferation of different B-lymphoma cell lines in response to
BS9520 antibody
20 000 cells/well were incubated for 24 h with different antibody concentrations and then
pulsed with [methyl-3H]-thymidine. % inhibition of proliferation was calculated as de-
scribed in section 2.5.1.1 on page 53. Each data point represents the mean value of
triplicate samples.
After these initial experiments, the bispecific antibodies (BS9520 and the control
antibody BS95Mel depicted in Fig. 3.2 b, c, page 61) were tested in functional assays
in comparison to various monospecific anti-CD20 antibodies (Fig.3.9 a, b). One of
them is the commercial FDA-approved chimeric anti-CD20 antibody Rituximab
nowadays used within standard first line treatment regimens for lymphoma. CH20
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Figure 3.9: CD20-antibodies compared in this work
(a) FDA-approved antibody Rituximab and CH20, a chimeric antibody with variable re-
gions derived from the anti-CD20 antibody (clone 2H7), (b) SDIE20, the chimeric anti-
CD20 antibody (clone 2H7) with an optimized Fc-part (S239D and I332E in CH2 domain),
(c) BS9520, a bispecific molecule in the FabSc-format with an N-terminal CD95-specificity
and a C-terminal single chain binding CD20.
is another chimeric, monospecific antibody directed against CD20 (derived from
clone 2H7 contained in the commercial antibody Ocrelizumab) and SDIE20 is an
optimised version thereof carrying amino acid modifications S239D and I332E in
CH2 domain for enhanced antibody-dependent cell-mediated cytotoxicity (ADCC)
activity (Lazar et al., 2006).
Due to the different mode of action of monospecific CD20 antibodies, all further
proliferation assays with lymphoma cell lines were performed in the presence of
different amounts of PBMC as a source of effector cells for ADCC. The thymidine
incorporation assay was termed in this setting “Proliferation inhibition assay” based
on the assumption that PBMC do not proliferate and the only cells incorporating
[methyl-3H]-thymidine are lymphoma cells.
Fig. 3.10 depicts the anti-proliferative activity of BS9520, CH20, SDIE20 and Ri-
tuximab antibodies towards various lymphoma cells in the presence of PBMC as
a source of effector cells. At concentrations ≥100 ng/ml and a PBMC : target ra-
tio of 5 : 1 (200 000 PBMC and 40 000 target cells) the activity of BS9520 antibody
was higher than that of monospecific CD20 antibodies. Rising the PBMC : target
ratio to 10 : 1 (200 000 PBMC and 20 000 target cells), however, attenuates this dif-
ference. The ADCC activity of Rituximab and CH20 was comparable and clearly
less pronounced than that of the Fc-optimized SDIE20 antibody. Cytotoxic activity
of BS9520 with PBMC is only marginally diminished compared to results obtained
without effector cells (Fig. 3.8).
Whereas this pattern held true for three of the four cell lines tested, Raji cells were
different: not only the cytotoxic activity of BS9520 against these cells was marginal,
killing by the monospecific antibodies was also markedly reduced.
When we assessed depletion of SKW6.4 cells (Fig. 3.11) and Raji cells (Fig. 3.12) in
a flow cytometry based assay, again at a PBMC : target ratio of 10 : 1, similar obser-
vations were made. After 48 hours almost complete depletion of the SKW6.4 cells
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Figure 3.10: Proliferation inhibition assay
Antibody dependent cellular cytotoxicity against various lymphoma cell lines. PBMC and
target cells were incubated with the indicated antibodies at PBMC : target ratios of 5 : 1
or 10 : 1 and pulsed after 24 h with [methyl-3H]-thymidine. Mean values and standard
deviations of triplicate samples are indicated.
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by all CD20 targeting antibodies was observed. At low concentrations (≤ 100 ng/ml)
the Fc-optimized CD20 antibody was more efficient (Fig. 3.11). If Raji cells were
used as targets (Fig. 3.12), the activity of BS9520 and monospecific antibodies was
again largely reduced, but it was more pronounced than in the proliferation inhi-
bition assay. Thus, these results confirm in principle the data of the Thymidine-
incorporation assay, but with a higher sensitivity. Antibodies, especially SDIE20,
were able to decrease the amount of Raji cells at concentrations ≥ 10 ng, but were un-
able to deplete them completely even at the concentration of 1µg/mL. Furthermore
reduction of monocytes upon incubation with BS9520 but not with the monocpecific
antibodies was noticed. In any case, it is notable that normal B-cells remain almost
unaffected by the BS9520 construct. In contrast, upon incubation with monospe-
cific antibodies, normal B-cells expressing high amounts of CD19 disappear and a
population of “CD19-low” cells remains (Fig. 3.11 and 3.12).
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Figure 3.11: Depletion of SKW6.4 lymphoma cells in the presence of
PBMC
200 000 PBMC and 20 000 SKW6.4 were co-cultured in the presence of the indicated anti-
bodies at different concentrations (indicated on the right) and analysed after 48 h by flow
cytometry. SKW6.4 were defined as FSC-A high and CD19+, monocytes as FSC-A inter-
mediate and CD19−, B-cells as FSC-A low and CD19+. Absolute cell numbers (mean and
range of technical duplicates) of these populations are indicated on FACS plots as italic
numbers.
72 CHAPTER 3. RESULTS
0-10
3
10
3
10
4
10
5
0
50K
100K
150K
200K
250K
0-10
3
10
3
10
4
10
5
0
50K
100K
150K
200K
250K
0-10
3
10
3
10
4
10
5
0
50K
100K
150K
200K
250K
0-10
3
10
3
10
4
10
5
0
50K
100K
150K
200K
250K
0-10
3
10
3
10
4
10
5
0
50K
100K
150K
200K
250K
0-10
3
10
3
10
4
10
5
0
50K
100K
150K
200K
250K
0-10
3
10
3
10
4
10
5
0
50K
100K
150K
200K
250K
0-10
3
10
3
10
4
10
5
0
50K
100K
150K
200K
250K
0-10
3
10
3
10
4
10
5
0
50K
100K
150K
200K
250K
0-10
3
10
3
10
4
10
5
0
50K
100K
150K
200K
250K
0-10
3
10
3
10
4
10
5
0
50K
100K
150K
200K
250K
0-10
3
10
3
10
4
10
5
0
50K
100K
150K
200K
250K
BS9520 CH20 SDIE20
F
S
C
-A
CD19-Pacific Blue
Raji
23610 ±3082
Monocytes
5469 ±779
B-cells
8162 ±660
30951 ±626
6819 ±1731
9591 ±231
42048 ±734
18315 ±883
10919 ±17
49800 ±1386
20761 ±352
10460 ±461
22833 ±4097
18709 ±130
7153 ±1008
28317 ±10081
15826 ±3171
9608 ±1155
34092 ±9628
14299 ±4169
9968 ±162
42429 ±3845
15845 ±206
9349 ±121
13595 ±724
20158 ±348
5516 ±455
13039 ±1185
20021 ±51
5331 ±101
22072 ±1054
22378 ±474
8508 ±19
37857 ±81
19322 ±462
9349 ±121
1
µ
g
/m
L
1
0
0
 n
g
/m
L
1
0
 n
g
/m
L
1
 n
g
/m
L
Figure 3.12: Depletion of Raji lymphoma cells in the presence of PBMC
200 000 PBMC and 20 000 Raji cells were co-cultured in the presence of the indicated
antibodies at different concentrations (indicated on the right) and analysed after 48 h by
flow cytometry. Raji cells were defined as FSC-A high and CD19+, monocytes as FSC-
A intermediate and CD19−, B-cells as FSC-A low and CD19+. Absolute cell numbers
(mean and range of technical duplicates) of these populations are indicated on FACS plots
as italic numbers.
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3.2.3 Functional assays in vivo: determination of antibody
half-life in mouse serum
For comparison of bispecific BS9520 antibody kinetics with monospecific anti-CD20
antibodies in mouse serum, C57BL/6 mice were injected with 50µg of the respective
antibody i.v. and blood samples were collected at the indicated time points. The
serum concentration of BS9520, CH20 and SDIE20 was determined by FACS anal-
ysis.
As depicted in Fig. 3.13, a serum concentration of 15µg/ml is easily maintained for
monospecific antibodies for ≥24 h, whereas the concentration of BS9520 falls rapidly
below this value within 4 h.
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Figure 3.13: Serum kinetics of anti-CD20 antibodies
C57BL/6 mice were injected with 50µg of the respective antibody i.v. and blood samples
were taken at the indicated time points. Antibody concentration in mouse serum was
determined by FACS analysis. Mean values and standard deviations obtained with three
mice per time point are indicated.
3.2.4 Functional assays in vivo: SCID mouse xenograft model
In order to compare the anti-tumour activity of mono- and bispecific antibodies in
vivo, six groups of eight C.B.-17 SCID mice were inoculated with a lethal dose of
1× 107 SKW6.4 cells i.v. After 24 h different antibodies in 100µL DPBS or DPBS
alone were applied by intraperitoneal (i.p.) injection. Monospecific antibodies CH20,
SDIE20 and anti-epidermal growth factor receptor antibody (EGFR) were applied
once (60µg) at the first day and bispecific antibodies (BS9520 and BS95Mel) were
applied 3× 20µg on three consecutive days to compensate for their lower serum
half-life (Table 3.3). BS95Mel was used as a control for bispecific BS9520 antibody
and anti-EGFR was used as a control for monospecific anti-CD20 antibodies. Mice
were observed every day and as soon as they developed paralysis of the hind legs,
animals were sacrificed.
74 CHAPTER 3. RESULTS
Most of untreated (DPBS) and control antibody (BS95Mel and anti-EGFR) treated
animals survived only until day 40 (Fig. 3.14). SDIE20 and CH20 were able to
prolong survival of 2 mice until day 120. In contrast, BS9520 was found to be the
most effective reagent. 6 of 8 animals survived until day 120 when the experiment
was terminated.
Table 3.3: SCID mouse xenograft model experiment schedule
Respective antibodies were diluted in 100µL DPBS and applied to the C.B.-17 SCID mice
by intraperitoneal (i.p.) injection. Each group consisted of eight mice.
Group Antibody Day 1 Day 2 Day 3
1 DPBS 100µL DPBS 100µL DPBS 100µL DPBS
2 BS9520 20µg 20µg 20µg
3 BS95Mel 20µg 20µg 20µg
4 CH20 60µg
5 SDIE20 60µg
6 EGFR 60µg
0 20 40 60 80 100 120
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Figure 3.14: SCID mouse xenograft model survival curves
Anti-tumour activity of the BS9520 antibody compared to anti-CD20 and control antibo-
dies.
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3.3 Induction of apoptosis in normal activated B-
lymphocytes
Although the bispecific BS9520 antibody showed promising results against malig-
nant B-cells in vivo and in vitro, its activity against malignant B-cells in a clinical
setting may be limited due to the resistance of the lymphoma cells acquired in
vivo. In contrast to malignant cells normal B-cells maintain their well established
CD95 sensitivity acquired during B-cell activation. Thus, activated and CD95 ex-
pressing normal B-cells producing autoantibodies are promising alternative targets
for BS9520. Thus, this antibody will be tested in this section against normal and
activated B-cells as a model for use in B-cell mediated autoimmune disease.
3.3.1 Expression of CD95 on resting leukocytes
In order to evaluate the expression of CD95 on different normal resting leukocyte
populations, peripheral blood leukocytes isolated from heparinized blood samples by
red blood cell (RBC) lysis were used. After staining with directly labelled antibo-
dies, specimens were analysed by flow cytometry. Cell populations were determined
according to their morphology and surface antigen expression (Fig. 3.15 a-c).
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Figure 3.15: FACS gating strategy for peripheral blood leukocytes
a) Populations of lymphocytes, monocytes and granulocytes were first identified according
to their morphology. b) Populations of T-lymphocytes and NK-cells were determined
according to CD3 and CD56 expression on their cell surface. c) B-cells were identified
according to CD19 expression.
As depicted in Fig. 3.16 a, expression of CD95 on resting B-cells is marginal. In
contrast, almost one half of T-cells are bearing CD95. Some detectable expression
of CD95 was also observed on NK cells and this expression varies between different
donors (Fig. 3.16). Monocytes and granulocytes were found to be CD95-positive in
all of the tested donors.
Plasma cells are B-cells producing immunoglobulins. Thus, CD95 expression was
also verified on healthy resting plasma cells to find out whether they could be affected
upon BS9520 treatment. To this end fresh bone marrow cells from 5 healthy donors
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Figure 3.16: CD95 expression on peripheral blood lymphocytes
CD95 expression on different leukocyte populations (indicated on the right) from three
different donors: empty histograms represent samples stained with APC-labelled isotype
control and shaded histograms CD95 staining (samples were analysed in technical dupli-
cates).
3.3. INDUCTION OF APOPTOSIS IN NORMAL B-CELLS 77
(kindly provided by the bone marrow transplantation department in Tu¨bingen) were
tested. Red blood cells were removed by RBC lysis. After staining with directly
labelled antibodies samples were analysed by flow cytometry. Fig. 3.17 represents the
gating strategy (according to (Halliley et al., 2015)) and CD95 expression on CD138+
plasma cells of one representative donor. More than one half of the CD138+ plasma
cells in bone marrow were found to express CD95 on the cell surface (Fig. 3.17 d).
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Figure 3.17: CD95 expression on plasma cells in bone marrow
Plasma cells isolated from the bone marrow of healthy donors were gated by excluding cells
that express CD3, CD14 (a) and IgD (b). Panel (c) represents CD19 negative and positive
plasma cells identified by CD138 expression. CD95 expression on CD138+ plasma cells of
one representative healthy donor is depicted in the panel (d). Empty histogram represent
a sample stained with APC-labelled isotype control and shaded histograms CD95 staining
(samples were analysed in technical duplicates).
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3.3.2 Kinetics of CD95 expression and antibody production
by activated B-cells
As a model for B-cell activation, stimulation of freshly isolated PBMC with pokeweed
mitogen (PWM) was performed. PWM is a lectin purified from the plant Phytolacca
americana. It is frequently used as a T-cell dependent B-cell mitogen to trigger
proliferation of B-cells and immunoglobulin secretion in vitro (Keightley et al., 1976;
Bekeredjian-Ding et al., 2012).
PBMC from healthy donors were stimulated with 1µg/mL PWM for various times
as described by Daniel and Krammer (Daniel and Krammer, 1994). CD95 expres-
sion on activated cells was subsequently analysed by flow cytometry. Cell culture
supernatants from the same samples were analysed by ELISA for immunoglobulin
secretion (as described in 2.4.5 section on page 53). As depicted in Fig. 3.18, the ex-
pression of CD95 on CD19+ B-cells was marginal at the initiation of the experiment.
It increases significantly after 24 h of PWM stimulation, reaches a maximum at day
3 and remains at this maximum up to 10 days despite removal of PWM at day 6.
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Figure 3.18: Expression of CD95 on PWM activated human B-cells
Human PBMC were activated for 1 to 10 days with PWM and then analysed by FACS.
CD95 expression on B-cells was determined by gating on the CD19+ population (empty
histograms represent samples stained with APC-labelled isotype control antibody and
shaded histograms represent CD95 staining).
In contrast to CD95 expression on B-cells, IgG production requires at least 4 days of
stimulation to become detectable and, despite washing of the cells at day 6, steadily
rises up to day 8, which was the termination point for most of the experiments
(Fig. 3.19).
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Figure 3.19: Kinetics of IgG production in PWM activated PBMC cul-
tures
Cell culture supernatans were taken on indicated days from 24-well plates containing
2× 106 cells/well/mL of untreated or PWM stimulated PMBC. Supernatants were anal-
ysed by ELISA for human IgG secretion as described in 2.4.5 section on page 53.
3.3.3 Induction of apoptosis in activated B-cells in vitro
Previous results suggested that anti B-cell activity of BS9520 as well as of the
monospecific CD20 antibodies is maximal at concentrations ≥100 ng/mL. Thus,
BS9520 and BS95Mel were compared in functional assays to the monospecific CD20
antibodies (Fig. 3.9) using this concentration. PBMC cultures that contained either
resting cells or cells that had been activated for 6 days with PWM were used as a
target cells.
Cytolytic activity of the antibodies against normal resting or PWM-activated B-cells
within PBMC cultures was evaluated using a flow cytometry (FACS) based assay
as described in 2.4.4.4 on page 52. To illustrate this assay FACS plots of one rep-
resentative donor are presented in Fig. 3.20. Fig. 3.21 summarizes results obtained
with unstimulated PBMC from 4 healthy donors and with PWM-stimulated PBMC
from 5 healthy donors. SDIE20 effectively depleted B-cells in resting as well as in
activated cultures. The activity of CH20 as well as that of Rituximab was clearly
less pronounced and highly variable between different donors, in particular, if resting
cells were used. BS9520 is only marginally effective against resting cells, however, it
effectively kills B-cells in PWM activated PBMC cultures. Interestingly, we noted
that BS9520 in contrast to the monospecific antibodies affected not only B-cells but
also CD4+ and CD8+ T-cells present in the PBMC cultures, albeit to a lesser extent.
Again, bystander killing of T-cells by BS9520 was observed only in PWM activated
cultures.
The pattern of cytolytic activity against activated B- and T-cells described above
was also observed when early apoptosis was measured by staining with AnnexinV
and subsequent analysis by flow cytometry (Fig. 3.22): killing of activated B-cells
by the Fc-optimized mono- and the bispecific antibody was comparable, but only
the bispecific reagent causes significant apoptosis of activated T-cells.
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Figure 3.20: Depletion of B-cells in resting and PWM-activated PBMC cultures.
PBMC, either untreated (resting) or activated with 1µg/mL PWM for six days, were incubated for two days with the indicated antibodies
(0,1µg/mL) and analysed by flow cytometry. FACS analysis of B-cell and T-cell depletion within a) resting and b) PWM stimulated PBMC
cultures of one donor is shown.
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Figure 3.21: Summarised FACS depletion experiments of activated and
resting PBMC
Depletion of (a, b) B-, (c, d) CD4+ T-cells and (e,f) CD8+ T-cells in PWM-activated
and resting PBMC cultures. PBMC, either untreated (resting) or activated with 1µg/ml
PWM for six days, were incubated for two days with the indicated antibodies (0.1µg/ml)
and analysed by flow cytometry. Different symbols indicate the mean values of technical
duplicates obtained with PBMC from different healthy donors.
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Figure 3.22: AnnexinV staining of activated PBMC after antibody treat-
ment
CD19+ and CD4+ cells in PWM activated PBMC cultures were incubated with the re-
spective antibodies (1µg/mL) for 4 h. The cells were stained subsequently with AnnexinV
and analysed by flow cytometry. One representative experiment of three is shown. Empty
histograms represent samples without antibody treatment and filled histograms show An-
nexinV staining after antibody treatment.
3.3.4 Suppression of PWM-induced IgG synthesis in vitro
Next, we investigated the capability of BS9520 to suppress antibody production
in PBMC cultures in comparison with anti-CD20 antibodies. To this end, 6 days
PWM activated PBMC cultures from 6 healthy donors were incubated with or with-
out 0.1µg/mL of each antibody for 2 days. Then, cell culture supernatants were
analysed by ELISA for human IgG production as described in 2.4.5 section on page
53. Monospecific and bispecific antibodies used in this assay did not interfere with
the ELISA detection system at the concentration used (0.1µg/mL).
Results depicted in Fig. 3.23 a show significant suppression of polyclonal IgG produc-
tion in PBMC cultures incubated with BS9520, which was superior to that achieved
with optimized SDIE20 antibody, although both reagents demonstrated comparable
reduction of the B-cells in FACS based depletion assay. Chimeric CH20 antibody
as well as Rituximab were not effective in these experiments.
3.3.5 Suppression of TT induced IgG synthesis in vitro
The same experimental setting was used to address the question whether BS9520
is also able to suppress IgG production in PBMC cultures stimulated with specific
antigen. In this case Tetanus toxoid (TT)-specific IgG was measured in cell culture
supernatants using a TT specific ELISA.
As depicted in Fig. 3.23 b, Tetanus-specific antibody production was significantly
suppressed by BS9520, SDIE20 induced a marginal suppression. The chimeric anti-
CD20 antibody CH20 and Rituximab did not exert significant effects.
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Figure 3.23: Suppression of IgG production in vitro
Suppression of polyclonal and specific IgG production in PBMC cultures by various anti-
bodies. PBMC of different healthy donors were stimulated for six days with PWM (a) and
tetanus toxoid (b). Cells were then washed and incubated for two days with the indicated
antibodies. Antibody production in the culture supernatants was estimated by ELISA as
described in section 2.4.5. Different symbols indicate the mean values of technical ELISA
duplicates obtained with PBMC from different healthy donors.
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3.4 Generation of recombinant CD95-Ag fusion
proteins
The concept of bispecific antibodies depleting activated B-cells and suppressing IgG
production via the CD95 death receptor was further developed to increase target-
specificity of such reagents. A significant subsequent step of this concept would be
suppression and depletion of antigen-specific B-cells.
To this end, novel fusion proteins containing agonistic anti-CD95 antibody and
an antigen (Ag) were generated by replacing the C-terminal single chain antibody
within the FabSc format by the antigen resulting in a “FabAg-format”. In this case
CD95-mediated apoptosis is supposed to be induced in activated B-cells carrying a
certain antigen-specific B-cell receptor (BCR) and CD95 receptor on their surface.
The expected mode of action of such bispecific fusion proteins is depicted in Fig. 3.24.
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Figure 3.24: Induction of apoptosis by CD95×Ag fusion proteins
a) Bispecific CD95×Ag fusion protein binds to Ag-specific BCR and CD95 death receptor
on B-cells and induces apoptosis. b) In the absence of the specific BCR apoptosis does
not occur.
For proof of principle Tetanus toxoid (TT) and Diphtheria toxoid (DT) were chosen
as model antigens. Fusion proteins, generated with these antigens were designated
BS95TT and BS95DT, respectively. An expression vector for BS9520 antibody
(Fig. 2.4, page 41) developed in the first part of this work was used as a backbone
for cloning and transfection of Sp2/0 cells.
3.4.1 Generation and characterisation of BS95TT
The part of the BS9520 vector containing the sequence for the CD20 ScFv was
replaced by various truncated sequences for tetanus toxoid (TT) heavy chain. A
part of TT heavy chain, also known as Hc or C fragment consists of 451 a.a. (Gen-
Bank:#1AF9 A). Three different variants of this fragment capable to induce an
immune response in mice (Figueiredo et al., 1995) were linked to CD95 antibody
and produced by transfected Sp2/0 cells as fusion proteins in the FabAg format.
BS95TT fusion proteins were purified from cell culture supernatant as described in
2.4.1.1 section. Determination of protein concentration was achieved using molar
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Figure 3.25: Assembling of improved BS95TT and BS95DT expression
vector
a) BS95TT plasmid containing introns between CH1 and CH3 antibody domains. The
vector part coding for constant domains, hinge region and introns between CH1 and CH3
was removed using AgeI and BspEI restriction sites. DNA sequence without introns (b)
was obtained by isolation of cytoplasmic mRNA from Sp2/0 transfected with BS95TT1−451
and reverse transcription of the RNA sequence into cDNA. This sequence was inserted into
the plasmid c) using AgeI and BspEI restriction sites. Next, TT Hc fragment sequence
was replaced with DT sequence (d) using BspEI and SpeI restriction sites.
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Table 3.4: Recombinant BS95TT fusion proteins
Overview of generated CD95×TT constructs bearing different truncated variants of
tetanus Hc fragment, calculated theoretical MW (kDa) and extinction coefficient of the
generated proteins.
Construct TT Hc a.a. Calculated MW Extinction coef.
in construct (kDa) (M−1 cm−1, 280 nm)
BS95TT1−271 1-271 89.926 137015
BS95TT80−451 80-451 101.996 168875
BS95TT1−451 1-451 110.763 177355
extinction coefficients calculated for each protein separately (Table 3.4 8).
BS95TT1−451 fusion protein capable of folding properly was further improved by
modifying the expression vector by removing introns between CH1 and CH3 domains
of the heavy chain to avoid alternative splicing in the Hinge region as described in
the section 3.1.2.2. The main cloning steps leading to improvement of the expres-
sion vector are represented in Fig. 3.25. Improved BS95TT1−451 (without introns in
the expression vector) was produced in Sp2/0 cells and purified from cell culture
supernatant using KappaSelect affinity chromatography.
Analytical size exclusion chromatography
Elution profiles of BS95TT constructs are depicted in Fig. 3.26. BS95TT1−271 and
BS95TT80−451 containing truncated parts of Tetanus Hc fragment failed to fold
properly. BS95TT1−271 (Fig. 3.26 a) showed a non-symmetric main peak and various
smaller protein fragments. BS95TT80−451 (Fig. 3.26 b) contained a multimerized
and aggregated protein. Only one construct containing the whole C-part of TT
heavy chain (BS95TT1−451) was produced and folded properly (Fig. 3.26 c). Elution
profile of the improved BS95TT1−451 fusion protein represented in Fig. 3.26 d showed
an identical peak compared to that depicted on Fig. 3.26 c. No additional protein
fragments or multimers were detectable.
SDS-PAGE analysis
In order to separate BS95TT proteins based on their primary structure SDS-PAGE
analysis was performed. Fig. 3.27 depicts gel electrophoresis of generated fusion
proteins under non-reduced (lanes 2-5) and β-mercaptoethanol reduced (lanes 7-10)
conditions compared to a pre-stained protein ladder.
BS95TT1−271 shows multiple bands in the non-reduced sample. In the reduced sam-
ple, the heavy chain (upper band) is significantly smaller (approx. 40 kDa) than
expected. BS95TT80−451 shows more than one band under non-reduced condi-
tions. The upper band might be aggregated protein (according to SEC results
in Fig. 3.26 b), the second band is complete BS95TT80−451 fusion protein and the
bands below could be monomeric heavy and light chains (calculated size 78.2 kDa
and 23.6 kDa).
8Enumeration of amino acids is assigned to the Tetanus Hc fragment sequence and not to the
whole BS95TT fusion protein.
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Figure 3.26: Analytical size exclusion chromatography of different BS95TT
fusion proteins
a) BS95TT1−271 fusion protein containing 271 a.a. of Tetanus toxoid on the C-terminus of
the heavy chain, b) BS95TT80−451 fusion protein containing 371 a.a. (80-451) of Tetanus
toxoid, c) BS95TT1−451 fusion protein containing 451 a.a. of Tetanus toxoid, d) improved
BS95TT1−451 fusion protein containing 451 a.a. of Tetanus toxoid. 10µg of purified fusion
proteins were separated using a Dionex™ UltiMate™ 3000 BioRS system equipped with
Superdex 200™ increase 10/300 GL column.
Two different variants of one construct – primary and improved BS95TT1−451 – are
analysed in lanes 4 and 5 as well as in 9 and 10. The upper band in lane 4 repre-
sents complete BS95TT1−451 fusion protein. The bands below could be monomeric
heavy and light chains (calculated size 86.7 kDa and 23.6 kDa, respectively). In
contrast, improved BS95TT1−451 does not contain any additional bands under non-
reducing conditions as depicted in lane 5. Under reduced conditions (lanes 9 and
10) both proteins seems to be identical (calculated molecular weight of the heavy
chain 110.7 kDa).
FACS analysis
In order to measure binding activity, BS95TT1−451 fusion protein was tested by flow
cytometry on SKW6.4 cells (Fig. 3.28). As expected, BS95TT1−451 exhibit very
good binding properties on CD95 as well as on TT fusion protein part. Binding
on CD95+ SKW6.4 cells is comparable to that obtained with BS9520 and BS95Mel
FabSc constructs.
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Figure 3.27: Non-reducing and reducing SDS-PAGE of BS95TT fusion
proteins
2µg of each antibody pro lane were tested in SDS-PAGE compared to pre-stained protein
ladder indicating molecular weight in kDa.
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Figure 3.28: FACS analysis of BS95TT1−451 fusion protein on CD95
+
SKW6.4 cells
Binding to SKW6.4 cells was detected with Goat anti-Human Igγ-APC secondary anti-
body (empty squares) and binding to Tetanus part of the fusion protein was detected using
anti-Tetanus Hc fragment Rabbit serum, subsequently visualised with Donkey anti-Rabbit
Igγ-APC secondary antibody (black squares).
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3.4.2 Generation and characterisation of the control protein
BS95DT
For construction of the control protein BS95DT the part of the BS95TT vector
containing the sequence for Tetanus toxoid was replaced with various truncated
sequences of non-toxic Diphtheria toxin Mutant CRM197 (Giannini et al., 1984)
using BspEI and SpeI restriction sites (Fig. 3.25 d). First only one part of the DT
protein known to be immunogenic (Romaniuk et al., 2012) was coupled to CD95
antibody and produced by transfected Sp2/0 cells as fusion protein. Additionally,
constructs with different CRM197 parts and amino acid substitutions were created
due to problems concerning protein folding and aggregation. An overview of the
generated BS95DT fusion proteins is summarised in the table 3.5.
Table 3.5: Recombinant BS95DT fusion proteins
Overview and calculated MW (kDa) of generated CD95×DT constructs bearing different
domains (C, T and R) of non-toxic Diphtheria toxin Mutant CRM197.
Construct CRM197 a.a. Calculated MW Extinction coef.
in construct (kDa) (M−1 cm−1, 280 nm)
BS95DT-TR 194-535 97.864 114555
BS95DT-TR (C201G) 194-535 97.910 114555
BS95DT-CTR 1-535 119.073 140580
(R173Q R193Q)
BS95DT-CT 1-384 103.084 130485
(R173Q R193Q)
BS95DT-CTR 1-535 118.981 140455
(R173Q R193Q C186G C201G)
BS95DT-CT 1-384 102.390 130360
(R173Q R193Q C186G C201G)
Size exclusion chromatography
Elution profiles of all generated BS95DT constructs are depicted on Fig. 6.2 in the
appendix on page 126. Almost all of them aggregated extensively. Only BS95DT-CT
constructs carrying C and T domains (Fig. 6.2 d,f) contained detectable amounts of
monomers, which could be separated using preparative size exclusion chromatogra-
phy. To this end, KappaSelect purified BS95DT-CTR173QR193Q (clone 5B1) fusion
protein was loaded onto Superdex™ 200 Prep Grade 16/60 HiLoad column and
separated from multimers and smaller protein fragments using A¨KTApure chroma-
tography system. Separated protein was tested again using analytical size exclusion
chromatography (Fig. 3.29).
FACS analysis
To measure binding activity, BS95DT-CTR173QR193Q fusion protein and purified
monomer thereof were tested by flow cytometry. As depicted in Fig. 3.30 a BS95DT
is saturated at the concentration about 1µg/mL. At the concentrations ≥ 1µg/mL
unspecific fluorescence increases suggesting the presence of aggregated protein. In
contrast, purified monomeric BS95DT does not show this phenomenon (Fig. 3.30 b).
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Figure 3.29: Analytical SEC of BS95DT (clone 5B1) before and after
preparative FPLC separation
a) BS95DT-CTR173QR193Q (clone 5B1) containing C and T domains after initial Kappa-
Select purification. b) BS95DT-CTR173QR193Q (clone 5B1) preparative FPLC purification
using Superdex™ 200 Prep Grade 16/60 HiLoad column. 2µg of multimeric and monomeric
proteins were separated using a Dionex™ UltiMate™ 3000 BioRS system equipped with
Superdex 200™ increase 10/300 GL column 10.
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Figure 3.30: FACS analysis of BS95DT (clone 5B1) before and after prepar-
ative FPLC separation
a) BS95DT-CTR173QR193Q (clone 5B1) containing C and T domains after initial Kappa-
Select purification. b) BS95DT-CTR173QR193Q (clone 5B1) after preparative FPLC purifi-
cation. Binding of different BS95DT fusion proteins to SKW6.4 cells was detected with
Goat anti-Human Igγ-APC secondary antibody (black circles) and with anti-Diphtheria
rabbit serum, subsequently visualised with Donkey anti-Rabbit Igγ-APC secondary anti-
body (empty circles).
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3.4.3 Suppression of specific IgG production
The induction of in vitro anti-tetanus toxoid IgG synthesis was performed according
to the protocol described by Lum and Culbertson (Lum and Culbertson, 1985).
Freshly isolated PBMC from 6 recently TT/DT immunized donors were stimulated
with Tetanus toxoid for 6 days. For an indirect detection of B-cell killing the cells
were washed three times and incubated with different antibody- or fusion protein
constructs. After two days suppression of specific anti-tetanus IgG production in
cell culture supernatants was measured using specific ELISA as described in 2.4.5
section on page 53.
A moderate suppression of tetanus-specific antibody production by BS95TT was
observed in 4 of 6 tested donors (Fig. 3.31). It is clearly less efficient than suppression
achieved with BS9520. BS95Mel as well as the control fusion protein BS95DT did
not exert significant suppressive effects.
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Figure 3.31: Suppression of anti-TT IgG production in vitro
Suppression of specific anti-TT IgG production in TT-stimulated PBMC cultures. Dif-
ferent symbols indicate the mean values of technical ELISA duplicates obtained from 6
different healthy donors.
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4.1 Development of the CD95×CD20 antibody
4.1.1 Challenges in protein engineering and production
The selective stimulation of the CD95 death receptor is one of several attractive
applications for bispecific antibodies. However, the production of such reagents in
pharmaceutical quality and quantity remains a formidable challenge despite consi-
derable progress in recombinant antibody technology (Wo¨rn and Plu¨ckthun, 2001;
Hust et al., 2007).
The development of the bispecific CD95×CD20 antibody strikingly illustrates this
problem: production of a functional bispecific antibody containing the CD95 bin-
ding part as a ScFv (single-chain fragment variable) molecule, irrespective of VH-VL
orientation, was not successful due to extensive aggregation of this moiety. Single
chain antibodies can aggregate owing to physical and chemical instabilities that pre-
clude the folding of stable molecules (Perchiacca and Tessier, 2012). It is known
that the sequence of CDR loops can significantly impact the folding stability of
multidomain antibody fragments. The group of A. Plu¨ckthun in Zu¨rich described in
2003 two ScFvs that differed only in the sequence of CDR3 loops in the VL domain.
They provided a striking example of the sensitivity of antibody folding stability to
the sequence of CDRs (Ewert et al., 2003; Perchiacca and Tessier, 2012). Thus we
speculate, that the CDR regions of the CD95 antibody used in this work are simply
not suitable for expression as ScFv.
Despite these problems ScFv fragments serve as an important building block for
the construction of bispecific antibodies. The “benchmark” BiTe™ (Bi-specific T-
cell engager) format consisting of two ScFv (Bargou et al., 2008) might thus be
particularly susceptible to aggregation. This has been demonstrated by Durben et
al. comparing otherwise identical antibodies with FLT3×CD3 specificities in the
FabSc and BiTe™ format. It was found that the FLT3×CD3 antibody in the FabSc
format was superior to the BiTe™ format with respect to:
• affinity to the target antigen,
• production yield by transfected cells,
• the diminished formation of aggregates
In general the FabSc format avoids one of ScFv in the bispecific construct replacing
it by a more “physiological” Fab moiety. This moiety can be used if a particular anti-
body cannot be expressed as a ScFv as observed by the anti-CD95 antibody APO-1.
However, the C-terminal ScFv within the BS9520 FabSc constuct is still a problem:
a significant loss of affinity towards CD20 was noticed when compared to intact,
monospecific and bivalent CD20 antibodies as well as to monovalent chemically
digested anti-CD20 F(ab’) fragments (Fig. 3.6). In contrast, the affinity of BS9520
towards CD95 was only moderately reduced when compared to the parental CD95
antibody APO-1 (Fig. 3.6 on page 65). These results demonstrate that monovalency
affects the affinity to CD95 only marginal and that the N-terminal F(ab’) is less
prone to affinity loss than the C-terminal ScFv.
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SDS-PAGE analysis revealed that separated heavy and light chains of BS9520 and
BS95Mel antibodies are visible if testing proteins under non-reduced conditions
(Fig. 3.5 on page 63, lanes 2 and 3). Moreover, the heavy chain under reduced
conditions appear as a double band suggesting that two types of the heavy chain
are present in the protein solution. mRNA analysis of antibody producing Sp2/0
cells revealed that alternative splicing in the hinge region of the heavy chain results
in a heavy chain missing 15 amino acids as shown in section 3.1.2.2 on page 63. This
leads to two variants of the protein. Since one cysteine in the hinge-spliced variant
is missing, interaction with the corresponding light chain is weaker. It is strong
enough to pass purification using KappaSelect affinity chromatography media, but
it did not withstand incubation at 95°C for 5min required for sample preparation
in SDS-PAGE analysis. As a result, the association of heavy and light chains is
weaker and some separated heavy and light chains are visible in SDS-PAGE even
under non-reduced conditions. However, antibodies containing spliced heavy chain
were not distinguishable in analytical size exclusion chromatography, suggesting that
interaction between heavy and light chain is strong enough to preserve antibody in-
tegrity under physiological conditions.
For early development and functional characterisation of BS9520 antibody in this
work, the quality of the produced protein was defined as sufficient. However, the
use of introns in the expression vector should be avoided during production of this
molecule in pharmaceutical quality and quantity.
4.1.2 Depletion of B-lymphoma cells
Monospecific, CD20-targeting antibodies are meanwhile firmly established for the
treatment of B-cell malignancies. The chimeric, second generation antibody Ritu-
ximab in combination with cyclophosphamide, hydroxydaunorubicin, oncovin (vin-
cristine) and prednisone (R-CHOP) is currently the front-line regimen for diffuse
large B-cell lymphoma (Coiffier et al., 2002; Mishima et al., 2012). Nevertheless,
the field of CD20-targeting antibodies is developing further. In order to decrease
immunogenicity, novel humanized and Fc-optimized anti-CD20 agents were develo-
ped. These “third-generation” antibodies are currently undergoing development in
numerous clinical trials. The glyco-optimized anti-CD20 antibody Obinutuzumab
(GA-101), for instance, was shown to be clearly superior over Rituximab in B-cell
chronic lymphocytic leukaemia (B-CLL) patients (Goede et al., 2014; Goede et al.,
2015).
Therefore in this work the activity of BS9520 was compared not only to the “gold
standard” – Rituximab, but also to a comparable chimeric anti-CD20 antibody
(clone 2H7) and in particular to the “third-generation” – Fc-optimized version
thereof.
4.1.2.1 BS9520 antibody suppresses growth of lymphoma cells in vitro
When comparing the cytotoxic effects of BS9520 to that of the various monospecific
anti-CD20 antibodies, the different cytolytic mechanisms used by these reagents had
to be taken into account: killing by monospecific antibodies requires the presence
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of FcR expressing effector cells, whereas BS9520 acts via CD95-mediated apop-
tosis in the absence of effector cells. Whereas BS9520 is clearly superior to the
most effective monospecific CD20 antibody at a PBMC : target ratio of 5 : 1 these
difference in favour of the bispecific antibody is – as expected – diminished at
higher PBMC : target ratio of 10 : 1 (Fig. 3.10). In a clinical situation, however,
such favourable ratios rarely prevail. Moreover, the amount and activity of FcR
expressing effector cells is known to exhibit intra-individual variations affecting
monospecific antibody-mediated cytotoxicity. Thus, the complete independence on
the presence of effector cells argues in favour of BS9520.
The selectivity of BS9520 towards malignant rather than of resting B-cells is advanta-
geous as well. As demonstrated by FACS analysis, normal B-cells within PBMC cul-
tures remain almost unaffected by the BS9520 construct during co-cultivation with
SKW6.4 or Raji cells. In contrast, upon incubation with monospecific antibodies,
malignant as well as normal B-cells are depleted or affected in terms of their CD19 ex-
pression (Fig. 3.11 and Fig. 3.12). Resting B-cells expressing high amounts of CD19
disappear and a small population of “CD19-low” cells remains. This phenomenon
was explained by D. Jones at al. in 2012. They concluded that the addition of Ri-
tuximab to healthy donor PBMCs in vitro can result in complement-independent
loss of CD19 without causing B-cell death. CD19 is transferred from B-cells to
monocytes and neutrophils during shaving of the Rituximab-CD20 complex in an
Fc-dependent manner (Jones et al., 2012). These data explain also the shift of CD19
on Raji cells treated with anti-CD20 antibodies (Fig. 3.12) and suggest that ther-
apeutic effect of monospecific, and especially Fc-optimized, anti-CD20 antibodies
may be compromised by this activity. In any case, BS9520 spares resting B-cells
and thus, side effects such as long term depletion of normal B-cells as observed after
clinical application of monospecific CD20 antibodies may be avoidable.
However, there is a challenge rather typical for bispecific CD95-targeting antibody.
When PBMC from healthy donors were incubated with SKW6.4 or Raji cells in
the presence of BS9520 and analysed by flow cytometry, a slight bystander killing of
monocytes (Fig. 3.11 and Fig. 3.12) was noticed. Thus, CD95 expression was verified
in different populations of leukocytes freshly isolated from heparinized blood of
healthy donors by red blood cell lysis. As expected, expression of CD95 on resting
B-lymphocytes is only marginal. In contrast, almost one half of T-cells and NK-
cells express CD95 and this expression varies between different donors. Moreover,
entire populations of monocytes and granulocytes were shown to be CD95 positive
(Fig. 3.16).
Since monocytes express CD95 their killing in flow cytometry based assay might be
explained by bystander lysis induced after trans- binding of BS9520 to the target
cells according to a mechanism proposed by Herrmann et al. (Herrmann et al., 2008).
The effect of BS9520 on monocytes in vivo should be further investigated since
human monocytes and monocyte-derived macrophages both express CD95 but are
differentially susceptible to CD95-induced apoptosis (Kiener et al., 1997; Perera
and Waldmann, 1998; Perlman et al., 1999). A similar consideration applies to
granulocytes, since these cells were also found to express CD95. Neutrophils are
known to be sensitive to CD95 death receptor signaling in vitro (O’Donnell et al.,
2015), but it is unknown if CD95-mediated apoptosis could be induced via direct
stimulation of the death receptor with agonistic anti-CD95 antibodies.
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4.1.2.2 BS9520 antibody suppresses tumour growth in vivo
When the pharmacokinetic properties of BS9520 in mouse serum were compared to
monospecific CD20 antibodies, it became obvious, that serum half life of BS9520 is
much shorter than that of whole IgG molecules. The difference can be explained by
the ability of monospecific antibodies to bind in vivo to the neonatal Fc receptor
(FcRn) preventing antibodies from degradation. The affinity of the mouse FcRn –
human IgG1 interaction is even higher than mouse FcRn – mouse IgG1 (Ober
et al., 2001) making this effect even more pronounced in mice if compared to humans.
In contrast, BS9520 antibody is lacking CH3 domain responsible for IgG-FcRn com-
plex formation and thus, does not interact with FcRn.
When the efficacy of BS9520 antibody was tested in a SCID mouse xenograft model,
it became obvious, that the therapeutic effect of BS9520 was clearly superior, even
though the dosing schedule did not fully compensate for the markedly lower serum
half-life. Monospecific anti-CD20 antibodies known to bind to FcγRIIIA receptors
conserved between mouse and human were able to slightly improve survival of the
treated mice possibly because of FcγRIIIA expression and ADCC by macrophages,
activated monocytes and NK-cells (Hashimoto et al., 1983) present in the SCID
mice (Bosma et al., 1983).
4.1.2.3 CD95 resistance in tumour cells
Despite its in vitro and in vivo activity, BS9520 suffers from a principle weakness
also depicted in Fig. 3.8 and Fig. 3.10: if CD95-resistant Raji cells were used as
targets, only weak inhibition of proliferation was observed. It has been reported
that these cells are deficient in phoshatidylserine externalization resulting in an
increased resistance towards apoptosis (Hammond et al., 2007). If Raji cells were
used as targets in a more sensitive flow cytometry based kill-assay (Fig. 3.12), the
activity of BS9520 in terms of B-cell depletion was again largely reduced as well as
cell depletion induced by monospecific antibodies.
It is well established that malignant cells may readily acquire resistance towards
CD95-mediated killing by down-regulation of CD95-expression or –sensitivity (Xerri
et al., 1998; Bullani et al., 2002; Fulda, 2009). In particular, it has been reported
that CD95-sensitivity of malignant lymphoma cells isolated from biopsies is null or
weak (Xerri et al., 1998; Plumas et al., 1998). The challenge of CD95 resistance
of tumour cells might be met by combining BS9520 with sensitizers for apoptosis
such as conventional cytostatic drugs or more specific apoptosis inducing reagents
developed more recently (Delbridge and Strasser, 2015).
In contrast to malignant cells, healthy B-cells acquire CD95 expression and- sensiti-
vity during activation (Daniel and Krammer, 1994). This constituted the rationale
of using BS9520 for selective depletion of normal B-cells in B-cell mediated auto-
immune diseases.
4.1.3 Induction of apoptosis in normal activated B-cells
Since B-cell directed anti-CD20 antibodies such as Rituximab, Obinutuzumab, Ofa-
tumumab, and Ocrelizumab are meanwhile widely used for the treatment of B-cell
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mediated autoimmune diseases, is seems to be reasonable to combine these principle
of CD20 targeting and the selective mode of action of the CD95-triggering antibodies.
Induction of CD95 mediated cell death in B-cells appears to be particularly promis-
ing if directed against activated normal (including “autoimmune cells”) rather than
malignant B-cells since these cells are less likely to develop CD95 resistance and
currently there are no data available linking B-cell mediated autoimmunity to the
CD95-mediated apoptosis resistance of B-cells. In addition, the specific expression
and sensitivity of CD95 on activated rather than resting B- and T-cells offers the per-
spective of a specific activity towards activated cells. Our observations confirm that
BS9520 meets this expectation: it appears to be active primarily against activated
B-cells whereas the monospecific anti-CD20 antibodies, including the Fc-optimized,
monospecific SDIE20 antibody depletes resting B-cells as well.
4.1.3.1 Suppression of activated B-cells in vitro
First we compared the cytolytic activity of BS9520 antibody to that of monospecific
antibodies directed to CD20 within PBMC cultures that contained either resting
cells or cells that had been activated for 6 days with PWM. We found that BS9520
as well as SDIE20 showed significant reduction of CD19+ B-cells in activated PBMC
cultures (Fig. 3.21 a). In contrast, B-cells from the resting PBMC cultures remained
unaffected upon BS9520 treatment, whereas SDIE20 and Rituximab demonstrated
a significant reduction (Fig. 3.21 b) or CD19 antigen shift (3.20). The variation of
activity between different donors (Fig. 3.21), particularly pronounced in the case
of the monospecific antibodies, is likely to be due to the known variation of NK
cell count and ADCC activity in PBMC cultures of normal healthy donors. These
findings confirm independence on the presence of effector cells and the selectivity
of BS9520 towards CD95-expressing rather than resting CD95-negative B-cells as
demonstrated previously (Fig. 3.11 and Fig. 3.12).
What was unexpected, however, was the superior suppression of antibody produc-
tion by BS9520 (Fig. 3.23) although the activity of the Fc-optimized CD20 antibody
against activated B-cells was comparable. BS9520 was demonstrated to suppress
polyclonal (PWM-) as well as antigen-specific (TT) activated B-cell more efficient
than monospecific anti-CD20 antibodies. This discrepancy might be due to by-
stander killing of activated T-cells by BS9520, a phenomenon readily explained
by the previously reported bi-cellular binding of bispecific antibodies stimulating
CD95. This phenomenon results in the killing of CD95 single positive cells when
these cells make contact with CD20-single positive target cells carrying a bispecific
antibody as demonstrated by Herrmann et al. (Herrmann et al., 2008). Given the
well-established helper function of T-cells during antibody production, it is tenta-
tive to speculate, that the killing of activated and CD95+ bystander T-cells enhances
the anti-B-cell activity of BS9520. Conceptually, this would constitute an additional
advantage of the bispecific vs. the monospecific CD20-targeting antibodies. Since
this type of cytolytic activity is restricted to in vitro PWM-activated (rather than
resting) T-cells (Fig. 3.21 d,f) in neighbouring CD20 expressing B-cells, we do not
expect it to result in intolerable T-cell depletion upon in vivo application of the
reagent.
4.2. DEVELOPMENT OF CD95×AG FUSION PROTEINS 99
An additional explanation for the superior suppressive effect of BS9520 on anti-
body production might be, that the susceptibility of B-cells towards CD95-mediated
killing may change during the process of B-cell activation that lasts 6 days in the
experiments described here. In this regard, we have noticed in preliminary experi-
ments that the sensitivity of B-cells towards CD95 mediated cell death is steadily
increasing in PWM activated PBMC cultures from day 3 to day 6 (data not shown).
Moreover, it has been reported that the small subpopulation of peripheral blood B-
cells in immunized human subjects capable of producing specific antibody is sensitive
to CD95 mediated cell death (Medina et al., 1997). Such cells might be killed by
BS9520 induced bystander lysis (Herrmann et al., 2008) even if they have lost CD20
expression during differentiation into antibody producing plasma cells. In any case,
the superior suppressive effects of BS9520 on antibody production implies that this
reagent may be particularly suitable for the treatment of autoantibody-mediated
mediated autoimmune diseases.
4.2 Development of CD95×Ag fusion proteins
The idea of selective therapeutic induction of inhibitory and suppressive function
of agonistic CD95 antibodies on normal B-cells was further developed. A signifi-
cant subsequent step would be antigen-specific B-cell suppression by engaging CD95
death receptor.
The concept of selective targeting of antigen-specific B-cells is intended to elimi-
nate pathogenic B-cells while sparing all unrelated cells. As an attractive option
for the treatment of autoantibody-mediated autoimmune diseases, BCR targeting
has also been investigated by other groups, using different effector mechanisms. For
example, Rammensee et al. investigated targeting of antigen-specific B-cells by cy-
totoxic T lymphocytes using conjugates of T-cell receptor (TCR) specific antibodies
and antigen (Rammensee et al., 1987). Taddeo et al. conjugated an antibody or a
F(ab) fragment recognizing the surface markers CD138 or CD44 with the antigen
of interest for detection and/or depletion of antigen-specific plasma cells (Taddeo
et al., 2015). Ellebrecht et al. engineered autoantigen-based chimeric immunorecep-
tors (CAAR T-cells) that can direct T-cells to kill autoreactive B-cells through the
specificity of the BCR (Ellebrecht et al., 2016). These findings suggest that BCR
is in principle suitable as a target molecule despite its physiological property to be
internalized after antigen exposure.
The basic idea in this work was to achieve antigen-specific B-cell depletion using
CD95×Ag fusion proteins binding to the specific BCR and inducing apoptosis in
activated antigen-specific B-cells (Fig. 3.24 on page 84). The BS95TT and BS95DT
were generated by replacing the CD20 targeting part of the BS9520 molecule by
tetanus and diphtheria toxoids (TT/DT) as a model antigens whereby the DT con-
taining protein served as a negative control. Thus, functional hybrid molecules con-
sisting of an anti-CD95 antibody and immunogenic parts of tetanus or diphtheria
toxoid were obtained after overcoming some protein engineering challenges. FabSc
format used for the BS9520 antibody was applied for construction of CD95×Ag
fusion proteins for the proof of principle of this novel idea.
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4.2.1 Suppression of Ag-specific IgG production
Suppression of Ag-specific IgG production in TT activated cultures by the BS95TT
fusion protein was analysed in the same way as with BS9520 construct using a spe-
cific ELISA. 6 days TT-stimulated PBMC from 6 recently immunised donors were
incubated with or without control antibodies and fusion proteins for 2 days. Sub-
sequently, cell culture supernatants were analysed by specific anti-TT IgG ELISA.
Using this experimental setting a moderate effect of the BS95TT fusion protein was
observed (Fig. 3.31). It was not as pronounced as the effect achieved using BS9520
antibody. It is tentative to speculate that the low frequency of Ag-specific B-cells
compared to normal activated B-cells is responsible for this limited effect. It is
known that the activity of BS9520 to same extend depends on the density of the
target cells (Herrmann et al., 2008). Activated cultures may require higher cell
density to achieve more pronounced BS95TT-mediated killing of Ag-specific B-cells.
Moreover, the ELISA assay used in this case should be ideally substituted with
more sensitive B-cell depletion assays. Direct FACS- or ELISpot-based assays could
be further developed for the direct detection and enumeration of specific antibody
producing B-cells to further confirm the antigen specific activity of the TT fusion
protein.
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4.3 Outlook
In the first part of this work a recombinant bispecific CD95×CD20 antibody desig-
nated BS9520 was developed. Specific cytotoxicity of this molecule towards CD95-
sensitive malignant B-cells and normal activated B-cells was shown to be superior
to that achieved using parental monospecific CD20 antibodies, Fc-optimised ver-
sions thereof and the FDA-approved anti-CD20 antibody Rituximab in vitro and in
vivo. Nevertheless, using this reagent for the treatment of B-cell malignancies could
be limited due to resistance towards the CD95-mediated apoptosis often present in
malignant cells. Overcoming this problem will probably need a combination ther-
apy with sensitizing reagents enhancing the susceptibility of tumour cells towards
apoptotic cell death. The selective targeting activity of BS9520 should be tested
especially in combination with BCL-2 inhibitors, BH3 mimetics and conventional
chemotherapeutics. In addition, it may be worth to try alternative anti-CD95 an-
tibody sequences with proper folding as ScFv on the C-terminus of the bispecific
antibody in FabSc format. In this case binding to CD20 could be significantly im-
proved by placing the anti-CD20 antibody at the N-terminus of the FabSc molecule.
The next step in the development of an optimized molecule will then be GMP-
compliant production of the improved molecule.
In the second part of this work a concept for selective antigen specific B-cell suppres-
sion was developed and tested. Tetanus (TT) toxoid coupled to the CD95 antibody
showed moderate suppression of tetanus specific antibody producing cells. Addi-
tional functional assays directly assessing the depletion of antigen-specific cells in
vitro should be developed. After confirming the activity of the fusion protein using
model antigens, a clinically relevant constructs might be developed containing known
antigens involved in autoimmune diseases such as acetylcholine receptor (AChR) or
desmoglein 3 inducing Myasthenia gravis and Pemphigus vulgaris, respectively.
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6.1 List of abbreviations
°C Degree Celsius
7-AAD 7-aminoactinomycin D
a.a. Amino acid
ADCC Antibody-dependent cellular cytotoxicity
AICD Activation-induced cell death
ALL Acute lymphocytic leukaemia
AML Acute myeloid leukaemia
Amp Ampicillin
APC Allophycocyanin
BCR B-cell receptor
BSA Bovine serum albumin
bp Base pair
BTK Bruton’s tyrosine kinase
CAR Chimeric antigen receptors
CDC Complement dependent cytotoxicity
CDR Complementarity-determining regions
CIP Calf Intestinal phosphatase
CLL Chronic lymphocytic leukaemia
cm Centimetre
C-Terminus Carboxy-Terminus
CTLs Cytotoxic T lymphocytes
CSPG4 Chondroitin sulfate proteoglycan 4
Da Dalton
DAMPs Damage-associated molecular patterns
DD Death domain
ddH2O Double-distilled water
DED Death effector domain
DLBCL Diffuse large B-cell lymphoma
DMSO Dimethyl Sulfoxide
DNA Deoxyribonucleic acid
DPBS Dulbecco’s phosphate buffered saline
DR Death receptor
dsDNA Double stranded deoxyribonucleic acid
EDTA Ethylenediaminetetraacetic acid
EGFR Epidermal growth factor receptor
ELISA Enzyme-linked immunosorbend assay
EtBr Ethidium bromide
FACS Fluorescence activated cell sorter
FCS Fetal calf serum
G418 Geneticin
GMP Good Manufacturing Practice
× g Times Earth’s gravitational force
HRP Horseradish peroxidase
IMDM Iscove’s Modified Dulbecco’s Medium
i.v. Intravenously
6.1. LIST OF ABBREVIATIONS 123
Kan Kanamycin
kb Kilobase
kDa Kilodalton
M Mol
MCL Mantle cell lymphoma
MFI Mean fluorescence intensity
mL Millilitre
MOPS 3-(N-morpholino)propanesulfonic acid
MW Molecular weight
MWCO Molecular weight cut off
µCi Microcurie
µF Microfarad
µg Microgram
µL Microliter
µM Micromol
N-Terminus Amino-Terminus
NHL Non-Hodgkin’s lymphomas
NK Natural killer cells
nm Nanometer
O.D. Optical density
PBMC Peripheral blood mononuclear cells
PBL Peripheral blood leukocytes
PMNs Polymorphonuclear leukocytes
PP Polypropylen
PS Polystyrol
PWM Pokeweed mitogen
RBC Red blood cells
RPMI Roswell Park Memorial Institute
ScFv Single chain Fragment variable
SDS-PAGE Sodium dodecyl sulfate Polyacrylamide gel electrophoresis
SEC Size exclusion chromatography
SLE Systemic lupus erythematosus
PET Positron emission tomography
TAA Tumour associated antigen
TAE Tris-acetate-EDTA
TDTH Delayed type hypersensitivity T-cells
TLR Toll-like receptor
TMB 3,3’,5,5’-Tetramethylbenzidine
TNF-α Tumor necrosis factor-α
U Unit
UV Ultraviolet
V Volt
v/v Volume/Volume
w/v Weight/Volume
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6.2 Single letter amino acid code
A Alanine
R Arginine
N Asparagine
D Aspartic Acid
C Cysteine
Q Glutamine
E Glutamic Acid
G Glycine
H Histidine
I Isoleucine
L Leucine
K Lysine
M Methionine
F Phenylalanine
P Proline
S Serine
T Threonine
W Tryptophan
Y Tyrosine
V Valine
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6.3 Antibody sequences
Mouse anti-human CD95 (APO-1) VH :
EVQLVETGGGLVQPKGSLKLSCAASGFTFNTNAMNWVRQAPGKGLEWVA
RIRSKSNNYATYYAESVKDRFTISRDDSQSMLYLQMNNLKAEDTAMYYCVT
DGYYWGQGTTLTVSS
Mouse anti-human CD95 (APO-1) VL:
DIVLTQSPASLAVSLGQRATISCRASESVEYYGTSLMQWYQQKPGQPPKLLI
YVASNVESGVPARFSGSGSGTDFSLNIHPVEEDDIAMYFCQQSTKVPWTFG
GGTKLEIK
6.4 Supplementary figures
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Figure 6.1: Preparative size exclusion chromatography of BS95Mel
A representative purification of the recombinant BS95Mel after initial KappaSelect pu-
rification. Approx. 2mg of protein were separated using FPLC system (Pharmacia LKB
Biotechnology) equipped with Superdex™ 200 Prep Grade 16/60 HiLoad column as de-
scribed in section 2.4.1.2 on page 49.
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Figure 6.2: Analytical size exclusion chromatography of different BS95DT
fusion proteins after KappaSelect purification
a) BS95DT-TR (clone 7H7) fusion protein containing T (transmembrane) and R
(receptor-binding) domains of Diphtheria toxin mutant CRM197 on the C-terminus of
the heavy chain. b) BS95DT-TRC201G (clone 4F11) containing T and R domains.
c) BS95DT-CTRR173QR193Q (clone 4E1) containing C (catalytic), T and R domains.
d) BS95DT-CTR173QR193Q (clone 5B1) containing C and T domains. e) BS95DT-
CTRR173QR193QC186GC201G (clone 2G6) containing C, T and R domains. f) BS95DT-
CTR173QR193QC186GC201G (clone 2H1) containing C and T domains. 10µg of purified
fusion proteins were separated using a Dionex™ UltiMate™ 3000 BioRS system equipped
with Superdex 200™ increase 10/300 GL column.
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